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ABSTRACT OF THE DISSERTATION 
Modulating Amyloid β Clearance by Altering Cellular and Whole Brain 
Apolipoprotein E Metabolism 
by 
Jacob Martin Basak 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Cell Biology 
Washington University in St. Louis, 2014 
Professor David Holtzman, Chairperson 
 
The aggregation and accumulation of the amyloid beta (Aβ) peptide in the brain is 
hypothesized to be an initial necessary event in the pathogenesis of Alzheimer’s disease 
(AD). Since the level of monomeric soluble Aβ as well as Aβ-binding molecules 
determine the onset and amount of Aβ aggregation, significant attention has been devoted 
to defining the molecular and systemic pathways that modulate Aβ synthesis and 
clearance in the brain.  Extensive evidence exists that both the isoform and amount of 
apolipoprotein E (apoE), an Aβ-binding molecule, influence Aβ aggregation and 
clearance from the brain. Therefore, studying how the molecular mechanisms that 
modulate apoE levels in the brain affect Aβ clearance will enhance our insight into the 
disease process. The apoE receptor low-density lipoprotein receptor (LDLR) and ATP-
binding cassette transporter A1 (ABCA1), a protein that regulates apoE lipidation, have 
previously been shown to modulate brain Aβ levels. In the work presented in this 
ix 
 
dissertation, we found that increasing LDLR levels enhanced the cellular uptake and 
degradation of Aβ by primary astrocytes, and increased Aβ transport to lysosomes. The 
effect of LDLR on Aβ uptake and clearance occurred independently of apoE, and 
potentially involved a direct interaction between Aβ and LDLR. To measure the 
clearance of apoE and Aβ in the mouse brain, we developed a technique that couples 
stable isotope-labeling kinetics (SILK) with mass spectrometry. We validated this 
technique by demonstrating that apoE clearance is enhanced in the brains of mice 
overexpressing LDLR. We also applied this technique to measure apoE clearance rates in 
the brains of human apoE targeted-replacement mice. Finally, we analyzed the effect of 
ABCA1 on apoE and Aβ clearance from the mouse brain. The fractional clearance rate of 
apoE was increased in amyloid precursor protein (APP) transgenic mice that either lacked 
or overexpressed ABCA1, while ABCA1 levels had no effect on Aβ clearance. 
Therefore, ABCA1 likely influences Aβ aggregation in vivo through a process other than 
modulating Aβ clearance. These data further our understanding of how proteins involved 
in apoE metabolism influence AD pathogenesis, and have important implications for 
future therapeutic strategies that target brain apoE levels and function.
1 
Chapter 1 
 
Introduction and Perspective
2 
Alzheimer’s disease: Epidemiology and pathology 
 Alzheimer’s disease (AD) is the most common cause of dementia in individuals 
older than 60 years of age, and currently afflicts an estimated 30 million people 
worldwide. Increases in the aging population are expected to greatly increase this 
number, with an estimated 4-fold rise in AD cases over the next forty years (World 
Alzheimer Report, 2009). The worldwide burden of AD from both an economical and 
societal viewpoint is alarming, as significant monetary and emotional resources are 
needed for the care of afflicted individuals. With no current effective treatment available 
for AD, further understanding of the disease pathogenesis is necessary to promote the 
development of novel therapeutics. 
 The main pathological hallmarks of AD, originally described by Alois Alzheimer 
in 1906, are extracellular amyloid plaques, intracellular neurofibrillary tangles (NFTs), 
and extensive neuronal loss (Holtzman et al., 2011). The amyloid plaques are primarily 
composed of the amyloid β (Aβ) peptide (Masters et al., 1985), and are characterized as 
either diffuse or dense-core depending on the aggregation state of Aβ . Diffuse plaques 
consist of Aβ present in a non-fibrillar form, while dense-core plaques contain fibrillar 
Aβ that aggregate into a β-sheet structure. Regions of the brain surrounding dense-core 
plaques are typically characterized by extensive neuritic degeneration, along with the 
local activation of astrocytes and microglia (Itagaki et al., 1989). Microglia secrete 
cytokines and other proteins involved in the immune response that promote inflammation 
within the neuropil (Wyss-Coray, 2006). Aβ aggregation in the blood vessel walls also 
occurs in AD brains and is termed cerebral amyloid angiopathy (CAA) (Smith and 
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Greenberg, 2009). Within neuronal cell bodies and processes, the microtubule-binding 
protein tau aggregates into paired helical filaments to form NFTs and neuropil threads, 
respectively (Mandelkow and Mandelkow, 1998). As the disease progresses, significant 
neuronal and synaptic loss occurs along with gross atrophy of the brain. These changes, 
along with the loss of neurotransmitters and network connections between different brain 
regions, ultimately lead to the cognitive symptoms that define the clinical course of AD. 
 
Amyloid β production and accumulation in the brain 
 One of the main theories explaining the mechanism of AD pathogenesis is the 
amyloid cascade hypothesis (Hardy and Selkoe, 2002). The central tenet of this 
hypothesis is that Aβ accumulation in the brain, along with the resulting aggregation of 
monomeric Aβ into higher order species and amyloid plaques, initiates a cascade of 
events that leads to synaptic dysfunction and neuronal cell death. In the healthy brain, 
steady-state Aβ levels are likely determined by the overall rates of Aβ production and 
clearance. Alterations in either of these processes via increased Aβ production or 
impaired clearance could increase Aβ levels and initiate the pathogenic cascade leading 
to AD. Aβ originates primarily from neurons and is produced by the proteolytic 
processing of the amyloid precursor protein (APP). Sequential cleavage of APP by the 
enzymes β-secretase and γ-secretase produces several different species of Aβ, including 
Aβ38, Aβ40, and Aβ42, that vary in length by the number of amino acids at the C-
terminus (De Strooper, 2010). Though Aβ40 is the most abundant species of Aβ found in 
the brain, Aβ42 is more amyloidogenic and thus exhibits a greater propensity to 
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aggregate (Jarrett et al., 1993). Aβ is produced in endosomes, where the environment is 
more favorable for enzymatic cleavage of APP, and subsequently secreted into the 
extracellular space (Cirrito et al., 2008; Koo and Squazzo, 1994). 
 Genetic and molecular evidence demonstrate that increased Aβ production can 
cause AD. Autosomal dominant mutations in the genes for either APP or presenilin, a 
component of the γ-secretase complex, are responsible for the early-onset familial form 
of AD (FAD) (Tanzi and Bertram, 2005). Most of these mutations increase either the 
amount of Aβ42 produced relative to Aβ40, or in some instances elevate the level of all 
Aβ species. Also, individuals with Down syndrome possess an extra copy of the 
chromosomal region in which APP is found, and the resulting increase in APP levels 
significantly heightens the likelihood of these patients developing AD later in life 
(Rovelet-Lecrux et al., 2006). However, the cause of Aβ deposition in the more common 
late-onset form of AD (LOAD) is less evident. Few current studies suggest that Aβ 
production is elevated in individuals with LOAD. A more likely cause for the amyloid 
formation in these cases is either a change in the aggregation properties of Aβ, impaired 
clearance of Aβ from the brain, or both. A study measuring Aβ kinetics in the human 
central nervous system (CNS) has provided direct evidence for a role of impaired Aβ 
clearance in AD pathogenesis, as the clearance rate of Aβ in individuals with AD was 
decreased compared to controls (Mawuenyega et al., 2010). However, the mechanisms 
underlying the decreased clearance are unknown. Therefore, greater understanding of the 
pathways that are responsible for Aβ removal from the brain and the molecular 
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mechanisms underlying Aβ degradation is necessary to further our knowledge of AD 
pathogenesis and identify new therapeutic targets. 
 
Aβ homeostasis in the brain 
According to studies of Aβ turnover in both humans and mice, Aβ is rapidly 
produced and metabolized in the central nervous system and the periphery. Studies in 
humans have shown that Aβ is synthesized and cleared from the cerebral spinal fluid at a 
rate of roughly 8% per hour (Bateman et al., 2006). In transgenic mice that overexpress 
human APP, the half-life of Aβ has been determined to be in the range of 30 minutes to 2 
hours (Abramowski et al., 2008; Barten et al., 2005; Cirrito et al., 2003; Savage et al., 
1998). The clearance rate of Aβ in the plasma is even greater than in the brain. The 
observed half-life of Aβ in the plasma of mice is in the range of 2.5 to 3 minutes (Ghiso 
et al., 2004). Efficient clearance of Aβ is likely a primary reason that Aβ levels are 
maintained at a low level in APP transgenic mice and humans without AD. 
In the brain, several different pathways for Aβ clearance have been proposed. Aβ 
is actively transported across the blood-brain barrier into the blood, where it is then either 
catabolized by the liver or excreted through the kidney (Ghiso et al., 2004; Zlokovic, 
2008). The lipoprotein receptor low-density lipoprotein receptor-related protein 1 (LRP1) 
has been proposed to be one of the main mediators of this process (Deane et al., 2004; 
Shibata et al., 2000). Aβ can also be passively transported from the brain interstitial fluid 
to the cerebral spinal fluid (CSF), where it is then removed into the circulation via bulk 
flow of the CSF (Weller et al., 2008). Another pathway for Aβ clearance is through direct 
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enzymatic degradation of Aβ in the brain. Several proteases have been shown to directly 
degrade Aβ, including neprilysin (Iwata et al., 2001), insulin degrading enzyme (Qiu et 
al., 1998), matrix metalloproteinases (Yin et al., 2006), and tissue plasminogen activator 
(Melchor et al., 2003). Finally, Aβ can be directly taken up and degraded by cells within 
the brain, as discussed in the following section. The relative contribution of each of these 
pathways to Aβ clearance, along with which pathway predominates in both healthy and 
pathogenic conditions is unknown. For instance, blood-brain barrier transport may be the 
primary method of Aβ clearance in young healthy individuals, but as vascular insults 
(such as hypertension and vascular disease) increase with age the cellular and enzymatic 
clearance of Aβ may become more important. It is also not known to what extent each of 
these pathways contributes to the removal of aggregated Aβ species and fibrillar amyloid 
plaques. 
 
Cellular metabolism of Aβ 
 Several cell-types in the brain have been shown to be capable of internalizing Aβ 
both in cell culture and in vivo, including neurons, microglia, astrocytes, and endothelial 
cells. However, the degradative capabilities of these cell types are not equal, and 
internalization of Aβ may have different consequences depending on its ultimate 
intracellular fate. Primary neurons endocytose Aβ in culture (Kanekiyo et al., 2011; 
Saavedra et al., 2007) and intraneuronal Aβ staining has been observed in vivo (LaFerla 
et al., 2007), but no solid evidence exists that neurons actively degrade Aβ in the brain. In 
fact, a potential reason for the accumulation of intraneuronal Aβ in individuals with AD 
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is that the degradative machinery has simply been overwhelmed in these cells due to 
increased Aβ levels. As suggested by one study, intraneuronal Aβ accumulation could 
play a role in promoting AD pathogenesis through the seeding of amyloid formation (Hu 
et al., 2009). 
The uptake of Aβ by microglia and astrocytes likely plays a more prominent role 
in the cellular clearance of Aβ than neuronal uptake because of the greater degradative 
capabilities of glial cells. Microglia have been postulated to play both a beneficial and 
detrimental role in the pathogenesis of AD. Microglia may promote the clearance of Aβ 
via uptake and degradation (Lee and Landreth, 2010), but because of their immuno-
modulatory function, they can also promote pro-inflammatory pathways that enhance Aβ 
deposition and neurotoxicity (Hickman et al., 2008). Microglia have been shown to 
internalize both soluble and fibrillar Aβ in culture (Chung et al., 1999; Mandrekar et al., 
2009; Paresce et al., 1997; Paresce et al., 1996) and in the brain (Bolmont et al., 2008; 
Pluta et al., 1999; Simard et al., 2006).  Different internalization pathways have been 
shown to facilitate the uptake of soluble and fibrillar Aβ. Soluble Aβ uptake is mediated 
primarily by fluid phase macropinocytosis (Mandrekar et al., 2009). Fibrillar uptake 
occurs through the binding of Aβ to scavenger receptors and Toll-like receptors on the 
surface membrane, followed by the activation of intracellular signaling cascades that turn 
on the phagocytic machinery (Bamberger et al., 2003; Paresce et al., 1996; Reed-
Geaghan et al., 2009). The ability of microglia to degrade Aβ also appears to depend 
upon the state of Aβ aggregation. Soluble Aβ has been shown to be efficiently degraded 
by microglia in culture (Jiang et al., 2008; Mandrekar et al., 2009), but internalized 
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fibrillar Aβ remained intact and was slowly released from the cells over time (Chung et 
al., 1999; Paresce et al., 1997; Paresce et al., 1996). These latter studies suggested that 
microglia may not play a major role in clearing amyloid plaques. The role of microglia in 
plaque homeostasis in the brain was formally tested in vivo in APP transgenic mice 
crossed with mice that have a CD11b-driven thymidine kinase (TK) protein (Grathwohl 
et al., 2009). Treating these mice with ganciclovir resulted in the ablation of all 
endogenous microglia. In comparison to CD11b/TK mice with intact endogenous 
microglia, ganciclovir-treated mice had the same levels of Aβ deposition in the brain. 
However, the ganciclovir mice also had higher levels of astrocytosis in the mouse brain. 
Though the authors of this study concluded that microglia play no role in the formation 
and maintenance of amyloid plaques, it is not possible to rule out the possibility that the 
resultant increase in astrocyte activity balanced out the lack of microglia. Therefore, the 
role of microglia in both soluble and fibrillar Aβ clearance in vivo remains an issue of 
debate. 
The roles of astrocytes in the degradation of Aβ and the molecular pathways that 
regulate Aβ uptake in these cells are more poorly defined than for microglia. Astrocytes 
have been shown to internalize Aβ in the brain via immunohistochemical studies (Funato 
et al., 1998; Nagele et al., 2003; Thal et al., 2000). Other papers have also described the 
ability of primary astrocytes grown in culture to endocytose and degrade soluble Aβ 
(Mandrekar et al., 2009; Nielsen et al., 2009; Shaffer et al., 1995; Wyss-Coray, 2006) and 
fibrillar Aβ present in the plaques of murine brain slices (Koistinaho et al., 2004; Wyss-
Coray et al., 2003). In the latter studies, the ability of astrocytes to degrade fibrillar Aβ 
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was inhibited in the presence of the receptor-associated protein (RAP), a known 
antagonist of receptors in the low-density lipoprotein receptor (LDLR) family 
(Koistinaho et al., 2004). These results suggest that a member of the LDLR family may 
play an important role in facilitating the uptake of Aβ by astrocytes, though the specific 
LDLR receptors have yet to be identified. Therefore, further studies are necessary to 
characterize the specific molecular pathways that mediate astrocytic Aβ endocytosis, and 
to determine whether astrocytes contribute to the in vivo clearance of Aβ. 
 
Apolipoprotein E and Alzheimer’s disease 
 One protein that has been shown to potentially influence amyloid aggregation 
through the modulation of Aβ clearance is apolipoprotein E (apoE). ApoE is a 34 kDa 
glycoprotein whose main function outside of the brain is to regulate cholesterol and lipid 
metabolism (Mahley, 1988). ApoE is expressed at the highest level in the liver, followed 
by the brain (Elshourbagy et al., 1985). Astrocytes are the main cell-type in the brain that 
produces apoE, though microglia also express apoE (Fig. 1) (Grehan et al., 2001; Pitas et 
al., 1987). In the periphery, apoE is one of the protein constituents present on very low-
density lipoprotein (VLDL) and high-density lipoprotein (HDL) particles. ApoE 
functions in the transport and redistribution of cholesterol by binding to receptors of the  
LDLR family, and consequently facilitating the uptake of VLDL and HDL into hepatic 
and extra-hepatic cells (Mahley, 1988). In the brain, the normal physiological function of 
apoE is poorly defined. Unlike in the periphery, where HDL particles contain 
apolipoprotein A-1 (apoA-1) as the major lipoprotein, apoE is the predominant 
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apolipoprotein in the brain (Pitas et al., 1987). In the brain, apoE is present on HDL-like 
lipoprotein particles that are discoidal in shape and possess cholesterol and phospholipids 
(DeMattos et al., 2001b; Fagan et al., 1999). The role of these particles in normal brain 
function is unclear, although some evidence suggests that cholesterol released from these 
particles is used to promote synaptogenesis (Mauch et al., 2001; Pfrieger and Ungerer, 
2011).  
 ApoE has been the focus of considerable attention in AD research because APOE 
genotype is currently the strongest genetic risk factor for LOAD. The human APOE gene 
contains several single-nucleotide polymorphisms (SNPs), with three SNPs resulting in 
the most common isoforms of apoE: apoE2 (cys112, cys158), apoE3 (cys112, arg158), 
and apoE4 (arg112, arg158) (Zannis et al., 1982). Prior to its known genetic association 
with AD, apoE immunoreactivity was observed in amyloid plaques (Namba et al., 1991; 
Wisniewski and Frangione, 1992). The ε4 allele of the APOE gene was subsequently 
discovered to be a major risk factor for the likelihood of developing AD (Corder et al., 
1993; Strittmatter et al., 1993a), with one ε4 allele and two ε4 alleles conferring an 
approximate 3-fold and 12-fold increased risk, respectively (Bertram et al., 2007). The 
APOE ε4 allele is also associated with an earlier age of AD onset (Corder et al., 1993; 
Roses, 1996). Conversely, the ε2 allele of APOE confers a protective effect and lowers 
the risk of developing AD (Corder et al., 1994). Currently, one of the main hypotheses 
for how apoE affects AD pathogenesis is that it regulates the ability of Aβ to deposit in 
the brain. As described in the next two sections, the mechanism for this effect could 
occur through the ability of apoE to either influence the aggregation properties of Aβ, 
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modulate Aβ metabolism,  or both (Kim et al., 2009a; Verghese et al., 2011). Therefore, 
understanding how various aspects of apoE biology influence Aβ metabolism and 
aggregation are important for further characterizing the role of apoE in AD pathogenesis. 
 
Effect of apoE on Aβ aggregation 
 In vitro and in vivo studies in mice and humans have clearly demonstrated that the 
apoE isoforms differentially regulate the propensity of Aβ to aggregate. In vitro 
biophysical assays have been used to assess the effect of apoE on the nucleation and 
fibrillization of synthetic Aβ into filaments. ApoE has been shown to enhance the 
fibrillization of both Aβ40 and Aβ42, with apoE4 having a greater effect than apoE2 and 
apoE3 (Castano et al., 1995; Ma et al., 1994; Wisniewski et al., 1994). However, other 
studies observed that apoE decreases the nucleation of Aβ into fibrils, with no apparent 
isoform-dependent effects (Evans et al., 1995; Wood et al., 1996). Studies in APP-
transgenic mouse models have shown an apoE isoform-dependent effect on amyloid 
deposition in vivo. In PDAPP mice (APP transgenic mice expressing the human APP 
gene via the platelet-derived growth factor promoter) that express the individual human 
apoE isoforms via transgenic expression, apoE4-expressing mice had increased levels of 
Aβ deposits and thioflavine-S-positive amyloid deposition than apoE3-expressing mice 
(Fagan et al., 2002; Holtzman et al., 2000a; Holtzman et al., 1999). Similar results were 
obtained when APP transgenic mice were crossed to apoE2, apoE3, and apoE4 targeted-
replacement mice, which express human apoE under the endogenous mouse promoter. 
ApoE4 targeted-replacement mice had significantly more Aβ accumulation than apoE2 
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and apoE3 targeted-replacement mice (Bales et al., 2009; Fryer et al., 2005b). In humans, 
autopsy studies from AD brains have demonstrated that APOE ε4 allele dosage is 
associated with increased plaque amounts (Rebeck et al., 1993; Schmechel et al., 1993; 
Tiraboschi et al., 2004). The effect of apoE4 on amyloid deposition has also been 
measured in living subjects whose brains were imaged with an amyloid imaging agent to 
detect fibrillar Aβ levels. In cognitively normal individuals, APOE ε4 carriers had 
increased amyloid levels compared to non-carriers in all age groups analyzed (Kantarci et 
al., 2012; Morris et al., 2010; Reiman et al., 2009). Therefore, apoE4 increases the 
amount of amyloid deposition in the human brain prior to the onset of clinical AD. 
 Studies in mice have demonstrated that the level of apoE is also a critical factor in 
regulating amyloid deposition. Deletion of mouse apoE led to a significant decrease in 
Aβ deposition and an almost complete lack of amyloid plaques in the PDAPP and 
Tg2576 APP-transgenic mouse models (Bales et al., 1999; Bales et al., 1997; Holtzman 
et al., 1999; Holtzman et al., 2000b). Genetically decreasing human apoE levels in 
APP/PS1 transgenic mice crossed with human apoE3 or apoE4 targeted-replacement 
mice also decreased Aβ deposition in the brain (Kim et al., 2011). Significantly decreased 
Aβ and amyloid deposition were detected in the brains of APP/PS1 mice with one copy 
of the APOE ε3 allele or APOE ε4 allele compared to mice with two copies of APOE ε3 
or APOE ε4, respectively. Therefore, lower levels of human apoE in the mouse brain 
decreased Aβ deposition in a manner that was independent of apoE isoform status.  
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Effect of apoE on Aβ clearance 
 In addition to exerting an effect on Aβ aggregation, apoE has been shown to alter 
the transport and metabolism of Aβ in cultured cells and the brain. Several studies using 
various types of neuronal cells have demonstrated that apoE facilitates the binding and 
internalization of soluble Aβ, though no overall trend in the effect of the apoE isoforms 
has emerged (Beffert et al., 1998, 1999a; Cole and Ard, 2000; Nielsen et al., 2009; 
Yamauchi et al., 2002; Yamauchi et al., 2000; Yang et al., 1999). The ability of both 
microglia and astrocytes to degrade Aβ in vitro was also enhanced in the presence of 
apoE in several studies (Jiang et al., 2008; Koistinaho et al., 2004; Lee et al., 2012). 
Though apoE appears to enhance Aβ clearance in vitro, in vivo studies in mice have 
shown that apoE impairs Aβ clearance (Bell et al., 2007; Deane et al., 2008; DeMattos et 
al., 2004). The reason for the difference in the effect of apoE between in vitro and in vivo 
studies is currently unknown. In terms of apoE isoforms, the clearance of Aβ from the 
brain interstitial space is significantly decreased in PDAPP mice that express apoE4 
compared to mice that express apoE2 and apoE3 (Castellano et al., 2011). The transport 
of Aβ across the blood-brain-barrier (BBB) was also significantly impaired when Aβ was 
complexed with apoE4, in comparison to Aβ complexed with either apoE2 or apoE3 
(Deane et al., 2008). 
At a molecular level, the mechanism explaining the effect of apoE on Aβ 
clearance largely depends upon whether apoE interacts with the Aβ peptide directly in the 
brain (Fig. 1). An abundance of in vitro studies have demonstrated an interaction between 
apoE and Aβ (LaDu et al., 1994; Strittmatter et al., 1994; Tokuda et al., 2000). However, 
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many of these studies used sub-physiological molar ratios of apoE to Aβ, and often 
demonstrated that a very small fraction of Aβ is bound to apoE. Therefore, the relevance 
of the described apoE-Aβ interactions to the in vivo environment remains unknown. If an 
apoE-Aβ complex is present, apoE-containing lipoprotein particles may sequester Aβ in 
the brain. The apoE-Aβ complex could then be taken up by cells via receptor-mediated 
endocytosis or transported across the blood-brain-barrier (Fig. 1). In this scenario, the 
clearance of soluble Aβ would likely depend upon the uptake/transport rates of each 
individual apoE isoform, which could be faster or slower than the rates for the uptake 
/transport of unbound Aβ. It is also possible that the amount and/or isoform of apoE 
could influence Aβ clearance without interacting with Aβ. One possibility is that apoE 
and Aβ may bind to the same receptors. In this case, apoE could function as a competitive 
ligand for the receptor-mediated uptake of Aβ into cells or transport across the BBB, 
effectively blocking Aβ clearance. Further studies are needed to characterize the 
interaction of Aβ with known apoE receptors to determine the feasibility of this 
mechanism.  
 
ApoE levels and turnover in the brain 
Since the amount of apoE in the brain regulates the extent of Aβ deposition, 
understanding the mechanisms regulating apoE levels and kinetics in the brain will 
further elucidate the role of apoE in AD pathogenesis. For instance, the difference in 
amyloid deposition and clearance between apoE isoforms could be mediated by 
differences in apoE levels. In humans, multiple studies have analyzed the effect of apoE 
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isoform status on apoE protein levels in the CSF (Bekris et al., 2008; Castellano et al., 
2011; Fukumoto et al., 2003; Lehtimaki et al., 1995; Wahrle et al., 2007) and brain 
(Beffert et al., 1999b; Bertrand et al., 1995; Harr et al., 1996; Wood et al., 1996). 
However, results from these studies have not demonstrated any clear trend in apoE levels, 
likely due to issues with sample stability following collection and heterogeneity in the 
subject population. Many of the techniques used to measure apoE also rely upon different 
apoE antibodies which may not recognize the various apoE isoforms with equal affinity. 
ApoE targeted-replacement mice have become popular tools to measure the effect of the 
apoE isoforms on Aβ deposition in vivo, and attention has been devoted to characterizing 
the apoE levels in these mice. Since apoE is expressed in these mice under the control of 
the endogenous mouse APOE gene promoter and regulatory elements (Sullivan et al., 
1997), protein levels should be a reflection of the natural turnover rates of apoE in the 
mouse CNS. An initial study characterizing apoE levels in the brains of these mice 
detected no differences between apoE2, apoE3, and apoE4 (Sullivan et al., 2004). 
However, subsequent studies have described a genotype-dependent difference in apoE 
levels (apoE2 > apoE3 > apoE4) in the brain and CSF of these mice (Fryer et al., 2005b; 
Mann et al., 2004; Ramaswamy et al., 2005; Riddell et al., 2008; Vitek et al., 2009). 
Further studies are needed to verify these differences and to investigate whether apoE 
synthesis and degradation rates differ between apoE isoforms. 
Mechanistic insight into differences in apoE levels in the brain could be gained by 
measuring the kinetics of apoE turnover. However, few studies have analyzed apoE 
turnover in the brain. The clearance of apoE across the BBB has been assessed in mice by 
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infusing both unlabeled and radiolabeled apoE into the brain and measuring 
disappearance of the infused proteins over time (Bell et al., 2007; Deane et al., 2008). 
Clearance of lipid-poor apoE3 occurred at a very slow rate across the BBB and via bulk 
flow through the ISF (0.03-04 pmol/min g ISF), and the rate was even slower with 
lipidated apoE3. Using this same technique, the clearance of radiolabeled apoE4 across 
the BBB was demonstrated to be significantly slower than the clearance of apoE2 and 
apoE3 (Deane et al., 2008). No studies have analyzed the kinetics of endogenous apoE in 
the brain, largely because of the lack of techniques to measure protein turnover in the 
brain. Therefore, the development of methods to measure brain protein dynamics in vivo 
will significantly enhance the mechanistic understanding of apoE dynamics and their 
relationship to apoE levels. 
 
ApoE receptors and brain apoE metabolism 
 Given the proposed effect of apoE levels on Aβ clearance, significant attention 
has been devoted to understanding the cellular pathways for apoE clearance in the brain. 
Modulating the clearance of apoE via these pathways represents a potential therapeutic 
strategy for decreasing Aβ deposition in the brain. In the periphery, apoE is internalized 
by receptor-mediated endocytosis via members of the LDLR family (Mahley, 1988). The 
LDLR family consists of several different receptors with both endocytic and signaling 
functions (Herz and Bock, 2002). The low-density lipoprotein receptor (LDLR) is the 
original member of this family and has been shown to play a central role in the removal  
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Figure 1.1: Effects of apoE and apoE receptors on Aβ clearance and 
deposition: ApoE is produced by astrocytes and microglia, and is lipidated by 
ABCA1 to form lipoprotein particles. ApoE-containing lipoprotein particles are 
endocytosed into various cell-types via LDLR and LRP. ApoE facilitates the 
aggregation of soluble Aβ into amyloid plaques in an isoform specific manner 
(apoE2>apoE3>apoE4). ApoE could bind to Aβ and facilitate its uptake into cells 
or transport across the blood-brain-barrier. Soluble Aβ could also be cleared by 
apoE receptors in an apoE-independent process, as has been shown for LRP1. 
(Reprinted from (Kim et al., 2009a) with permission from Elsevier).  
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of cholesterol containing low-density lipoprotein particles from the circulation (Brown 
and Goldstein, 1986). Apolipoprotein B (apoB) or apoE bind to LDLR and facilitate the 
uptake of lipoprotein particles into cells. In the acidic environment of the endosome, 
thelipoproteins are released from LDLR and cholesterol is released into the cell, while the 
receptors are recycled back to the cell surface. Both the lipidation state and isoform status 
of apoE regulate the binding affinity of apoE with LDLR. ApoE binding to LDLR 
requires the presence of lipids (Blacklow, 2007), and apoE2 has only 1-2% of binding 
affinity to LDLR in comparison to apoE3 and apoE4 (Weisgraber et al., 1982). 
Several LDLR family members are expressed in various cell-types in the brain, 
including LDLR, lipoprotein receptor-related protein 1 (LRP1), very low-density 
lipoprotein receptor (VLDLR), and apolipoprotein E receptor 2 (apoER2) (Herz and 
Bock, 2002). Current evidence suggests that LDLR and LRP1 are the primary receptors 
that regulate brain apoE levels. LDLR is more highly expressed on glial cells, while 
LRP1 is predominately expressed on neurons and to a lesser extent in glia (Rapp et al., 
2006). Deletion of the LDLR gene in the mouse brain led to a significant increase in the 
amount of apoE in the brain and CSF (Fryer et al., 2005a), while overexpression of 
LDLR in the brain decreased apoE levels (Kim et al., 2009b). Alterations of LRP1 
showed a similar effect, with conditional deletion of LRP1 leading to increased brain 
apoE levels (Liu et al., 2007) and overexpression of an LRP1 mini-receptor causing 
decreased apoE levels (Zerbinatti et al., 2006). Taken together, these studies suggested 
that LDLR and LRP1 regulate metabolism of apoE in the brain. 
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Effect of apoE receptors on Aβ metabolism 
The effect of LRP1 on Aβ metabolism has been studied both in culture and in 
vivo. LRP1 has been demonstrated to promote the clearance of Aβ via cellular uptake and 
the BBB (Fig. 1). Increasing LRP1 levels in neuronal cell lines and primary neurons led 
to increased Aβ uptake, whereas decreasing LRP1 levels had the opposite effect 
(Fuentealba et al., 2010; Kanekiyo et al., 2011). LRP1 has also been shown to facilitate 
the binding and internalization of Aβ by mouse brain capillaries (Deane et al., 2004), and 
inhibition of LRP1 with an antibody impairs the BBB transport of Aβ in the mouse brain 
(Shibata et al., 2000). The detailed mechanism for how LRP1 facilitates Aβ 
transport/uptake remains unclear, but may involve a direct physical interaction between 
LRP1 and Aβ (Deane et al., 2004). 
LDLR has been shown to regulate Aβ deposition and clearance in the mouse 
brain. The effect of deleting the LDLR gene on Aβ deposition in APP transgenic mice has 
produced conflicting results. A study using the Tg2576 mouse (mice that express human 
APP with the Swedish familial AD mutation) observed a modest increase in amyloid 
deposition with LDLR deletion (Cao et al., 2006), while a second study using PDAPP 
mice showed no effect (Fryer et al., 2005a). The effect of increasing LDLR on Aβ levels 
in the brain has also been studied using LDLR transgenic mice. LDLR overexpression in 
APP/PS1 transgenic mice led to a significant decrease in amyloid load in the brain, and 
significantly enhanced clearance of Aβ from the interstitial space (Kim et al., 2009b). The 
mechanism for how LDLR regulates Aβ clearance remains largely unknown. LDLR 
overexpression in the brain may act indirectly on the clearance of Aβ by decreasing apoE 
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levels, or LDLR could directly modulate Aβ clearance. In the latter case, it is possible 
that LDLR may regulate the cellular uptake and degradation of Aβ. This could occur 
through an apoE-dependent process, such as the uptake of an apoE-Aβ complex. An 
apoE-independent effect of LDLR on Aβ uptake is also possible, such as a direct 
interaction with Aβ. 
 
ApoE lipidation in the brain 
 Along with apoE receptor levels, the amount of lipids and cholesterol associated 
with apoE in the brain is another factor that regulates the apoE protein level. In the 
periphery, apoE-containing HDL particles acquire cholesterol and phospholipids from 
cells through a process known as reverse cholesterol transport (RCT) (Mahley et al., 
2006). This process is mediated by the cholesterol transporter ATP-binding cassette A1 
(ABCA1), which mediates the efflux of cholesterol to lipid-poor apoA-1 and apoE to 
form nascent-HDL particles (Krimbou et al., 2004; Wang et al., 2007). Loss-of-function 
mutations in ABCA1 in humans cause Tangier’s disease, which is characterized by 
extremely low plasma HDL levels and intracellular cholesterol accumulation (Bodzioch 
et al., 1999; Brooks-Wilson et al., 1999; Rust et al., 1999). Following the ABCA1-
mediated formation of nascent HDL particles, further cholesterol efflux to the partially 
lipidated HDL particles occurs via the protein ATP-binding cassette G1 (ABCG1) 
(Kennedy et al., 2005). Finally, subsequent maturation of the HDL particles occurs by 
cholesterol esterification via the enzyme lecithin:cholesterol acyltransferase (LCAT) 
(Jonas, 1998). 
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 Studies in mice have shown that many of the RCT proteins function in a similar 
manner in the brain to modulate the lipidation of apoE (Fig. 1). ABCA1, ABCG1, and 
LCAT are all expressed in the brain (Tachikawa et al., 2005; Warden et al., 1989; 
Wellington et al., 2002). In culture, ABCA1 was shown to play an important role in the 
cholesterol efflux capacity of primary astrocytes and microglia (Hirsch-Reinshagen et al., 
2004). Deletion of the ABCA1 gene in the mouse brain led to a significant decrease in 
apoE levels in the brain, and apoE isolated from the CSF was poorly lipidated (Hirsch-
Reinshagen et al., 2004; Wahrle et al., 2004). Interestingly, overexpression of the 
ABCA1 protein in the brain also decreased apoE levels, although to a lesser extent than 
ABCA1 deletion (Wahrle et al., 2008). Analysis of the CSF from ABCA-overexpressing 
mice showed an increase in the size of apoE-containing lipoprotein particles, likely due to 
increased lipidation. The effect of both ABCG1 and LCAT on apoE levels in vivo has 
also been assessed. Overexpression of ABCG1 had no effect on apoE levels in the mouse 
brain (Burgess et al., 2008), while deletion of the LCAT gene significantly increased 
mouse brain apoE levels (Hirsch-Reinshagen et al., 2009). These studies suggest that 
altering the properties of apoE lipidation alters its stability in the brain. 
 
ABCA1 and Aβ deposition 
Since lowering apoE levels decreased amyloid deposition in the mouse brain, it 
was hypothesized that altering ABCA1 levels would also alter amyloid deposition in APP 
transgenic mice. APP transgenic mice have been generated that have either the ABCA1 
gene deleted or overexpressed. Despite decreased apoE levels with both ABCA1 deletion 
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and overexpression, only ABCA1 overexpression caused a significant decrease in 
amyloid load in the mouse brain of APP transgenic animals (Wahrle et al., 2008). The 
amyloid load in APP transgenic mice lacking ABCA1 remained stable or even increased 
when ABCA1
-/-
 mice were crossed to various APP transgenic models (Hirsch-
Reinshagen et al., 2005; Koldamova et al., 2005a; Wahrle et al., 2005). The opposing 
effects of ABCA1 deletion and overexpression on Aβ deposition suggests that ABCA1 
likely alters Aβ levels and deposition through a mechanism distinct from modulating 
apoE levels. None of the above studies observed any changes in secreted or cell-
associated APP fragments, suggesting ABCA1 does not affect APP processing to form 
Aβ. Other possible mechanisms may be that the lipidation state of apoE alters the 
fibrillization or clearance of Aβ from the brain (Hirsch-Reinshagen and Wellington, 
2007; Wahrle et al., 2008). ABCA1 could also alter these properties of Aβ in a manner 
that is independent of apoE. However, none of these possibilities have been thoroughly 
investigated in vivo. 
 
Directions 
 Provided this background, this thesis work had several aims to further 
characterize how the pathways that regulate apoE levels modulate Aβ metabolism. The 
initial aim of this work was to further characterize the role LDLR plays in the metabolism 
of Aβ by demonstrating an effect of LDLR on the cellular uptake and degradation of Aβ. 
We further defined the mechanism dictating LDLR-mediated cellular uptake of Aβ by 
determining whether apoE plays a role in this process and whether LDLR could 
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physically interact with Aβ. We then designed a new technique for the characterization of 
apoE turnover in the mouse brain using stable isotope labeling coupled to mass 
spectrometry. This technique was used to measure the effect of LDLR on apoE clearance 
in the brain, and to measure the kinetics of the human apoE isoforms in the mouse brain. 
Finally, to further define the role of ABCA1 in apoE and Aβ clearance, we applied stable 
isotope labeling kinetics to measure the effect of ABCA1 levels on the clearance of both 
apoE and Aβ in the mouse brain. 
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Chapter 2 
Low-density Lipoprotein Receptor Represents an Apolipoprotein E-Independent 
Pathway of Aβ Uptake and Degradation by Astrocytes 
 
(This work was completed with the assistance of several individuals. Dr. Philip Verghese 
performed the SPR binding experiments. Hyejin Yoon and Dr. Jungsu Kim performed the 
qPCR experiments. Dr. David Holtzman, Dr. Verghese, and Dr. Kim provided guidance 
and helpful discussion throughout the study. This work was published in the The Journal 
of Biological Chemistry.) 
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Summary 
Accumulation of the amyloid beta (Aβ) peptide within the brain is hypothesized 
to be one of the main causes underlying the pathogenic events that occur in Alzheimer’s 
disease (AD). Consequently, identifying pathways by which Aβ is cleared from the brain 
is crucial for better understanding of the disease pathogenesis and developing novel 
therapeutics. Cellular uptake and degradation by glial cells is one means by which Aβ 
may be cleared from the brain. In the experiments described in this chapter, we 
demonstrate that modulating levels of the low-density lipoprotein receptor (LDLR), a cell 
surface receptor that regulates the amount of apolipoprotein E (apoE) in the brain, altered 
both the uptake and degradation of Aβ by astrocytes. Deletion of LDLR caused a 
decrease in Aβ uptake, while increasing LDLR levels significantly enhanced both the 
uptake and clearance of Aβ. Increasing LDLR levels also enhanced the cellular 
degradation of Aβ and facilitated the vesicular transport of Aβ to lysosomes. Despite the 
fact that LDLR regulated the uptake of apoE by astrocytes, we found that the effect of 
LDLR on Aβ uptake and clearance occurred in the absence of apoE. Finally, we provide 
evidence that Aβ can directly bind to LDLR, suggesting an interaction between LDLR 
and Aβ could be responsible for LDLR-mediated Aβ uptake. Therefore, these results 
identify LDLR as a receptor that mediates Aβ uptake and clearance by astrocytes, and 
provide evidence that increasing glial LDLR levels may promote Aβ degradation within 
the brain. 
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Introduction 
Alzheimer’s disease (AD), the most common cause of dementia, is characterized 
by the appearance of extracellular amyloid plaque deposition in the brain, intraneuronal 
neurofibrillary tangle formation, and marked neuronal and synaptic loss (Holtzman et al., 
2011). Aggregation of the amyloid β (Aβ) peptide into oligomers and fibrils is 
hypothesized to lead to a pathological cascade resulting in synaptic dysfunction, neuronal 
loss, and ultimately cognitive decline (Hardy and Selkoe, 2002). Aβ is produced by the 
proteolytic processing of the amyloid precursor protein (APP) via the proteases β- and γ-
secretase, and is subsequently secreted into the extracellular space (De Strooper, 2010). 
Familial mutations in APP, presenilin 1 (PSEN1), and presenilin 2 (PSEN2) cause the 
rare early-onset form of AD primarily through altering the production of Aβ (Hardy, 
2006). However, Aβ production does not appear to be altered in the more common late-
onset form of AD (Holtzman et al., 2011; Selkoe, 2001). In fact, a recent study suggests 
that Aβ clearance from the central nervous system, and not production, may be impaired 
in individuals with late-onset AD (Mawuenyega et al., 2010). Therefore, better 
characterization of the mechanisms underlying Aβ elimination from the brain may lead to 
insights into the pathogenesis of the disease and reveal unique therapeutic targets.  
Several clearance pathways for Aβ likely exist in the central nervous system, 
including cellular uptake and lysosomal degradation, transport across the blood-brain 
barrier, extracellular degradation by proteolytic enzymes, and bulk flow drainage of 
interstitial fluid and CSF. Aβ clearance via the blood-brain barrier and degradation by 
extracellular enzymes has been extensively studied (Selkoe, 2001; Tanzi et al., 2004; 
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Zlokovic, 2008). However, the mechanisms regulating the process of cellular uptake and 
degradation of Aβ are less characterized. Current evidence suggests that astrocytes are 
one of the main cell-types in the brain that play a central role in the clearance of Aβ. 
Astrocytes localize around Aβ plaques in AD brains (Itagaki et al., 1989; Mandybur and 
Chuirazzi, 1990; Pike et al., 1995), and have been shown to exhibit intracellular Aβ 
immunoreactivity in histological studies (Funato et al., 1998; Nagele et al., 2003; Thal et 
al., 1999; Thal et al., 2000). Cell-based assays have shown that cultured astrocytes take 
up and degrade soluble Aβ and enhance the clearance of fibrillar Aβ from ex vivo brain 
slices (Koistinaho et al., 2004; Nielsen et al., 2009; Shaffer et al., 1995; Wyss-Coray et 
al., 2003). However, the receptors mediating Aβ uptake into astrocytes are currently 
unknown. 
An isoform of apolipoprotein E (apoE4) is currently the strongest known genetic 
risk factor for AD. ApoE is a ligand that facilitates the receptor-mediated endocytosis of 
lipoprotein particles into cells (Mahley, 1988).  ApoE is hypothesized to play a central 
role in AD pathogenesis in large part through the regulation of Aβ deposition and 
clearance (Kim et al., 2009a; Verghese et al., 2011). Murine studies have shown that the 
amount of apoE in the brain dramatically affects the extent of Aβ deposition, as deletion 
of apoE in APP transgenic mouse models significantly decreased brain amyloid levels 
(Bales et al., 1999; Bales et al., 1997). Therefore, targeting proteins in the brain that 
modulate apoE levels represents an attractive pathway for decreasing amyloid deposition. 
The low-density lipoprotein receptor (LDLR) family of receptors is a group of proteins 
sharing similar structural characteristics that exhibit various important endocytic and 
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signaling functions. Members of this family include LDLR, lipoprotein receptor related-
protein 1 (LRP1), very-low density lipoprotein receptor (VLDLR), apolipoprotein E 
receptor 2 (ApoER2), and megalin (LRP2) (Herz and Bock, 2002). LDLR plays a key 
role in cholesterol metabolism in the periphery through facilitating the removal of 
cholesterol-containing lipoprotein particles from the circulation (Brown and Goldstein, 
1986). The uptake of lipoprotein particles occurs through the binding of apolipoprotein 
B-100 (apoB-100) or apoE to LDLR and subsequent clathrin-mediated endocytosis. In 
the central nervous system, the function of LDLR is less well-characterized. Recently, we 
have shown that increasing LDLR levels in the brain significantly decreased apoE levels 
and markedly inhibited amyloid deposition in the APPswe/PSEN1ΔE9 (APP/PS1) 
transgenic mouse model (Kim et al., 2009b). Using in-vivo microdialysis, we also 
observed that LDLR overexpression decreased steady-state interstitial fluid Aβ levels and 
enhanced the clearance of Aβ from the brain extracellular space (Kim et al., 2009b). 
These findings clearly demonstrated that LDLR is capable of regulating brain Aβ levels. 
However, the possibility that LDLR-mediated endocytosis represents a pathway for the 
cellular regulation of Aβ levels has yet to be analyzed. 
In the first part of this thesis work, we investigated how altering LDLR levels in 
primary astrocytes affects Aβ uptake and degradation. We provide evidence that both 
LDLR overexpression and deletion alters soluble Aβ uptake. We demonstrate that 
increasing levels of LDLR facilitates Aβ transport to lysosomes and enhances Aβ 
intracellular degradation. We also show that LDLR can modulate cellular Aβ uptake and 
clearance through a pathway that does not require the presence of apoE. Finally, we 
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provide evidence that Aβ directly binds to LDLR. The findings from this study identify a 
specific receptor-mediated pathway for the uptake and clearance of Aβ by astrocytes, and 
suggest that enhancing LDLR levels in glial cells represents a potential approach to 
lowering Aβ levels in the brain. 
 
Experimental Procedures 
Reagents - Aβ(1-40), Aβ(1-42), and Aβ(40-1) were purchased from American Peptide 
Company (Sunnyvale, CA). HiLyte Fluor 488-labeled Aβ42, TAMRA-labeled Aβ42, and 
Dutch/Iowa Aβ40 were purchased from Anaspec (Fremont, CA). Aβ peptides were 
reconstituted in dimethylsulfoxide (DMSO) at a concentration of 200 μM and stored at  
-80°C prior to use. I
125
-Aβ(1-40) was purchased from PerkinElmer Life Sciences 
(Waltham, MA), reconstituted at a concentration of 22.7 nM in DMSO, and stored at -
20°C prior to use. Recombinant mouse LDLR protein (extracellular domain, amino acids 
1-790) was purchased from Sino Biological Inc. (Cat. # 50305-M08H, Beijing, China), 
reconstituted in water at a concentration of 500 μg/mL, and dialyzed in PBS overnight at 
4°C. The dialyzed peptide was then stored at -80°C prior to use. Lysotracker probe and 
DiI-LDL were purchased from Invitrogen. Recombinant RAP protein was purchased 
from EMD Biosciences (Cat# 553506). Recombinant mouse PCSK9 protein was 
purchased from Sino Biological Inc. (Cat. #50251-M08H, Beijing, China), reconstituted 
in water at a concentration of 500μg/mL, and stored at -80°C prior to use. 
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Primary cultures - The generation and characterization of the LDLR Tg mice were 
described previously (Kim et al., 2009b).  LDLR
-/-
 mice were purchased from Jackson 
Laboratory (Catalog # 002207, Bar Harbor, ME). For all experiments, wild type (Wt) 
littermates were used as controls. All experimental protocols were approved by the 
Animal Studies Committee at Washington University in St. Louis. Cortical primary 
murine astrocytes were cultured from postnatal day 2 (P2) mouse pups.  Cortices were 
dissected from the brain and placed in Hanks balanced salt solution (HBSS).  The brain 
tissue was then washed with HBSS and treated with 0.05% trypsin/EDTA for 15 min at 
37°C.  Following trypsin digestion, the tissue was resuspended and triturated using fire-
polished pipets in growth media containing DME/F12, 20% fetal bovine serum (FBS), 10 
ng/ml epidermal growth factor, 100 units/ml penicillin/streptomycin, and 1 mM sodium 
pyruvate.  The cell suspension was then passed through a 100-μm nylon filter and plated 
into T75 flasks coated with poly-D-lysine.  The media of the mixed glial cultures was 
changed after six days, and every three days following the initial change.  Once the cells 
reached confluency, they were shaken at 250 rpm for three hours and the media was 
aspirated to remove the less adherent microglial cells.  The astrocyte-enriched cultures 
were then washed with PBS, detached from the plate using 0.05% trypsin/EDTA and 
passaged into 6, 12, or 24 well plates for experiments.   
 
Measurement of apoE levels by ELISA - Primary astrocytes were plated into 12 well 
plates and grown to confluency. The cell monolayers were then washed twice with serum 
free media (SFM) (DME/F12, N-2 growth supplement, 100 units/ml 
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penicillin/streptomycin, and 1 mM sodium pyruvate) and 500 μL of fresh SFM was 
added. The cells were then incubated at 37°C for 3, 8, or 24 hrs. Following incubation, 
the media was removed and protease inhibitor was added to the media (Complete 
protease inhibitor cocktail, Roche, USA). The cells were washed three times in PBS and 
lysed in 1% Triton X-100 lysis buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris-
HCl, and Complete protease inhibitor cocktail). The lysate was then cleared by 
centrifugation at 14,000 rpm and total protein content measured by BCA assay. The apoE 
level in the media was quantified using a sandwich ELISA for apoE. Mouse monoclonal 
antibody HJ6.2 was used as the capture antibody and mouse monoclonal antibody HJ6.3-
biotin was used as the detection antibody (both antibodies were produced in-house with 
full length astrocyte-derived mouse apoE-containing lipoproteins as the antigen). Pooled 
C57BL/6J plasma set at a concentration of 329 μg/mL was used as the standard for 
ELISA. 96 well microtiter plates were coated overnight at 4°C with HJ6.2 antibody (5 
μg/mL). All washes were performed 5 times/well using a standard microplate washer. 
Coated plates were washed and blocked for 1 hr at 37°C in 1% milk in PBS. The plates 
were then washed again and samples and standards were loaded in 0.5% bovine serum 
albumin in PBS-0.025% Tween 20 and incubated overnight at 4°C. Then, plates were 
washed and incubated with HJ6.3-biotin antibody at a concentration of 400 ng/mL in 
0.5% bovine serum albumin/PBS-0.025% Tween 20 at 37°C for 90 minutes. Plates were 
washed and horseradish-peroxidase conjugated streptavidin at a 1:5000 dilution was 
incubated for 90 min at room temperature. Plates were washed, tetramethylbenzidine 
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substrate was added, and the absorbance was measured at 650 nm. All apoE values were 
normalized to total cell protein levels. 
 
Aβ uptake and clearance assays - Primary astrocytes were plated into either 12 or 24 
well plates and grown to confluency. To measure Aβ uptake, the cells were first washed 
twice with SFM, and fresh SFM was added to the cells. Soluble Aβ(1-40) or Aβ(1-42) 
was then added to the media at a concentration of 2 μg/mL and the cells were incubated 
at 37°C for 3 hrs. The media was then removed and the cells washed twice with PBS. To 
remove cell surface-bound Aβ, the cells were incubated with 0.05% trypsin/EDTA for 20 
minutes. The cells were then pelleted by centrifugation and the pellet washed twice with 
PBS. Following centrifugation, 1% Triton X-100 lysis buffer (1% Triton X-100, 150 mM 
NaCl, 50 mM Tris-HCl, and Complete protease inhibitor cocktail) was added to the cell 
pellet and the cells were incubated at 4°C for 30 min. The cell lysates were then cleared 
by centrifugation at 14,000 rpm. For the clearance assays, the cells were first washed 
twice with SFM and fresh SFM was added to the cells. Soluble Aβ(1-40) or Aβ(1-42) 
was then added to the media at a concentration of 2 μg/mL and the cells were incubated 
at 37°C for 24 hrs. A control group was also included in which the Aβ was added directly 
to fresh SFM in order to calculate how much Aβ was initially added to the cells (0 hr 
time point). The media was then collected from the cells and Complete protease inhibitor 
(Roche) was added to the media. The cell monolayer was then washed twice with PBS 
and 1% Triton X-100 lysis buffer was added to the cells and they were incubated at 4°C 
for 30 min. The cell lysates were then cleared by centrifugation at 14,000 rpm. Protein 
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content was measured in all cell lysates using a BCA protein assay (Thermo Scientific). 
Aβ(x-40) and Aβ(x-42) specific sandwich ELISA’s developed in our lab were used to 
quantify Aβ40 and Aβ42 levels, respectively, in the lysate or media. For the Aβ(x-40) 
assay, HJ2 (anti-Aβ35-40) was used as the capture antibody and HJ5.1-biotin (anti-Aβ13-
28) as the detection antibody. For the Aβ(x-42) assay, HJ7.4 (anti-Aβ37-42) was used as 
the capture antibody and HJ5.1-biotin (anti-Aβ13-28) as the detection antibody. 
 
I
125
-Aβ degradation assays - Primary astrocytes were plated into 12 well plates and 
grown to confluency. The cells were then washed twice with SFM and 0.25 nM of I
125
-
Aβ(1-40) was added to the cells in 500 μL of SFM. The cells were then incubated for 3, 
8, or 24 hrs at 37°C. The media was then collected and the cells washed three times in 
PBS. The cells were then lysed in the plate by the addition of radioimmunoprecipitation 
assay (RIPA) buffer (1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 25 mM Tris-HCl, 
150 mM NaCl) (Cat. # 89901, Thermo Scientific) and the lysate cleared by centrifugation 
at 14,000 rpm. Total protein content was measured by BCA assay. The media was then 
subjected to a trichloroacetic acid (TCA) precipitation. 50 mg/mL of BSA and 2% 
deoxycholate was added to the media and the tubes were vortexed and then incubated on 
ice for 30 minutes. TCA (20% of final volume) was added to the tubes and following a 
quick vortex, and the tubes were incubated on ice for 1 hr. All tubes were then spun down 
at 14,000 rpm for 30 minutes. CPM in both the supernatant and pellet were measured by 
a gamma counter. To measure Aβ degradation by astrocyte-conditioned media (ACM), 
primary astrocytes were plated into 12 well plates and grown to confluency. The cells 
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were then washed twice with SFM and fresh SFM was added to the cells. The cells were 
then incubated for 3, 8, or 24 hrs at 37°C. The media was then collected, and I
125
-Aβ(1-
40) was added to the ACM for 3, 8, or 24 hrs at 37°C. A TCA acid precipitation was then 
performed on the media as explained above. The cells from which the media was 
originally collected were also lysed as above, and total protein content measured with a 
BCA protein assay. 
 
Fluorescent Aβ uptake and colocalization analysis - Primary astrocytes were plated 
into 35 mm μ-dish chambers. For DiI-LDL imaging experiments, the cells were washed 
twice with SFM and HiLyte Fluor 488-labeled Aβ42 (3 μg/mL) was added to the cells in 
SFM. The cells were then incubated at 37°C for 3 hrs prior to imaging. One hour prior to 
imaging, DiI-LDL was added to the cells (0.5 μg/mL). The cells were then washed twice 
with SFM, and fresh SFM medium was added for imaging. For the lysotracker 
experiments, TAMRA-labeled Aβ42 (2 μg/mL) was added to the cells in SFM and the 
cells were incubated at 37°C for 3 hrs prior to imaging. Fresh SFM was then added to the 
cells with 50 nM of the lysotracker probe and the cells were incubated for another 15 min 
at 37°C. Fresh SFM was then added to the cells prior to imaging. The cells were imaged 
using a Zeiss LSM5 Pascal system coupled to an Axiovert 200M microscope equipped 
with an argon 488 and He/Ne 543 laser. For the colocalization studies, the Zeiss AIM 
software was used. Threshold quadrants were set using cells incubated only with either 
TAMRA-labeled Aβ42 or lysotracker. Colocalization coefficients were calculated by 
summing the pixels in the colocalized quadrant and then dividing by the sum of pixels in 
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the colocalized and non-colocalized quadrant. 2-3 cells were quantified in 5-6 regions of 
each dish for the statistical analysis. 
 
Construction of LDLR lentivirus and transduction of astrocytes - The LDLR cDNA 
was subcloned from the pcDNA3.1 vector used to make the LDLR Tg mouse (Kim et al., 
2009b) into the FCIV (FM5) lentiviral vector (generous gift of Dr. Jeffrey Milbrandt lab, 
Washington University). This vector uses the ubiquitin promoter to express the gene of 
interest and also expresses the Venus protein via an internal ribosome entry site. Using 
PCR, the LDLR cDNA was amplified from the pcDNA3.1 vector with primers 
containing the AgeI and AscI restriction sites (forward primer 5’-ACTGGTACCGGTG 
CCACCATGAGCACCGCGGATC-3’ and reverse primer 5’GTACCAGGCGCGCC 
TCATGCCACATCGTCCTCCAGG-3’). Following digestion of both the LDLR PCR 
product and FCIV with AgeI and AscI, LDLR was ligated into the FCIV vector. The 
sequence and orientation of the insert was verified by complete sequencing. Lentivirus 
(FCIV-LDLR and FCIV) was produced and the titer calculated as described previously 
(Li et al., 2010). Prior to transduction, primary astrocytes were plated in 24 well plates 
and grown to 60% confluency. Lentivirus was then added to the cells (multiplicity of 
infection of 1.5) and they were incubated at 37°C for 48 hrs. Fresh medium was then 
added to the cells and they were cultured for 24 hrs. A second dose of lentivirus was then 
added to the cells (MOI of 0.75) and they were incubated at 37°C for 24 hrs. Fresh 
medium was then added and the cells were cultured for 8 to 10 days prior to performing 
experimental assays, changing the medium every two to three days. Lentivirus 
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transduction was confirmed by both Venus expression and immunoblot for hemagglutinin 
(HA) and LDLR (see below). 
 
Immunoblots - Primary astrocytes were lysed in either RIPA buffer (1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS, 25 mM Tris-HCl, 150 mM NaCl) to measure LDLR, 
apoE, LRP1, and RAP levels or 1% Triton X-100 lysis buffer to measure Aβ levels. The 
lysates were spun down at 14,000 rpm for 20 minutes and the supernatant was collected. 
Protein concentration was determined by bicinchoninic acid (BCA) protein assay. Equal 
amounts of protein for each sample were run on 4-12% Bis-Tris XT gels for apoE, 
LDLR, LRP1, and RAP and 16.5% Tris-Tricine gels for Aβ (Bio-Rad), and transferred to 
polyvinylidene fluoride (PVDF) membranes (0.45 µm pore size) and nitrocellulose 
membranes (0.2 µm pore size), respectively. Prior to blocking, the Aβ membranes were 
boiled for 10 minutes in PBS. All membranes were then blocked in 5% milk in TBS-T 
(tris-buffered saline with 0.125% Tween-20). Blots were probed for LDLR (Novus 
Cat#NB110-57162 and MBL Cat#JM3839-100), HA (Covance), Aβ (82E1, IBL 
International), apoE (Calbiochem), LRP1 (generous gift of Dr. Guojun Bu, Mayo Clinic, 
Jacksonville, FA), RAP (R&D Systems Cat # AF4480), actin (Sigma), and tubulin 
(Sigma). Protein signal from the membranes was measured using a Lumigen TMA-6 
ECL detection kit (Lumigen, USA) and quantified using ImageJ software (NIH). 
 
Coimmunoprecipitation of Aβ and LDLR - His-tag purified recombinant LDLR (5 
μg/mL, extracellular domain) was incubated with Aβ40 (400 nM) for 4 hrs at 37°C in 
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binding buffer (50 mM NaCl, 50 mM Tris-HCl, 2 mM CaCl2, pH = 7.4). For the 
competition experiments, LDLR was pre-incubated with either RAP, PCSK9 or Aβ(40-1) 
for 2 hrs at room temperature in binding buffer. For the immunoprecipitation, the LDLR-
Aβ samples were diluted 1:1 in binding buffer with 0.1% Triton X-100. 50 μL of anti-His 
microbeads (Miltenyi Biotec Cat. # 130-091-124, Auburn, CA) were then added to each 
sample followed by a 30 min incubation with rotation at 4°C. The samples were then 
applied to μ-columns (Miltenyi Biotec, Cat. # 130-042-701) and the beads were washed 5 
times with wash buffer (binding buffer with 1% Triton X-100 and 0.25% sodium 
deoxycholate)  and once with binding buffer. Pre-heated elution buffer was then applied 
to the columns and the eluate was collected and analyzed by SDS-PAGE (16.5% Tris-
tricine). LDLR was detected using an anti-His antibody (Santa Cruz, Cat. # sc-8036HRP) 
and Aβ was detected using the 82E1 antibody (IBL International). 
 
Surface plasmon resonance (SPR) - Sensor chips were purchased from GE-BIAcore 
(USA). All SPR experiments were carried out on a BIAcore 2000 instrument at 25°C. 
Lyophilized Aβ(1-40) and Aβ(1-42) peptides were resuspended in trifluoroacetic acid 
and incubated at room temperature for 15 minutes. The peptides were then dried under 
nitrogen gas and resuspended in hexafluoroisopropanol (HFIP). The HFIP was then dried 
under nitrogen gas, and the peptides were resuspended in HFIP and aliquoted into 
separate tubes. The HFIP was then dried again under nitrogen gas. The dry Aβ film was 
then stored at -80°C. Prior to use, the Aβ film was dissolved in DMSO. Aβ(1-40) and 
Aβ(1-42) were immobilized onto a CM5 sensor chip surface at densities of approximately 
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4-5 fmol/mm
2
 by amine coupling with sodium citrate buffer, pH 4.75 in accordance with 
the manufacturer’s instructions (BIAcore AB). One flow cell was activated and blocked 
with 1 M ethanolamine without any protein and was used as a control surface to 
normalize SPR signal from Aβ immobilized on the flow cells. Experiments were 
conducted in PBS (pH 7.4) and the analyte was injected at a flow rate of 30 μl/min. 
Dissociation followed using the same buffer for 6 min. After each run, the sensor chip 
was regenerated using 2 M guanidine-HCl, 10 mM Tris-HC1, pH 8.0 and washed with 
running buffer for 5-10 min prior to the next injection. Data analysis was performed 
using Scrubber2 (Center for Bimolecular Interaction, Utah University) and 
BIAevaluation software (GE-BIAcore), and dissociation constants were calculated using 
a single-site binding model in GraphPad Prism Software. Data are based on 3 
independent measurements using 6 different concentrations for each measurement. KD 
values are presented as mean ± S.D. 
 
Quantitative real-time PCR (qPCR) - Total RNAs were extracted from cortical 
primary astrocytes using TRIzol® Reagent (Invitrogen). RNAs were reverse transcribed 
with High Capacity cDNA Reverse Transcription kit (Applied Biosystems). qPCR was 
performed with SYBR® Advantage® qPCR Premix (Clontech) in ABI 7500 instrument 
(Applied Biosystems) using the default thermal cycling. The forward primer for ApoE 
was 5’- CTGACAGGATGCCTAGCCG -3’, and the reverse primer was 5’- CGCAGGT 
AATCCCAGAAGC -3’. U6 primer sets included in the mir-X miRNA First-Strand 
Synthesis kit (Clontech) were used to normalize qPCR signals among samples. To 
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confirm the specificity of qPCR reactions, dissociation curves were analyzed at the end of 
qPCR assays. Relative mRNA levels were calculated by comparative Ct method using 
the Applied Biosystems 7500 software. 
 
Ligand blotting - Purified LDLR extracellular domain (2 μg, Sino Biological) was 
resolved on nonreducing SDS-PAGE (3-8% Tris-acetate, sample was not boiled and no 
reducing agent was added) and the protein was then transferred to a PVDF membrane. 
The LDLR protein was then denatured/renatured in Guan-HCl. The blot was incubated in 
sequential 30 min washes at room temperature of 6 M, 3 M and 1 M Guan-HCl. The blot 
was then washed in 0.1 M Guan-HCl for 30 min at 4°C and no Guan overnight at 4°C. 
For all of the steps the Guan-HCl was diluted into the denaturing/renaturing buffer (10% 
glycerol, 100 mM NaCl, 20 mM Tris (pH 7.6), 0.5 mM EDTA, 0.1% Tween-20, and 2% 
milk). The blot was then blocked in 2.5% milk in TBS-T (tris-buffered saline with 
0.125% Tween-20). Either Aβ or recombinant apolipoprotein E3 (5 μg/mL, Leinco 
Technologies, St. Louis, MO) was then incubated with the blot for 3 hr at room 
temperature in TBS (50 mM Tris-HCl, 150 mM NaCl, pH=7.5), followed by three 10 
minute washes in TBS-T. Immunoblotting for either Aβ, apoE, or the His tag was then 
performed. 
 
Statistics - All data are presented as mean ±standard error of the mean (SEM) unless 
otherwise noted. Statistical significance (*p<0.05, **p<0.01, ***p<0.001) was 
determined using GraphPad Prism Software. For the comparison of two means with one 
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independent variable (genotype), a two-tailed student’s t-test was used. For the 
comparison of multiple means with one independent variable (genotype), a one-way 
ANOVA followed by a Tukey's post-test was used. For the comparison of multiple 
means with two independent variables (genotype and time, genotype and lentivirus 
transduction), a two-way ANOVA followed by a Bonferroni post-test was used. 
 
Results 
LDLR overexpression in primary astrocytes increases Aβ uptake and clearance.  To 
determine whether LDLR mediates the uptake and clearance of Aβ by astrocytes, we first 
cultured primary astrocytes from the cortices of transgenic (Tg) mice that overexpress 
mouse LDLR under control of the mouse prion promoter (Kim et al., 2009b). The LDLR 
transgene in these mice contains an HA tag to facilitate detection of LDLR protein levels. 
Immunoblots were performed to measure the amount of LDLR overexpression in these 
cells. Consistent with our previous study, LDLR Tg astrocytes expressed about 8-fold 
higher LDLR levels than wildtype (Wt) cells (Fig. 2.1A). In order to assess the functional 
effect of increasing LDLR levels in astrocytes, we measured the extra- and intracellular 
levels of apoE. Astrocytes endogenously secrete lipoprotein particles with discoidal HDL 
structure and size that contain apoE (Fagan et al., 1999). Since LDLR overexpression 
dramatically decreased apoE levels in brain tissue (Kim et al., 2009b), we hypothesized 
that increasing LDLR levels in astrocytes would promote apoE uptake and consequently 
lead to decreased apoE levels outside of the cells. Wt and LDLR Tg primary astrocytes 
were cultured in serum-free conditions and the amount of apoE in the media was 
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measured at several time points. Serum-free conditions were used so that the majority of 
the lipoproteins present in the media were produced by astrocytes. The medium from 
LDLR Tg astrocytes had significantly decreased apoE levels at all time points measured, 
with a maximum 80% decrease observed after 24 hrs (Fig. 2.1B). The amount of 
intracellular apoE was also measured after 24 hrs by immunoblot, and LDLR Tg cells 
had increased levels of apoE in comparison to Wt cells (Fig. 2.1C). To confirm that the 
changes in apoE distribution in the LDLR Tg cells were due to an alteration in uptake rather than 
apoE production, apoE mRNA levels were measured by quantitative PCR. No differences were 
observed between Wt and LDLR Tg cells (Fig. 2.2). Therefore, the decrease in extracellular apoE 
levels and increase in intracellular apoE levels in LDLR-overexpressing astrocytes is likely due to 
enhanced uptake of apoE-containing lipoprotein particles.  
Previous studies have shown that cultured astrocytes are capable of taking up and 
clearing soluble Aβ from the media (Nielsen et al., 2009; Shaffer et al., 1995; Wyss-
Coray et al., 2003). Given the dramatic effect that LDLR overexpression has on lowering 
Aβ levels in the brain (Kim et al., 2009b), we hypothesized that increasing LDLR levels 
in astrocytes would enhance Aβ uptake and clearance. Aβ uptake was assessed by the 
addition of soluble Aβ40 (2 μg/mL) or Aβ42 (2 μg/mL) to the media of Wt and LDLR Tg 
astrocytes for 3 hrs at 37°C. Trypsin was added to the cells to remove Aβ bound to the 
extracellular cell surface and the amount of cell-internalized Aβ was measured by 
ELISA. LDLR overexpression enhanced the amount of intracellular Aβ40 and Aβ42 by  
3.1 fold and 2.2 fold, respectively (Fig. 2.3A,B). The differences in intracellular Aβ 
levels were also confirmed by immunoblot (Fig. 2.3C). These results suggest that  
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Fig. 2.1. Increased LDLR levels alter the extracellular and intracellular levels 
of apoE in primary astrocytes.  Primary astrocytes were cultured from the 
cortices of both Wt and LDLR transgenic mice. (A) LDLR and HA levels in the 
cells were measured by immunoblot. Unglycosylated LDLR migrates at 90 kDa 
and several glycosylated species of the protein migrate between 100 kDa and 150 
kDa. Representative images are shown. (B) The functional effect of increased 
LDLR levels on apoE uptake was assessed by measuring the levels of 
endogenously produced apoE in the culture media. Primary astrocytes were 
incubated for the indicated time points in serum-free media and the amount of 
apoE in the media was measured by ELISA. Mean ± SEM (n=4) * denotes 
p<0.05, ** denotes p<0.01, *** denotes p<0.001. (C) The amount of cell-
associated apoE was also measured by immunoblot of the cell lysates obtained 
after a 24 hr incubation. Representative image is shown. 
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Fig. 2.2. Effect of LDLR levels on apoE mRNA amount in astrocytes.  
Primary astrocytes were cultured from the cortices of Wt, LDLR
-/-
, and LDLR Tg 
mice. ApoE mRNA levels were then assessed by qPCR, and the values were 
normalized to U6 snRNA values. Mean ± SEM (n≥4) *** denotes p<0.001. 
 
increasing LDLR levels enhances Aβ uptake into primary astrocytes. To measure the 
effect of increasing LDLR levels on Aβ clearance from the media, soluble Aβ40 (2 
μg/mL) or Aβ42 (2 μg/mL) was added to the media of Wt and LDLR Tg astrocytes for 24 
hrs at 37°C. The amount of Aβ remaining in the medium was then measured by ELISA. 
After 24 hrs, 71% of Aβ40 remained in the medium of Wt astrocytes while only 30% of 
Aβ40 remained in the medium of LDLR Tg cells (Fig. 2.3D). For Aβ42, 43% remained 
in the medium of Wt astrocytes while only 17% remained in the medium of LDLR Tg 
cells after 24 hrs (Fig. 2.3E). Therefore, the amount of Aβ remaining in the medium after 
24 hrs was less for LDLR Tg cells in comparison to Wt cells, with a decrease of 58% for 
Aβ40 and a decrease of 61% for Aβ42.  
LRP1, another member of the LDL receptor family, has also been shown to 
promote the internalization of Aβ into neuronal cells (Kanekiyo et al., 2011). To 
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determine whether increasing LDLR levels alters LRP1 levels, the amount of LRP1 in Wt 
and LDLR Tg astrocytes was analyzed by immunoblot (Fig. 2.4A). LRP1 levels were 
decreased in LDLR overexpressing astrocytes, suggesting that the increase in Aβ uptake 
and clearance in these cells is not due to increased LRP1 levels. The levels of receptor-
associated protein (RAP), a chaperone for the LDL receptors, were also measured in 
LDLR Tg and Wt astrocytes (Fig. 2.4B). RAP has been shown to bind to Aβ and regulate 
its uptake into cells (Kanekiyo and Bu, 2009). LDLR overexpression did not significantly 
change RAP levels in astrocytes. In summary, these results demonstrate that increasing 
LDLR levels in primary astrocytes enhanced both the uptake and clearance of soluble Aβ. 
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Fig. 2.3. LDLR overexpression enhances the uptake and clearance of Aβ by 
primary astrocytes. Primary astrocytes from either Wt or LDLR transgenic mice 
were incubated with soluble (A) Aβ40 or (B) Aβ42 (2 μg/mL) for 3 hrs at 37°C. 
The cells were then washed with PBS, incubated with trypsin to remove cell-
surface bound Aβ, and lysed in Triton X-100 lysis buffer. The cell-internalized 
Aβ was then assessed by ELISA. Mean ± SEM (n≥4) *** denotes p<0.001. (C) 
Immunoblot analysis for Aβ was also performed on the cell lysates. 
Representative images are shown. Aβ clearance was assessed by the addition of 
either (D) Aβ40 or (E) Aβ42 (2 μg/mL) to the medium of primary astrocytes. 
After 24 hrs, the levels of Aβ remaining in the medium along with the starting 
amount of Aβ were measured by ELISA. Mean ± SEM (n≥4) * denotes p<0.05, 
*** denotes p<0.001, n.s. not significant. 
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Fig. 2.4. Effect of LDLR levels on the amount of LRP1 and RAP in 
astrocytes.  Primary astrocytes were cultured from the cortices of Wt, LDLR
-/-
, 
and LDLR Tg mice. (A) LRP1 levels and (B) RAP levels were measured by 
immunoblot and normalized to either actin or tubulin levels, respectively. Mean ± 
SEM (n≥4) *** denotes p<0.001, n.s. not significant. 
  
Increasing LDLR levels in primary astrocytes promotes the cellular degradation of 
Aβ. In order to verify that the increased Aβ uptake by LDLR-overexpressing astrocytes 
resulted in enhanced degradation of the peptide, we directly assessed Aβ degradation 
using I
125
-Aβ(1-40). I125-Aβ(1-40) was incubated with Wt and LDLR Tg cells at 37°C for 
several time points and a TCA precipitation was then performed on the cell media. In this 
assay, degraded Aβ peptide is not precipitated and therefore cannot be efficiently pelleted 
with centrifugation. The amount of Aβ that has been degraded can be directly quantified 
by measuring the radioactive counts in the supernatant following centrifugation (Fig. 
2.5A).  We observed that LDLR Tg cells degraded significantly more Aβ than Wt cells at 
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all time points analyzed. The amount of intact Aβ measured from the LDLR Tg cells was 
also lower for all time points (Fig. 2.5B). After 24 hrs of incubation, LDLR Tg cells 
degraded 80% of the Aβ while Wt cells degraded 53% of the Aβ that was initially added 
(Fig. 2.5C). These results demonstrate that LDLR overexpression enhances Aβ 
degradation by primary astrocytes. 
  Previously it has been shown that astrocytes secrete proteases that are capable of 
degrading Aβ, including insulin degrading enzyme (IDE) and matrix metalloproteinase 
(Jiang et al., 2008; Yin et al., 2006). Therefore, to determine whether the effect of LDLR 
on Aβ degradation is due to intracellular or extracellular degradation we analyzed the 
ability of astrocyte-conditioned medium from Wt and LDLR Tg astrocytes to degrade Aβ 
in the absence of cells. Medium from Wt and LDLR Tg primary astrocytes was collected 
and then incubated with I
125
-Aβ for the indicated time points. Aβ degradation was then 
assessed by TCA precipitation. Medium from both Wt and LDLR Tg astrocytes was 
capable of degrading Aβ, but to a lesser extent than when cells were present (compare 
Fig. 2.5B and 2.5D). After 8 hrs, medium from the LDLR Tg astrocytes degraded 
significantly more Aβ than the medium from the Wt cells. After 24 hrs, we observed that 
medium from LDLR Tg astrocytes degraded significantly less Aβ than the Wt media 
(Fig. 2.5E). Taken together, the difference in the effect of LDLR on Aβ degradation with 
and without cells after 24 hrs indicates that LDLR is capable of promoting cellular Aβ 
degradation. 
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Fig. 2.5. LDLR overexpression increases the cellular degradation of Aβ by 
primary astrocytes. (A) Schematic diagram of the experiments used to measure 
degradation of I
125
-Aβ by primary astrocytes. I125-Aβ was added to primary 
astrocytes from either Wt or LDLR Tg mice for the indicated time points. After 
each time point, the medium was collected and a TCA precipitation was 
performed to detect degraded Aβ. (B) The supernatant (sup) and pellet CPM are 
plotted as a function of time. Representative data from one experiment is shown. 
Experiment was repeated three times with similar results. (C) Degraded Aβ was 
quantified by calculating the percent of Aβ degraded as a percent of the total 
intact Aβ added. Mean ± SEM * denotes p<0.05, ** denotes p<0.01. (D) To 
measure the ability of astrocyte-conditioned media to degrade Aβ, medium was 
collected from either Wt or LDLR Tg primary astrocytes. I
125
-Aβ was then added 
to the astrocyte-conditioned media for the indicated time points and a TCA acid 
precipitation was performed. The supernatant (sup) and pellet CPM are plotted as 
a function of time. Representative data from one experiment is shown. 
Experiment was repeated two times with similar results. (E) Degraded Aβ was 
quantified by calculating the percent of Aβ degraded as a percent of the total 
intact Aβ added. Mean ± SEM * denotes p<0.05, n.s. not significant. 
 
 
LDLR facilitates the vesicular trafficking of Aβ to lysosomes. In order to determine 
whether LDLR promotes the vesicular uptake of Aβ, we incubated primary astrocytes 
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with fluorescently-labeled Aβ42 (fAβ42) and DiI-LDL. LDL is internalized by receptor-
mediated endocytosis through LDLR, and thus serves as an endocytic marker (Dunn and 
Maxfield, 1992; Goldstein et al., 1985). Wt and LDLR Tg primary astrocytes were 
incubated with fAβ42 and DiI-LDL for 3 hrs at 37°C. Microscopic visualization 
demonstrated a punctate pattern for both the DiI-LDL and Aβ42, demonstrating the 
uptake of both molecules into vesicular compartments. Notably, we observed that there 
was more DiI-LDL and Aβ42 endocytosed by the LDLR Tg cells (Fig. 2.6A). There was 
also considerable overlap between the DiI-LDL and Aβ42 signal in the LDLR Tg cells, 
demonstrating that LDLR overexpression increased the amount of Aβ in endocytic 
vesicles. To determine the intracellular fate of the internalized Aβ, we incubated primary 
astrocytes with fAβ42 for 3 hrs at 37°C and then added lysotracker to stain the lysosomes 
 (Fig. 2.6B). LDLR Tg astrocytes displayed significantly increased colocalization of Aβ 
with the lysosome signal in comparison to Wt cells, with 30% of the Aβ signal 
colocalized in the LDLR Tg cells and only 12% colocalized in the Wt cells (Fig. 2.6C). 
Therefore, increasing the LDLR levels in astrocytes enhanced the endocytic transport of 
Aβ to lysosomes. 
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Fig. 2.6. LDLR facilitates Aβ trafficking to lysosomes through a similar 
pathway as lipoprotein particles. (A) To demonstrate that increasing LDLR 
levels promotes the transport of Aβ in similar vesicles as lipoprotein particles, Wt 
and LDLR Tg primary astrocytes were incubated with fluorescent Aβ42 (3 
μg/mL) and DiI-LDL (0.5 ug/mL) for 3 hrs at 37°C. The cells were then washed 
and imaged using confocal microscopy. Overlap of Aβ and the DiI-LDL signal 
was observed in the LDLR Tg cells. (B) To observe Aβ uptake into lysosomal 
compartments, Wt and LDLR Tg primary astrocytes were incubated with 
fluorescent Aβ42 (2 μg/mL) for 3 hrs at 37°C. The cells were then washed and 50 
nM of lysotracker was added to the cells for 15 minutes. The cells were then 
washed again and imaged using confocal microscopy. (C) Colocalization of the 
Aβ and lysotracker signal was analyzed and quantified. Mean ± SEM *** denotes 
p<0.001. 
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Fig. 2.7. Comparison of LDLR levels in Wt and LDLR
-/- 
primary astrocytes. 
(A) Primary astrocytes were cultured from the cortices of Wt and LDLR
-/-
 mice. 
After reaching confluency, the cells were lysed in a 1% Triton X-100 lysis buffer. 
The lysates were then analyzed by SDS-PAGE and probed using an LDLR 
antibody. (B) LDLR was expressed in LDLR
-/-
 astrocytes via lentiviral 
transduction. LDLR expression was confirmed by immunoblot for HA. 
 
LDLR deletion decreases the uptake and clearance of Aβ by primary astrocytes. To 
further determine the role of LDLR in the cellular metabolism of Aβ, we analyzed 
whether endogenous LDLR levels in primary astrocytes participate in Aβ uptake and 
clearance. Primary astrocytes were cultured from the cortices of Wt and LDLR
-/-
 mice. 
Immunoblot analysis of the cell lysates confirmed that the LDLR protein was not 
expressed in LDLR
-/-
 astrocytes (Fig. 2.7). Previous studies have shown that LDLR 
deletion significantly increased apoE levels in the mouse brain, likely due to impaired 
uptake and clearance of apoE-containing lipoprotein particles (Cao et al., 2006; Fryer et 
al., 2005a). To determine whether LDLR deletion affects apoE uptake and clearance by  
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astrocytes, Wt and LDLR
-/-
 primary astrocytes were cultured in serum-free conditions 
and the amount of endogenously-produced apoE in the medium was measured after 
several time points. The cell medium from LDLR
-/-
 cells had significantly increased apoE 
levels at all time points measured, with a maximum 77% increase observed after 8 hrs 
and a 62% increase observed after 24 hrs (Fig. 2.8A). The amount of apoE in the cell 
lysates was also measured by immunoblot after 24 hrs. LDLR
-/-
 astrocytes had decreased 
apoE levels in comparison to Wt cells (Fig. 2.8B). 
Because we could not rule out that the changes in apoE levels in the media and 
cell lysate were due to changes in protein expression, we measured the amount of apoE 
mRNA in LDLR
-/-
 and Wt cells. LDLR
-/-
 astrocytes had elevated apoE mRNA amounts 
in comparison to Wt cells (Fig. 2.2). It is possible that increased apoE production could 
play a role in the elevation of apoE levels in the LDLR
-/-
 astrocyte media. However, the 
known role of LDLR in the uptake of lipoproteins combined with the observation that the 
LDLR
-/-
 astrocytes contained less intracellular apoE than Wt cells suggest the increase in 
media apoE levels in LDLR
-/-
 cells is primarily due to decreased uptake. 
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Fig. 2.8. LDLR deletion alters extra- and intra-cellular apoE levels. Primary 
astrocytes were cultured from the cortices of Wt and LDLR
-/-
 mice. (A) ApoE 
uptake was assessed by measuring the levels of endogenously produced apoE in 
the culture media. Primary astrocytes were incubated for the indicated time points 
in serum-free media and the apoE amount in the media was measured by ELISA. 
Mean ± SEM (n≥4) *** denotes p<0.001. (B) The amount of cell-associated apoE 
was also measured by immunoblot of the cell lysates obtained after the 24 hr 
incubation. Quantification of the apoE band intensity normalized to tubulin 
intensity is shown below the image. 
 
 The effect of LDLR deletion on Aβ uptake was assessed by the addition of 
soluble Aβ40 (2 μg/mL) to LDLR-/- and Wt primary astrocytes for 3 hrs. Quantification 
of Aβ ELISA showed that cellular Aβ levels decreased by 43% in LDLR-/- astrocytes 
compared to Wt cells (Fig. 2.9A). The difference in internalization was qualitatively 
confirmed by immunoblot analysis of the cell lysates (Fig. 2.9B). To confirm that the 
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decrease in Aβ uptake in LDLR-/- astrocytes was due to lack of LDLR rather than a non-
specific alteration in cellular function, we increased LDLR function by transducing the 
LDLR
-/-
 astrocytes with an LDLR-expressing lentivirus. Immunoblot analysis confirmed 
that the lentiviral-transduced astrocytes expressed LDLR (Fig. 2.7B). Cell-internalized 
Aβ increased by 1.4 fold in the LDLR-lentiviral transduced cells in comparison to cells 
transduced with an empty-virus control (Fig. 2.9C). Finally, to measure the effect of 
LDLR deletion on the clearance of Aβ from the medium, soluble Aβ40 (2 μg/mL) was 
added to the media of Wt and LDLR Tg astrocytes for 24 hrs at 37°C. The amount of Aβ 
remaining in the media was then measured by ELISA. LDLR
-/-
 astrocytes cleared less Aβ 
in comparison to Wt cells, however the difference was not significant (Fig. 2.9D).  
As measured with the astrocytes that overexpress LDLR, the effect of LDLR 
deletion on LRP1 and RAP levels was assessed by immunoblot (Fig. 2.4A,B). Deletion 
of LDLR resulted in a significant decrease in LRP1 levels, but did not affect RAP levels. 
As a result, we cannot rule out the possibility that a decrease in LRP1 plays a role in the 
effect of LDLR deletion on Aβ uptake. However, the LDLR overexpression data 
convincingly demonstrates that LDLR has an effect on Aβ uptake and clearance that is 
independent of LRP1. In summary, this data demonstrates that endogenous LDLR may 
represent a pathway of Aβ uptake in primary astrocytes, though this effect may also be 
mediated by compensatory decreases in LRP1 levels. 
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Fig. 2.9. Lack of LDLR impairs Aβ uptake in astrocytes. To assess the effect 
of LDLR deletion on Aβ uptake, Wt and LDLR-/- astrocytes were incubated with 
Aβ40 (2 μg/mL) for 3 hrs. The cells were then washed with PBS, incubated with 
trypsin to remove cell surface bound Aβ, and lysed in Triton X-100 lysis buffer. 
The amount of Aβ in the cell lysate was then assessed by (A) ELISA and (B) 
immunoblot. For the immunoblot, a representative image is shown. Mean ± SEM 
(n≥4) *** denotes p<0.001. (C) To verify the effect of LDLR deletion on Aβ 
uptake, LDLR function was restored in the LDLR
-/-
 astrocytes by transduction 
with an LDLR lentivirus. Aβ uptake was then assessed as in (A) and compared to 
the level of uptake by LDLR
-/- 
cells transduced with control lentivirus and Wt 
cells. Mean ± SEM (n≥4) ** denotes p<0.01. (D) The effect of LDLR deletion on 
Aβ clearance was assessed by the addition of Aβ40 (2 μg/mL) to the media of Wt 
and LDLR
-/-
 astrocytes. After 24 hrs, the amount of Aβ remaining in the media 
was measured by ELISA and compared to the starting amount. Mean ± SEM 
(n≥4) * denotes p<0.05, n.s. not significant. 
 
LDLR effect on Aβ uptake and clearance does not require apoE. ApoE has  
previously been shown to bind to Aβ (LaDu et al., 1994; Strittmatter et al., 1993b; 
Tokuda et al., 2000), and is capable of enhancing the cellular degradation of Aβ 
byprimary astrocytes and microglia (Jiang et al., 2008; Koistinaho et al., 2004). The 
effect of LDLR on Aβ uptake and clearance may therefore depend upon LDLR 
modulation of astrocyte apoE levels, or may occur due to direct binding of an apoE-Aβ 
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complex to LDLR. To determine if the effect of LDLR on Aβ uptake is dependent upon 
the presence of apoE, we overexpressed HA tagged-LDLR in apoE
-/-
 primary astrocytes 
through lentiviral transduction. Immunoblot detection of the HA tag showed that the 
amount of LDLR overexpressed in Wt and apoE
-/-
 astrocytes was comparable (Fig. 
2.10A). To determine if the LDLR expressed by the lentivirus had a functional effect in 
the cells, extracellular apoE levels were measured in LDLR lentiviral-transduced Wt 
astrocytes. Overexpression decreased apoE levels by 92% after 24 hrs, confirming that 
the LDLR expressed via the lentivirus was functional (Fig. 2.10B). Aβ uptake was 
assessed by the addition of soluble Aβ40 (2 μg/mL) to Wt and apoE-/- primary astrocytes 
transduced with LDLR lentivirus. LDLR overexpression increased Aβ uptake in Wt cells 
and apoE
-/-
 astrocytes to a similar extent, with a 2.1 fold increase in Wt cells and a 2.4 
fold increase in apoE
-/-
 cells (Fig. 2.10C). The effect of LDLR overexpression on Aβ 
clearance in the absence of apoE was also measured by determining the amount of Aβ 
remaining in the media of Wt and apoE
-/-
 astrocytes transduced with LDLR after a 24 hr 
incubation. LDLR overexpression decreased the amount of Aβ remaining in Wt cells by 
40% and in apoE
-/-
 cells by 43% (Fig. 2.10D). Therefore, the presence of apoE is not 
necessary for LDLR to modulate both Aβ uptake and clearance by primary astrocytes.  
 
LDLR binds directly to Aβ in an in vitro setting. Since apoE was not required for the 
effect of LDLR on Aβ internalization, we investigated whether LDLR may directly 
interact with the Aβ peptide. Coimmunoprecipitation experiments were carried out using  
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Fig. 2.10. The effect of LDLR on Aβ uptake and clearance is not dependent 
on apoE. (A) LDLR was expressed in apoE
-/-
 and Wt primary astrocytes via 
lentiviral transduction. LDLR expression was confirmed by immunoblot for HA. 
LDLR Tg astrocyte lysate is shown for comparison. (B) To confirm that the 
LDLR protein expressed after lentiviral transduction was functional, Wt cells 
were transduced and the amount of endogenously produced apoE was measured 
by ELISA in the cell media after a 24 hr incubation. Mean ± SEM (n≥4) ** 
denotes p<0.01. (C) Aβ uptake was measured in Wt and apoE-/- primary 
astrocytes transduced with LDLR lentivirus. Aβ40 (2 μg/mL) was incubated with 
the cells for 3 hrs. The cells were then washed with PBS, treated with trypsin to 
remove cell surface-bound Aβ, and lysed in Triton X-100 lysis buffer. The cell-
internalized Aβ was then measured by ELISA. Mean ± SEM (n≥4) ** denotes 
p<0.01, *** denotes p<0.001, n.s. not significant (D) Aβ clearance was assessed 
by the addition of Aβ40 (2 μg/mL) to the media of Wt and ApoE-/- astrocytes 
transduced with the LDLR lentivirus. After 24 hrs, the amount of Aβ remaining in 
the media was measured by ELISA and compared to cells transduced with empty 
lentivirus. Mean ± SEM (n≥4) *** denotes p<0.001, n.s. not significant. 
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Aβ and the extracellular domain of LDLR. Both Aβ40 and LDLR were incubated 
together for 4 hrs at 37°C, and LDLR was immunoprecipitated using anti-His beads. 
LDLR was efficiently pulled down by the anti-His antibody, as shown in Fig. 2.11A (lane 
1 and 3). A significant amount of Aβ40 was also pulled down with LDLR (lane 1), which 
was not due to nonspecific binding of Aβ40 to the anti-His beads (compare lanes 1 and 
2). Ligand blotting also verified the direct interaction between LDLR and Aβ40 (Fig. 
2.12). To demonstrate the specificity of the interaction between Aβ40 and LDLR, the 
immunoprecipitation experiment was repeated with the addition of increasing 
concentrations of either RAP or proprotein convertase subtlisin/kexin type 9 (PCSK9), 
two established ligands for LDLR. Both RAP and PCSK9 decreased the amount of Aβ 
bound to LDLR in a dose-dependent manner (Fig. 2.11). Addition of Aβ(40-1) did not 
impair binding between Aβ40 and LDLR, and interestingly led to an apparent increased 
binding (Fig. 2.11). Taken together these results demonstrate that Aβ directly binds to 
LDLR through an interaction that can be blocked using known ligands to LDLR.  
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Fig. 2.11. Direct interaction between Aβ and LDLR. (A) Aβ40 (500 nM) and 
recombinant extracellular LDLR (5 μg/mL) were incubated together and 
immunoprecipitated using anti-His beads to pull down LDLR. The isolated 
proteins were then eluted from the beads and subjected to SDS-PAGE and 
immunoblot analysis for LDLR (His) and Aβ.  (B) The specificity of the binding 
of Aβ to LDLR was determined by performing competition experiments with 
known LDLR ligands. Increasing amounts of either RAP or PCSK9 were pre-
incubated with recombinant extracellular LDLR for 2 hrs, and Aβ40 was then 
added to the protein mixture and incubated at 37°C for 4 hrs. LDLR was then 
immunoprecipitated using anti-His beads, and the eluted samples subjected to 
SDS-PAGE and immunoblot analysis for Aβ. The experiment was also repeated 
using Aβ(40-1) as a competing peptide. (C) Surface plasmon resonance was used 
to measure the interaction between the extracellular domain of LDLR and Aβ. 
Aβ40, Aβ42, or Aβ(40-1) were immobilized on the SPR chip and various 
concentrations of LDLR were flown over the surface. In order to calculate the 
dissociation constant for the interaction (KD), we plotted the resonance units as a 
function of LDLR concentration. 
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Fig. 2.12. Ligand blotting to detect Aβ-LDLR interaction. The extracellular 
domain of LDLR (2μg) was resolved by non-reducing SDS-PAGE and transferred 
to a PVDF membrane. The LDLR protein was then denatured and renatured on 
the membrane using sequential treatment with decreasing concentrations of 
guanidine-HCl. To detect the binding of proteins with LDLR in the membrane, 
either apoE or Aβ40 (5 ug/mL for each) was incubated with the membrane. NA 
represents no addition. Bound protein was then detected by immunoblot with the 
respective antibody. To analyze the size of nonreduced LDLR in the membrane, a 
His tag antibody was used. 
 
We used surface plasmon resonance (SPR) to quantify the affinity of the 
interaction between LDLR and Aβ. Soluble Aβ40 and Aβ42 were immobilized on the  
sensor chip, and binding to LDLR was measured by flow of the extracellular LDLR 
domain over the immobilized Aβ peptides. A dose-dependent interaction between LDLR 
and both Aβ40 and Aβ42 was detected (representative sensorgrams are shown in Fig. 
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 2.13). We then plotted the SPR response units for each concentration of LDLR tested in 
order to calculate the thermodynamic dissociation constants (KD) of the interactions (Fig. 
2.11C). The KD values were 47.4 ± 9.9 nM for Aβ40 and 37.4 ± 8.0 nM for Aβ42. The 
interaction between LDLR and the reverse Aβ peptide (Aβ40-1) was also measured (Fig. 
2.11C). Though Aβ40-1 still associated with LDLR, the interaction was weaker than that 
of Aβ40 and Aβ42, with a KD value of 106.7 ± 36.1 nM. Finally, the binding of a mutant 
form of Aβ (Dutch/Iowa Aβ40, DIAβ40) to LDLR was assessed. Interestingly, the 
binding of mutant Aβ was stronger than that of Aβ40 and Aβ42, with a KD of 4.54 ± 0.7 
nM (Fig. 2.13A). 
 
 
69 
 
Fig. 2.13. Assessment of Aβ-LDLR interaction via surface plasmon 
resonance. (A) The interaction between the extracellular domain of LDLR and 
Aβ was measured by SPR. Aβ40, Aβ42, or DIAβ40 were immobilized on the SPR 
chip and various concentrations of LDLR were flown over the surface. In order to 
calculate the dissociation constant for the interaction (KD), we plotted the 
resonance units as a function of LDLR concentration. (B) Representative 
sensorgrams show the response over time in resonance units (RU) for the binding 
of both Aβ40 and Aβ42 at a pH of 7.4 to LDLR. 
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Discussion 
Previously we have shown that LDLR overexpression in the mouse brain 
markedly decreased the levels of Aβ and extent of plaque deposition in the APP/PS1 
transgenic mouse model brain (Kim et al., 2009b). In the experiments performed in this 
chapter, we analyzed how LDLR regulates the cellular uptake and metabolism of Aβ by 
astrocytes. Overexpression of LDLR significantly increased the uptake and clearance of 
both Aβ40 and Aβ42 by astrocytes, while deletion of LDLR had the opposite effect. 
Increasing LDLR levels also enhanced the cellular degradation of Aβ through facilitating 
intracellular trafficking of Aβ to the lysosome. Despite the observation that increasing 
LDLR levels in astrocytes led to a decrease in extracellular apoE levels and increase in 
intracellular apoE levels, the effect of LDLR on Aβ uptake and clearance did not require 
apoE. Finally, we show that Aβ is capable of directly binding to LDLR. Overall, these 
results identify LDLR as a novel pathway for Aβ uptake into astrocytes and suggest that 
increasing glial levels of LDLR may be a feasible therapeutic strategy for promoting Aβ 
clearance from the extracellular space. 
 Several cell-types in the brain are capable of internalizing both fibrillar and 
soluble Aβ, including astrocytes (Koistinaho et al., 2004; Mandrekar et al., 2009; Nielsen 
et al., 2009; Wyss-Coray et al., 2003), microglia (Jiang et al., 2008; Mandrekar et al., 
2009), neurons (Saavedra et al., 2007), and endothelial cells (Deane et al., 2004; Yamada 
et al., 2008). The ability of microglia and astrocytes to degrade soluble Aβ suggests that 
both of these cell types play a role in Aβ clearance from the brain. Several pathways and 
receptors regulate Aβ clearance by microglia, including scavenger receptors, Toll-like 
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receptors, and fluid phase macropinocytosis (for a review, see (Lee and Landreth, 2010)). 
However, the cellular pathways that facilitate Aβ uptake and clearance by astrocytes have 
not been extensively characterized. Previously it has been shown that primary astrocytes 
grown in culture were capable of degrading soluble Aβ and fibrillar Aβ present in the 
plaques of murine brain sections (Koistinaho et al., 2004; Wyss-Coray et al., 2003). 
ApoE appears to play an important role in this process, as astrocytes cultured from apoE
-/-
 
mice were not capable of degrading Aβ in tissue sections. Furthermore, co-incubation of 
primary astrocytes with receptor-associated protein (RAP), a protein that antagonizes 
ligand binding to receptors of the LDLR family, inhibited the ability of astrocytes to 
degrade Aβ (Koistinaho et al., 2004). These results suggest that both apoE and a receptor 
from the LDLR family function in regulating the clearance of Aβ by astrocytes. In our 
current study, we extend these previous findings by highlighting the importance of LDLR 
in regulating both the uptake and clearance of soluble Aβ by astrocytes. 
 The ε4 allele of the APOE gene is currently the strongest genetic risk factor for 
late-onset AD (Kim et al., 2009a). Data from human studies and animal models suggest 
that apoE primarily influences AD pathogenesis through altering the aggregation of Aβ 
and its clearance from the brain (Castellano et al., 2011; Deane et al., 2008; Kim et al., 
2009a; Verghese et al., 2011). Altering the amount of apoE in the brain influences 
amyloid deposition and clearance (Bales et al., 1999; Bales et al., 1997; DeMattos et al., 
2004). For this reason, recent attention has been devoted to identifying receptors in the 
brain that regulate apoE levels. In mouse studies, modulation of LDLR protein levels in 
the brain altered apoE amounts. LDLR
-/-
 mice had significantly elevated amounts of apoE 
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in the brain and the CSF (Cao et al., 2006; Elder et al., 2007; Fryer et al., 2005a; Katsouri 
and Georgopoulos, 2011), whereas mice overexpressing LDLR in the brain had lower 
levels of apoE (Kim et al., 2009b). In the current study, we demonstrate that modulation 
of LDLR levels in astrocytes similarly alters apoE levels. Astrocytes that overexpress 
LDLR have decreased apoE levels in the medium and increased levels within the cell, 
while LDLR
-/-
 astrocytes have elevated apoE levels in the media and decreased 
intracellular levels of apoE. Notably, we observed a statistically significant increase in 
apoE mRNA levels in LDLR
-/-
 astrocytes. The reason for this increase is unclear, but it 
may be a compensatory response of the cells to the decrease in intracellular apoE and 
cholesterol. Despite the increase in apoE mRNA, total intracellular apoE levels in the 
LDLR
-/-
 cells were lower than Wt cells. Therefore, this data strongly suggests that LDLR 
regulates the uptake of apoE-lipoprotein particles from the media. Though several cell-
types in the brain likely mediate the effect of LDLR on apoE levels in vivo, these in vitro 
results provide evidence that astrocytes may contribute to the differences in apoE amount 
observed in the mouse brain following LDLR deletion or overexpression. 
The effect of LDLR on the amount of Aβ in the brain has been studied through 
genetic modulation of LDLR levels in transgenic mouse models of human Aβ deposition. 
Although several groups have analyzed the effect of LDLR deletion on Aβ deposition, 
the results have been inconsistent. In Tg 2576 APP transgenic mice and 5XFAD 
APP/PS1 transgenic mice, LDLR deletion caused an increase in human amyloid 
deposition (Cao et al., 2006; Katsouri and Georgopoulos, 2011). However, in PDAPP 
mice crossed to LDLR
-/-
 mice there was no significant change in human Aβ levels, 
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though there was a trend toward increased Aβ deposition in mice lacking LDLR (Fryer et 
al., 2005a). A different group looking at the effect of LDLR deletion on mouse Aβ levels 
found no changes in comparison to Wt mice (Elder et al., 2007). Our studies have found 
that LDLR overexpression in the mouse brain dramatically decreased Aβ deposition in 
APP/PS1 transgenic mice. Furthermore, we observed that the clearance of Aβ from the 
interstitial fluid was significantly increased in LDLR transgenic mice (Kim et al., 2009b). 
Several mechanisms could be responsible for this effect, including increased cellular 
catabolism of Aβ or increased transport of Aβ across the BBB into the plasma where it is 
rapidly degraded. In these mice, one of the primary cell-types expressing the transgene 
was astrocytes. In the current study, we provide a potential cellular mechanism for the 
effect of LDLR overexpression on Aβ levels in the brain. LDLR overexpression in 
primary astrocytes by expression of an LDLR transgene or through LDLR lentiviral 
transduction significantly increased Aβ uptake and enhanced Aβ clearance from the 
medium. LDLR
-/-
 astrocytes internalized less Aβ in comparison to Wt cells and exhibited 
less Aβ clearance from the medium, though the effect on clearance was not statistically 
significant. Taken together, these results suggest that LDLR is an important mediator of 
Aβ uptake and clearance in astrocytes, and differences in astrocyte-mediated clearance of 
Aβ may explain the decrease in extracellular Aβ levels observed in the LDLR Tg mouse 
brain. However, LDLR could also influence other pathways of Aβ clearance from the 
brain, including transport across the blood-brain barrier or clearance by other cell-types. 
Also, we observed that altering LDLR levels changes LRP1 levels in primary astrocytes, 
another LDL receptor that has been shown to regulate Aβ levels. However, LDLR 
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overexpression actually led to a decrease in LRP1 levels, suggesting the increase in Aβ 
uptake and clearance is due to LDLR rather than LRP1 in these cells. In future studies, it 
will be important to determine whether LDLR alters other modes of Aβ clearance and to 
better characterize the interaction between LDLR and LRP1-mediated Aβ uptake. 
We also provide evidence in this study that LDLR overexpression in astrocytes 
directly promotes the cellular degradation of Aβ. Quantification of I125-Aβ degradation 
via TCA precipitation showed that LDLR-overexpressing astrocytes degraded 
significantly more Aβ than Wt cells. Secreted extracellular proteases were not responsible 
for the effect of LDLR on Aβ degradation. The medium from LDLR-overexpressing 
astrocytes degraded even less Aβ than Wt cells after a 24 hr incubation. Regardless of 
genotype, we observed that the extent of Aβ degradation by astrocyte-conditioned media 
was minor in comparison to the Aβ degradation that occurred in the presence of primary 
astrocytes. Previous groups have demonstrated significant Aβ clearance in the presence 
of astrocyte-conditioned media due to the presence of extracellular proteases such as 
metalloproteinases and insulin degrading enzyme (IDE) (Jiang et al., 2008; Yin et al., 
2006). The reason for the difference between our findings and these previous studies is 
not clear, but may be due to methodological differences in how Aβ degradation was 
measured. Previous studies described the degradation of Aβ by measuring the 
disappearance of full-length Aβ as detected by ELISA or immunoblot, or the appearance 
of large proteolytic fragments (Jiang et al., 2008; Yin et al., 2006). However, our study 
quantified Aβ degradation products that were too small to be precipitated by TCA acid, 
and likely represent complete digestion of the Aβ peptide.  Despite the lack of significant 
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extracellular Aβ degradation by astrocyte-conditioned media, our results show that 
increasing the levels of LDLR in astrocytes enhances intracellular Aβ degradation. The 
increased degradation likely occurs though the lysosomal pathway, as LDLR promoted 
the intracellular trafficking of Aβ to the lysosome. It is important to point out that Aβ in 
the brain exists in several different aggregation states, including oligomers and fibrils 
(Holtzman et al., 2011). Since our study focused on the degradation of soluble Aβ, it will 
be important in the future to determine whether LDLR enhances the ability of astrocytes 
to degrade higher-order species of Aβ associated with amyloid plaques. 
 The effect of LDLR on Aβ uptake and clearance does not appear to be dependent 
upon apoE. Several studies have shown that apoE is capable of binding to Aβ (LaDu et 
al., 1994; Strittmatter et al., 1993b; Tokuda et al., 2000). Therefore, we hypothesized that 
apoE may facilitate the uptake of Aβ via LDLR through binding of an apoE-Aβ complex 
to LDLR. However, we found that LDLR was capable of promoting the uptake of Aβ 
into primary astrocytes even in apoE
-/-
 cells. Therefore, it is likely LDLR regulates the 
internalization of apoE and Aβ through independent processes, though we cannot rule out 
that a small amount of Aβ is taken up as a complex with apoE. ApoE also can enhance 
the ability of both astrocytes and microglia to degrade Aβ (Jiang et al., 2008; Koistinaho 
et al., 2004). Despite the increased intracellular apoE levels in LDLR-overexpressing 
astrocytes that could promote intracellular Aβ degradation, apoE was not required for the 
effect of LDLR on Aβ clearance. Support also exists in vivo that LDLR can regulate Aβ 
levels independently of apoE. A recent study demonstrated that deletion of LDLR 
increases the level of amyloid and Aβ deposition in the brains of 5XFAD APP/PS1 
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transgenic mice even in the brains of mice lacking apoE (Katsouri and Georgopoulos, 
2011). 5XFAD/LDLR
-/-
 mice had decreased astrocytosis regardless of whether apoE was 
present, suggesting LDLR may function in the astrocytic response to Aβ deposition in 
vivo (Katsouri and Georgopoulos, 2011)  Therefore, although apoE may regulate Aβ 
uptake and clearance by astrocytes, the effect of LDLR and apoE on these processes 
appears to be independent. In the future, it will be of interest to determine if LDLR 
overexpression can decrease plaque deposition in the brain in the absence of apoE. 
 Since apoE did not appear to regulate the uptake of Aβ via LDLR, we analyzed 
whether Aβ could directly bind to LDLR in vitro. We showed via immunoprecipitation 
and surface plasmon resonance that both Aβ40 and Aβ42 can bind to the extracellular 
domain of LDLR with KD values of 47.4 nM and 37.4 nM, respectively. Competition 
experiments using both PCSK9 and RAP demonstrated that these LDLR ligands impaired 
Aβ binding to LDLR. These results suggest that Aβ may interact with the domains of 
LDLR that bind PCSK9 and RAP. Future studies will be necessary to define the exact 
Aβ-binding site on LDLR. Another member of the LDLR receptor family, LRP1, has 
also been shown to bind directly to Aβ with KD values in the low nanomolar range 
(Deane et al., 2004). Despite the fact that the binding we observe between LDLR and Aβ 
is slightly weaker than the binding of Aβ to LRP1, a direct interaction with LDLR may 
still be relevant for Aβ internalization. Furthermore, we cannot rule out the possibility 
that Aβ binds to the cell surface through another protein that potentially functions as a co-
receptor with LDLR, and LDLR then subsequently facilitates Aβ uptake after it binds to 
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the cell surface. Such a cooperative process has recently been proposed for Aβ uptake 
into neuronal cells via LRP1 and heparan sulfate proteoglycan (Kanekiyo et al., 2011). 
 
Conclusions 
In summary, we identified LDLR as a novel pathway of Aβ uptake and 
degradation in primary astrocytes. We also show that the ability of LDLR to facilitate Aβ 
uptake and clearance is not dependent upon apoE. Finally, we have identified a potential 
interaction between Aβ and LDLR that may play a role in the ability of LDLR to regulate 
Aβ internalization into cells. Regulating glial levels of LDLR appears to be a potential 
approach toward lowering brain Aβ levels. Therefore, it will be important in the future to 
better characterize how brain LDLR levels can be regulated from both a molecular and 
pharmaceutical perspective in order to identify unique therapeutic targets to treat AD. 
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Chapter 3 
Measurement of Protein Kinetics in the Mouse Brain Using 
Bolus Stable Isotope Labeling 
 
(This work involved the collaboration of several labs, and could not have been completed 
without the contribution of several individuals. Dr. Jungsu Kim and Dr. David Holtzman 
originally conceived the ideas for these experiments; Dr. Kim also aided with the method 
development and optimization. Hong Jiang and Maia Parsadanian aided with mouse 
tissue sample collection. All of the mass spectrometry data collection and analysis was 
performed in the lab of Dr. Randall Bateman. In particular, Dr. Yuriy Pyatkivskyy and 
Dr. Kristin Wildsmith aided in the mass spectrometry method development. Finally, Dr. 
Bruce Patterson provided expertise and helpful discussion for interpreting the data. Work 
from this chapter is included in manuscripts published in the journals Molecular 
Neurodegeneration and PLoS ONE.) 
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Summary 
Abnormal proteostasis due to alterations in protein synthesis and clearance has 
been postulated to play a central role in several neurodegenerative diseases, including 
Alzheimer’s disease. In chapter 2, our experiments were focused on characterizing a 
molecular pathway for the cellular clearance of apoE and Aβ. However, it is of interest 
ultimately to study pathways and processes that regulate whole brain apoE and Aβ 
clearance in vivo. Therefore, the development of techniques to quantify protein turnover 
in the brain is critical for understanding the pathogenic mechanisms of these diseases. We 
have developed a bolus stable isotope-labeling kinetics (SILK) technique coupled with 
multiple reaction monitoring mass spectrometry to measure the clearance of proteins in 
the mouse brain. In this technique, cohorts of mice are pulse labeled with 
13
C6-leucine 
and the brains are isolated after pre-determined time points. Following lysis of the brain 
tissue, the extent of 
13
C6-leucine incorporation in the cohort of mice is measured over 
time using mass spectrometry to measure the ratio of labeled to unlabeled protein. The 
fractional clearance rate is then calculated by analyzing the time course of disappearance 
for the labeled protein species. In this chapter, we provide a description of this technique 
and its application to measuring the kinetics of apoE turnover in both LDLR 
overexpressing mice and human apoE targeted-replacement mice. 
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Introduction 
In the proteomics era, significant effort has been devoted to developing 
techniques that accurately and efficiently determine differences in protein amounts under 
normal physiological conditions and disease states (Ong and Mann, 2005). However, 
quantifying protein turnover rates at both a cellular and systemic level is also necessary 
for a complete understanding of the mechanisms dictating changes in protein levels 
(Doherty and Beynon, 2006). Several neurodegenerative diseases are characterized by the 
accumulation of protein aggregates in the brain, including Alzheimer’s disease (AD) 
(Holtzman et al., 2011), Parkinson’s disease (Goedert, 2001), Huntington’s disease 
(DiFiglia et al., 1997), and frontotemporal dementia (Trojanowski and Dickson, 2001). 
Although the underlying cause of protein aggregation in these diseases remains unclear, it 
is likely due to abnormal proteostasis caused by alterations in protein production or 
clearance (Balch et al., 2008; Mawuenyega et al., 2010). Therefore, the development of 
techniques that can assess protein dynamics in the brain are fundamental for advancing 
our understanding of these disease processes and aiding the conception of innovative 
therapeutics. 
Stable isotope tracers have been in use for many years to facilitate the analysis of 
protein turnover in cells and whole organisms (Wolfe and Chinkes, 2005). Mass 
spectrometry (MS) has proven an effective tool for the analysis of stable isotope 
incorporation into individual proteins (Aebersold and Mann, 2003). Liquid 
chromatography-mass spectrometry (LC-MS) analysis allows for the comparison of the 
relative abundance of labeled to unlabeled peptides due to their mass separation. 
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Coupling stable isotope amino acid labeling with LC-MS has been applied to quantify 
protein synthesis and degradation in yeast (Pratt et al., 2002), mammalian cell lines 
(Doherty et al., 2009; Schwanhausser et al., 2009), and small animals (Doherty et al., 
2005; Price et al., 2010). However, protein turnover studies in animals have been limited 
due to issues with MS detection sensitivity and accurate label quantification, along with 
difficulties in achieving cost-effective and practical methods for tracer administration. 
Recently, Bateman et al. have developed a method using stable isotope labeling kinetics 
(SILK) to measure the dynamics of low abundance proteins in the cerebral spinal fluid 
(CSF) of humans (Bateman et al., 2006). In this technique, 
13
C6-leucine is injected 
intravenously into research participants and samples of the lumbar CSF are serially 
collected for a predetermined time period. The synthesis and clearance rates of proteins 
are then measured by quantifying the appearance and disappearance of the 
13
C6-leucine in 
proteins over time via LC-MS (Bateman et al., 2007; Bateman et al., 2006). The value of 
this technique has specifically been highlighted for the amyloid β (Aβ) peptide, which 
accumulates in the brains of AD patients and has been implicated in the disease 
pathogenesis (Holtzman et al., 2011). Application of stable isotope labeling to studies of 
Aβ dynamics have demonstrated impaired Aβ clearance in individuals with AD and the 
ability of a gamma secretase inhibitor to decrease Aβ synthesis in the CNS (Bateman et 
al., 2006; Bateman et al., 2009; Mawuenyega et al., 2010). 
Apolipoprotein E (apoE) plays a central role in the transport of cholesterol by 
functioning as a ligand for the receptor-mediated endocytosis of lipoprotein particles into 
cells (Mahley, 1988). In humans, three common apoE isoforms exist (apoE2, apoE3, and 
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apoE4) that differ by amino acids at positions 112 and 158. ApoE4 is currently the 
strongest known genetic risk factor for late-onset AD, and as a result significant effort 
has been devoted to understanding apoE’s physiological function in the brain along with 
its role in AD pathogenesis (Kim et al., 2009a). A major hypothesis for how apoE4 
affects the onset of AD contends that apoE promotes the aggregation of Aβ into amyloid 
plaques in the brain, either through impairing Aβ clearance (Castellano et al., 2011; 
Deane et al., 2008), directly regulating the propensity of Aβ to form amyloid fibrils 
(Evans et al., 1995; Ma et al., 1994), or both mechanisms. The amount of apoE in the 
brain also appears to be critical for determining the extent of amyloid deposition (Bales et 
al., 1997; Kim et al., 2011). Therefore, understanding how apoE levels in the brain are 
regulated has been the focus of significant attention in AD research. ApoE receptors, 
including LDLR and LRP1, have been shown to regulate the amount of apoE in the 
mouse brain. Increasing both LDLR and LRP1 levels in the mouse brain significantly 
decreased apoE levels (Kim et al., 2009b; Zerbinatti et al., 2006). It has also been 
hypothesized that the isoform-specific effects of apoE on Aβ deposition may be due to 
differences in the apoE amount between isoforms (Bales et al., 2009). Several studies 
have shown that in the human apoE targeted-replacement mice, mice with apoE4 have 
less total apoE than mice with apoE2 or apoE3 (Bales et al., 2009; Castellano et al., 2011; 
Fryer et al., 2005b; Ramaswamy et al., 2005; Riddell et al., 2008). However, other studies 
have found no differences in the amount of apoE between isoforms (Korwek et al., 2009; 
Sullivan et al., 2004). The reason for the discrepancy in these results is unknown, but 
may be due to different tissue lysis conditions or the use of antibodies that recognize the 
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apoE isoforms with different affinities. Since the apoE protein levels are intrinsically 
related to the turnover of apoE, studying the kinetics of apoE in these mice will provide a 
mechanistic explanation for the differences, or lack thereof, in apoE protein levels in the 
mouse brain. 
In this chapter, we describe an adaptation of the SILK analysis technique to study 
protein clearance in the mouse brain. We show that following a bolus injection of 
13
C6-
leucine into mice, LC-MS analysis of brain tissue can be used to measure the fractional 
clearance rate (FCR) of individual proteins. We validate our technique by analyzing 
changes in the clearance of apolipoprotein E (apoE) in mice that have been genetically 
engineered to overexpress LDLR. Finally, we apply this technique to study the clearance 
of the human apoE isoforms in the brains of human apoE targeted-replacement mice. 
 
Experimental Procedures 
Materials - 
13
C6-leucine was obtained from Cambridge Isotope Laboratories (Andover, 
MA, USA). HJ6.3 (mouse ApoE) and WUE4 (human apoE) antibodies were made in-
house. Protein G Sepharose 4 Fast Flow beads were obtained from GE Healthcare 
(Piscataway, NJ, USA). Formic acid (Optima LC-MS) was obtained from Fisher 
Scientific and triethylammonium bicarbonate was obtained from Sigma-Aldrich (St. 
Louis, MO, USA). Trypsin Gold (mass spec grade) was purchased from Promega 
(Madison, WI, USA). 
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Animal labeling and tissue collection - The production and characterization of the 
LDLR transgenic mice were described previously (Kim et al., 2009b). LDLR Tg
+/-
 mice 
(B line, roughly 8 fold overexpression of LDLR) were bred to Wt mice to generate mice 
that were LDLR Tg
+/-
 and LDLR Tg
-/-
. Homozygous PDAPP mice containing the human 
APP V717F mutation were generated on a mixed background of DBA/2J, C57BL/6J, and 
Swiss Webster (gift from Eli Lilly and Co.). To generate APP transgenic mouse models 
with human apoE, PDAPP mice were crossed with human APOE targeted-replacement 
mouse models in which the endogenous murine APOE gene is replaced with the APOE2, 
APOE3, or APOE4 gene (gift from Dr. Patrick Sullivan, Duke University) (Sullivan et 
al., 1997). 3.5 month old mice were used for all experiments. Mice were maintained 
under constant light/dark conditions and had free access to food and water. All 
experimental protocols were approved by the Animal Studies Committee at Washington 
University in St. Louis. 
 Prior to injection, the 
13
C6-leucine was dissolved in medical-grade normal saline 
to a concentration of 7.5 mg/mL. The mice were weighed and then intraperitoneally 
injected with 
13
C6-leucine (200 mg/kg of body weight). After predetermined time points, 
the animals were anesthetized and the blood was collected by cardiac puncture. The mice 
were then perfused with PBS-heparin and regional brain dissection was performed. All 
brain samples were subsequently frozen on dry ice. 
 
Primary astrocyte cell culture and in vitro labeling - Primary astrocytes were cultured 
from postnatal day 1 (P1) C57/BL/6J mouse pups as described previously (Kim et al., 
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2009b). Cells were cultured in serum-containing growth medium (DME/F12, 15% fetal 
bovine serum, 10 ng/mL epidermal growth factor, 100 units/mL penicillin/streptomycin, 
and 1 mM sodium pyruvate) until they reached 70 percent confluency. The cell medium 
was then changed to serum free medium that did not contain any leucine (DME/F12 
without leucine prepared by the Washington University Tissue Culture Support Center, 
N2 growth supplement, 100 units/mL penicillin/streptomycin, and 1 mM sodium 
pyruvate) and cultured for 12 hr. 
13
C6-leucine was then diluted into unlabeled leucine to 
make labeled/unlabeled percentages that were either 0, 1.25, 2.5, 5, 10, or 20%. These 
different percent-labeled leucine solutions were then added to separate flasks of primary 
astrocytes, and the cells were cultured for an additional 48 hrs. The media was then 
collected from the cells, spun down at 1500 rpm to clear cellular debris, and stored at -
80°C. 
 
ApoE immunoprecipitation - Mouse and human apoE were immunoprecipitated from 
the brain tissue using the antibodies HJ6.3 and WUE4, respectively. HJ6.3 antibody was 
produced by immunizing apoE
-/-
 mice with mouse apoE immunopurified from the media 
of primary astrocyte cultures. Four different mouse apoE antibodies were produced 
(HJ6.1, HJ6.2, HJ6.3, and HJ6.4), however only HJ6.3 antibody was capable of 
immunoprecipitating mouse apoE from brain tissue lysate (Fig. 3.1). Antibody beads 
were prepared by covalently binding either HJ6.3 (mouse apoE) or WUE4 (human apoE) 
to Protein G Sepharose 4 Fast Flow beads. The beads initially were washed 3 times with 
ice-cold PBS and then resuspended in ice-cold PBS to make a 50% slurry of beads. 
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Fig. 3.1. Immunoprecipitation of mouse apoE with HJ6 antibodies. The 
ability of the HJ6 antibodies to immunoprecipitate mouse apoE from the brain 
cortex lysate was evaluated. Only beads conjugated with the HJ6.3 antibody 
pulled down apoE protein, as shown via immunoblot analysis of the pre-IP, post-
IP and eluted samples. No eluted protein was observed with HJ6.1, HJ6.2, and 
HJ6.4. 
 
300 µL of the washed 50% beads were then mixed with antibody (0.4 µg/µL of 50% bead 
mixture), 10 µL of 1% Triton X-100 and ice-cold PBS to make a final volume of 1000 
µL. This mixture was then tumble incubated overnight at 4°C. The beads were then 
washed 3 times with 1% Triton X-100 lysis buffer (Triton X-100, 150 mM NaCl, 50 mM 
Tris-HCl) and 2 times with 0.2 M triethanolamine (pH = 8.2). Freshly prepared dimethyl 
pimelimidate in 0.2 M triethanolamine (pH = 8.2) was then added to the beads, followed 
by a 30 minute (min) incubation with tumbling at room temperature to allow for 
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crosslinking. The beads were then washed once with 50 mM Tris (pH = 7.5) to stop the 
crosslinking reaction, and twice with 0.1% Triton X-100 in PBS. The washing solution 
was removed by vacuum aspiration, and the beads were resuspended in PBS to make a 
50% bead slurry. 
 Brain cortex samples were weighed and one cortical hemisphere was lysed using 
a 1% Triton X-100 lysis buffer (Triton X-100, 150 mM NaCl, 50 mM Tris-HCl, 1 X 
Roche Complete Protease Tablet) and the other cortical hemisphere was lysed using a 
PBS lysate buffer (with 1 X Roche Complete Protease Tablet). The lysis buffers were 
added at a concentration of 150 mg brain tissue/mL of lysis buffer. The triton samples 
were then sonicated (2 rounds of 20 1-sec pulses) and centrifuged at 14,000 rpm for 30 
min. The PBS samples were homogenized with a manual grinder and centrifuged at 
14,000 rpm for 30 min. The supernatant was collected and used for subsequent 
immunoprecipitation steps. Brain lysates and cell media were pre-cleared with 50 µL of 
the 50% bead slurry (no antibody coupled) for 4 hrs at 4°C. The pre-cleared lysate and 
media samples were then tumble incubated with antibody-conjugated beads overnight at 
4°C. The beads were then washed 3 times with PBS and 3 times with 25 mM 
triethylammonium bicarbonate (TEABC). Following the last TEABC wash, the TEABC 
was removed via vacuum aspiration with a pipette tip. Formic acid was then added to the 
beads to elute the bound proteins, and the mixture was vortexed for 20 minutes. The 
beads were then centrifuged at 14,000 rpm for 5 min and the supernatant was collected 
from the beads. The formic acid supernatant was transferred to a new microcentrifuge 
tube and evaporated in a Savant SpeedVac for 60 min (37°C). The dried proteins were 
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then resuspended in 20% acetonitrile/80% 25 mM TEABC and vortexed for 30 minutes. 
The samples were then digested with 500 ng of mass spectrometry-grade trypsin 
(Promega) and incubated at 37°C for 16 hrs. The digested samples were dried again by 
vacuum evaporation, resuspended in 10% acetonitrile and 0.1% formic acid in water, and 
transferred to mass spectrometry vials.  
 
Liquid Chromatography/Mass Spectrometry - LC-MS/MS measurements were 
performed on a Waters Xevo TQ-S triple quadrupole mass spectrometer (Waters Inc., 
Milford, MA) coupled to a Waters nano-ACQUITY ultra performance liquid 
chromatography (UPLC) system, equipped with a Waters nano-ESI ionization source. To 
identify multiple reaction monitoring (MRM) transitions, the synthetic mouse ApoE 
peptide LQAEIFQAR and synthetic human apoE peptide SWFEPLVEDMQR were 
purchased from AnaSpec, Inc. (Fremont, CA), and directly infused into the LC-MS for 
automatic tuning of optimized MRM transitions produced by the peptide. For both the 
mouse and human apoE peptide, optimal conditions were identified as a capillary voltage 
of 3.3 kV, source temperature of 80
°
C, cone voltage of 52 V, purge gas flow rate set at 
100 L/hr, and cone gas at 50 L/hr. Obtained MRM transitions (Table 3.1) were then 
validated by the analysis of apoE cell culture media standards. For the actual 
experiments, all digested peptide samples were kept at 4
°C and 1 μL aliquots were 
injected onto a Waters BEH130 nanoAcquity UPLC column (C18 particle, 1.7 μm, 100 
μm x 100 mm). The peptide mixtures were separated on a reverse-phase nanoUPLC 
operated at a flow rate of 500 nL/min with a gradient mixture of solvents A (0.1% formic 
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acid in water) and B (0.1% formic acid in acetonitrile). The column was initially kept at 
99% solvent A for 1.5 min, followed by a separation gradient of 1% to 97% solvent B 
from 1.5 to 18 min. The column was then kept at 97% solvent B for another 5 min 
followed by 1% solvent B to re-equilibrate for 10 min to prepare for the next injection. 
All raw data were acquired and quantified using Waters MassLynx 4.1 software suite. 
The labeled/unlabeled ratio was obtained by dividing the area under the curve (AUC) of 
the MRM total ion for the labeled peptide by the AUC for the unlabeled peptide, and 
converted to tracer-to-tracee ratios (TTRs) by reference to the standard curve. 
 
Table 3.1. MRM Transitions for Mouse and Human ApoE 
Protein Peptide sequence Precursor 
m/z 
Product 
m/z 
Collision Energy 
(V) 
Mouse ApoE LQAEIFQAR 538.2852 634.2609 14 
Mouse ApoE LQAEIFQAR 538.2852 763.2590 12 
Mouse ApoE LQAEIFQAR 538.2852 834.2775 14 
Mouse ApoE [
13
C
6
]LQAEIFQAR 541.2852 634.2609 14 
Mouse ApoE [
13
C
6
]LQAEIFQAR 541.2852 763.2590 12 
Mouse ApoE [
13
C
6
]LQAEIFQAR 541.2852 834.2775 14 
Human ApoE SWFEPLVEDMQR 769.177 987.660 28 
Human ApoE SWFEPLVEDMQR 769.177 1116.727 30 
Human ApoE SWFEP[13C6]LVEDMQR 772.177 993.660 28 
Human ApoE SWFEP[13C6]LVEDMQR 772.177 1122.727 30 
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Gas chromatography/mass spectrometry - The free leucine tracer-to-tracee ratio was 
measured from the mouse plasma using GC/MS. Plasma proteins were precipitated with 
ice-cold acetone, and lipids were extracted using hexane solvent. The resulting aqueous 
fraction was then dried with a vacuum (Savant Instruments, Farmingdale, NY) and 
converted to t-butyldimethylsilyl derivatives. The free leucine TTR was then measured 
by monitoring ions with m/z ratios of 200 (unlabeled) and 203 (labeled) (Patterson et al., 
1993). 
 
Kinetic analysis - The mice were in steady-state conditions, since the amount of apoE 
did not significantly change over the time period of the kinetic analysis. This was 
determined by measuring the protein level (via ELISA as described below) for the 
cohorts of mice at each time point following the stable isotope injection, and comparing 
across groups (see Fig. 3.2 for human apoE data). At metabolic steady state, the fraction 
of the pool that is synthesized per unit time equals the fraction of the pool catabolized per 
unit time (FCR), which can be calculated as the negative of the slope of the natural log of 
TTR plotted over time (Patterson et al., 2002). Production rates (PRs) were determined 
as: PR (protein amount/mg/hr) = [FCR (pools/hr) x protein concentration (protein 
amount/mL) x lysate volume (mL)]/brain weight (mg). The half-lives (t½) were calculated 
using the equation t½ = ln 2/FCR. Protein concentrations of apoE in the lysates were 
determined by protein-specific sandwich ELISAs using in-house antibodies. For mouse 
apoE, HJ6.2 was used as the coating antibody and biotinylated HJ6.3 as the detection 
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antibody. Pooled C57/BL/6J mouse plasma was used as a standard. For human apoE, 
HJ6.2 and biotinylated HJ6.1 were used as the coating and detection antibody, 
respectively. Human apoE isolated from human plasma samples was used as a standard 
(Calbiochem). 
 
 
Fig. 3.2. ApoE levels during time course of injection. Human apoE levels were 
measured by ELISA for each group of mice at each time point following the 
injection. No differences in apoE levels were observed during the time course of 
injection for any of the isoforms (one-way ANOVA). 
 
Statistical Analysis - Data were analyzed using GraphPad Prism Software and presented 
as mean ± standard error of the mean (SEM, *p<0.05, **p<0.01, ***p<0.001). For 
analyzing differences in protein levels and production rates, a two-tailed student’s t-test 
92 
was used for the LDLR Tg study and a one-way analysis of covariance (ANOVA) 
followed by a Tukey’s post-test was used for the human apoE studies. Differences in the 
FCR values were compared using analysis of covariance (ANCOVA) of the slope of the 
natural log of TTR plotted over time, which was determined using linear regression 
analysis. 
 
Results 
Stable isotope labeling of mice and protein isolation. The outline of our experimental 
design for the labeling of mice and tissue processing for SILK analysis is shown in Fig. 
3.3A. Mice were intraperitoneally (IP) injected with a bolus of 
13
C6-leucine, a non-
radioactive stable isotope form of the amino acid leucine. We chose 
13
C6-labeled leucine 
because it is one of the essential amino acids that rapidly cross the blood brain barrier via 
facilitative neutral amino acid transport (Smith et al., 1987). IP administration of the label 
was chosen because it is straightforward and quick, and it allows for high bioavailability 
upon absorption into the bloodstream. Following the injection, we observed a rapid 
increase in the amount of 
13
C6-leucine in the plasma of the mice over the first hour, as 
measured by the ratio of labeled to unlabeled free leucine quantified by GC-MS (Fig. 
3.3B). After a predetermined time point, the mice were euthanized and the brains were 
quickly removed and frozen. Upon collection of all of the brain samples for each time 
course, the tissue was then lysed in a 1% Triton X-100 lysis buffer and the protein of 
interest (apoE for this study) was immunoprecipitated with protein-specific antibodies 
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covalently coupled to protein G sepharose beads. Only the cortex of the brain was used in 
this study; however this technique could easily be applied to measure protein turnover 
rates in other regions of the brain. The isolated proteins were eluted off the beads using 
formic acid, and the concentrated samples were digested with trypsin to generate protein-
specific peptides for each protein. These peptide mixtures were then subjected to LC-MS 
analysis for identification and characterization as described below. 
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Fig. 3.3. Experimental schematic for stable isotope labeling and isolation of 
mouse brain proteins. (A) Cohorts of mice were pulse-labeled with 
13
C6-leucine 
via a bolus intraperitoneal injection. After a pre-determined time following the 
13
C6-leucine administration, the mice were euthanized and the brains were 
removed. The brain tissue was then lysed, and the protein of interest was 
immunoprecipitated from the brain lysate (apoE is shown as an example). The 
precipitated proteins were then eluted from the antibody beads and subjected to 
trypsin digestion. The resulting peptide mixture was separated and analyzed via 
ultra performance liquid chromatography tandem mass spectrometry 
(UPLC/MS/MS) (yellow = apoE, blue = sepharose bead, red = trypsin). (B) To 
observe the bioavailability of the 
13
C6-leucine, plasma samples were collected at 
sequential time points following the bolus injection and subjected to GC-MS 
analysis. The tracer-to-tracee ratio (TTR, shown as labeled/unlabeled leucine) was 
then measured by quantifying the relative amounts of 
13
C6-leucine and dividing 
by the amount of unlabeled leucine in each sample. Each time point in the graph 
represents the average value from 5-6 individual mice. 
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Mass spectrometry analysis to calculate the ratio of labeled to unlabeled peptide. We 
used a targeted LC-MS approach to accurately and precisely quantify the amount of 
labeled apoE in the brain. Multiple reaction monitoring (MRM) assays were developed 
for mouse and human apoE protein by first selecting a peptide that shows high MS signal 
intensity, contains only one leucine residue, and is specific for each protein 
(LQAEIFQAR for mouse apoE, SWFEPLVEDMQR for human apoE). Synthetic 
peptides were then directly injected into the MS to select and optimize the MRM product 
transitions for each parent ion (Fig 3.4A, Table 3.1). These parent/precursor ion 
groupings were then used for the relative quantitation of the labeled and unlabeled 
peptides from the brain sample. The area under the curve (AUC) of the MRM ion count 
during the course of the parent ion elution was calculated for the labeled and unlabeled 
peptide peaks (Fig. 3.4B). The AUC for the labeled peak was then divided by the AUC 
for the unlabeled peak to calculate the TTR for each sample. 
 In order to accurately compare the TTR values between individual brain samples 
and across cohorts of animals, we developed standard curves for apoE using the stable 
isotope labeling of amino acids in cell culture (SILAC) method (Ong et al., 2002). Since 
astrocytes are the main cell type in the brain that produce apoE (Kim et al., 2009a), we 
used primary astrocyte cultures to produce a labeled apoE standard curve. For the human 
apoE, we used a stable astrocyte cell line derived from primary astrocytes cultured from 
the brains of the targeted-replacement mice (Morikawa et al., 2005). To label newly 
synthesized apoE, the astrocytes were cultured in leucine-free media supplemented with 
different ratios of 
13
C6-leucine to unlabeled leucine. Under these conditions, all apoE that 
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was synthesized and secreted into the cell media are labeled with the percentage of 
13
C6-
leucine provided to the cells. After a 48 hr incubation, the cell media was collected and 
apoE was immunoprecipitated. Following trypsin digestion, the apoE peptides were 
subjected to LC-MS as described above. The measured amount of percent labeled apoE 
gave values that were very close to the expected values (Fig. 3.5A). The linear fit for 
mouse apoE had a slope of 0.976 and an R
2 
value of 0.9954. The apoE media standards 
were used in all subsequent experiments to calibrate the quantitation of the mouse brain 
samples.  
In order to calculate the fractional clearance rates (FCRs) of apoE from the brain 
for each cohort of mice, mice were injected with 
13
C6-leucine and the brains were 
removed at predetermined time points following the label administration. To determine 
the optimal time course for analyzing apoE clearance, a preliminary experiment was 
performed with 1 to 2 mice at each time point. For the actual experiments, several mice 
(n=5 to 6) were labeled for each time point and the TTR values were averaged. The 
averaged TTR values were then plotted over time for the whole cohort of mice to obtain 
the kinetic time course of label disappearance (Fig. 3.5B). The slope of the 
monoexponential curve of the downslope was then calculated in order to determine the 
fractional clearance rate for each protein from the brain. 
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Figure 3.4. Tandem mass spectrometry (MS/MS) analysis of mouse apoE. (A) 
Tryptic peptides from immunoprecipitated apoE were separated by liquid 
chromatography and detected using a Xevo TQ-S triple quadrupole mass 
spectrometer. To facilitate the accurate and specific quantitation of labeled apoE, 
MRM transitions and conditions were optimized for the parent ion LQAEIFQAR. 
MS/MS spectrum for the product MRM transitions is shown. A similar analysis 
was performed for the human apoE specific peptide. (B) Representative relative 
ion count peaks from multiple reaction monitoring (MRM) analysis of the labeled 
and unlabeled apoE parent peptide LQAEIFQAR are shown [mass charge ratio 
(m/z) = 541.29 for labeled peptide and 538.29 for unlabeled peptide]. The area 
under the curve of the MRM ion counts were used for quantitation of the labeled 
and unlabeled peptide. 
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Fig. 3.5. Quantitation and analysis of stable isotope labeled mouse apoE. (A) 
Standard curve of labeled mouse apoE. To generate a standard curve for the MS 
quantitation, primary mouse astrocytes were incubated in culture medium with 
different percentages of labeled leucine. The medium of the astrocytes was then 
collected and the secreted apoE was immunoprecipitated, digested with trypsin, 
and analyzed using LC-MS. The measured labeled/unlabeled ratios along with the 
predicted labeled/unlabeled values are shown with a linear regression line (n = 3, 
dotted lines represent 95% confidence bands). (B) Representative diagram of time 
course of labeled proteins used for kinetic analyses. The labeled/unlabeled ratio 
was calculated for individual protein samples by dividing the area under the curve 
of the labeled ion count by the area under the curve of the unlabeled ion count. 
The labeled/unlabeled ratios were averaged for all of the mouse brain samples 
collected at each time point. The averaged labeled/unlabeled ratios were then 
plotted versus time to obtain the kinetic curve for each mouse genotype.
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LDLR overexpression enhances the apoE clearance rate. To verify that our labeling 
technique could measure differences in the clearance rates of proteins, we measured the 
effect of overexpressing LDLR on the apoE clearance rate from the brain. LDLR is a 
receptor that binds to apoB and apoE in the plasma to facilitate the uptake of cholesterol-
laden lipoproteins by cells (Brown and Goldstein, 1986). Previously we had shown that 
LDLR transgenic mice that overexpress LDLR in the brain had significantly decreased 
levels of brain apoE (Kim et al., 2009b). We therefore hypothesized that the apoE 
clearance rate in the brain would be increased in mice that have elevated LDLR levels. 
Wildtype (Wt) and LDLR Tg mice were labeled with 
13
C6-leucine and the apoE TTR 
values were measured after pre-determined time points. Plots of the TTR values 
(presented as labeled/unlabeled apoE) over time along with the monoexponential slopes 
of these curves are shown in Figures 3.6A and 3.6B, respectively. Table 3.2 shows the 
pool sizes (PS), fractional clearance rates (FCRs), production rates (PR), and half-lives of 
apoE from each genotype. The FCR of apoE was 2.7-fold faster in the LDLR Tg mice in 
comparison to the Wt mice, while the apoE pool size was 2.8-fold higher for the Wt mice 
in comparison to the LDLR Tg mice. These values were used to estimate the PR values 
for both genotypes (see Experimental Procedures section for explanation of PR 
calculation), and no statistical difference in the PR was observed between Wt and LDLR 
Tg mice. These results convincingly demonstrate that apoE clearance is enhanced in the 
brains of the LDLR Tg mice, providing the likely explanation for the decreased total 
apoE protein levels. We therefore concluded that the pulsed 
13
C6-leucine injection  
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Fig. 3.6. 
13
C6-leucine brain apoE labeling in the presence of increased LDLR 
levels. (A) Wildtype and LDLR transgenic mice (3.5 months old) were labeled 
with 
13
C6-leucine and the brains isolated after predetermined time points. ApoE 
was then immunoprecipitated from the cortex and the labeled/unlabeled ratios 
calculated via LC-MS. The labeled/unlabeled ratios were then plotted versus time 
for each genotype. (B) To calculate the FCR, the natural log of the 
labeled/unlabeled ratios were plotted over time and the monoexponential slopes 
were calculated (n=5 mice per time point, error bars represent SEM, dotted lines 
represent 95% confidence band). 
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labeling technique is effective for measuring the clearance of proteins from the brain, and 
could be used to detect differences in FCRs between genetically modified mouse models. 
 
Table 3.2. Pool Sizes (PS), Fractional Clearance Rates (FCR), Production Rates 
(PR), and Half-lives for ApoE in Wt and LDLR Tg mice 
Genotype PS 
(ng/mg) 
FCR  
(pools/hr) 
PR 
(ng/mg/hr) 
Half-life 
(t
1/2
, hrs) 
Wt 125.4±9.1 0.093±0.011 11.69±1.64 7.5 
LDLR Tg 44.7±1.9 0.25±0.019 11.07±0.96 2.8 
P <0.0001 <0.0001 0.75  
 
 
Measurement of human apoE kinetics in the mouse brain. To analyze the clearance of 
the human apoE isoforms in the mouse brain, human APOE targeted-replacement mice 
that are homozygous for either APOE2, APOE3, or APOE4 were pulse labeled with 
13
C6-
leucine and the apoE TTR values were measured after pre-determined time points. Plots 
of the TTR values (presented as labeled/unlabeled apoE) over time along with the 
monoexponential slopes of these curves are shown in Figures 3.7A and 3.7B. Table 3.3 
shows the pool sizes (PS), fractional clearance rates (FCRs), and production rates (PR) 
for apoE from each genotype. Though we observed a trend of apoE2 having the fastest 
FCR, followed by apoE3 and apoE4, the differences were not statistically different (Table 
3.3 and 3.4). The apoE4 pool size was 16% lower than apoE2 and 12% lower than apoE3, 
while the apoE4 PR was 48% slower than apoE2 and 32% slower than apoE3 (Table 3.3 
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and 3.4). We also measured apoE mRNA levels from these mice and observed that apoE4 
mice have significantly decreased levels compared to apoE2 and apoE3 mice (Table 3.3 
and 3.4). Therefore, these results suggest that the small but significant difference 
observed in the PS in these mice is likely due to changes in the production of apoE 
between the isoforms, rather than the clearance of apoE. 
 
Table 3.3. PS, FCR, PR, Half-life, and mRNA Values for ApoE in Human ApoE 
Targeted-Replacement Mice 
Genotype PS (ng/mg) FCR  
(pools/hr) 
PR 
(ng/mg/hr) 
Half-life 
(t
1/2
, hrs) 
mRNA 
(relative to 
apoE2) 
ApoE2 8.38±0.16 0.078±0.0088 0.65±0.074 8.9 1.0±0.016 
ApoE3 8.04±0.22 0.062±0.0048 0.50±0.041 11.2 1.09±0.022 
ApoE4 7.07±0.16 0.048±0.011 0.34±0.080 14.4 0.84±0.056 
P <0.0001 0.0832 0.009  0.0002 
 
Table 3.4. Statistical Analysis for Values in Table 3.3 
Genotype PS (ng/mg) FCR  
(pools/hr) 
PR 
(ng/mg/hr) 
mRNA (relative 
to apoE2) 
E2 vs. E3 N.S. N.S. N.S. N.S. 
E2 vs. E4 *** N.S. *** * 
E3 vs. E4 ** N.S. * *** 
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Fig. 3.7. 
13
C6-leucine brain apoE labeling in the human apoE targeted-
replacement mice. (A) APOE2, APOE3, and APOE4 mice (3.5 months old) were 
labeled with 
13
C6-leucine and the brains isolated after predetermined time points. 
Human apoE was then immunoprecipitated from the cortex and the 
labeled/unlabeled ratios calculated via LC-MS. The labeled/unlabeled ratios were 
then plotted versus time for each genotype. (B) To calculate the FCR, the natural 
log of the labeled/unlabeled ratios were plotted over time and the 
monoexponential slopes were calculated (n=3-5 mice per time point, error bars 
represent SEM, dotted lines represent 95% confidence band). 
 
Measurement of pool-dependent kinetics of human apoE. Since we did not observe 
any significant differences between the FCRs of the different human apoE isoforms, we 
decided to analyze whether we could detect a difference in the clearance of the apoE 
isoforms if we enriched the lysates with the extracellular fraction of apoE. The brain 
samples analyzed in Figure 3.7 were lysed with a Triton X-100 lysis buffer, which 
extracts both the intracellular and extracellular proteins from the brain tissue. To enrich 
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for extracellular apoE, we lysed the tissue from the other cortical hemisphere using a 
detergent-free PBS lysis buffer. Plots of the TTR values (presented as labeled/unlabeled 
apoE) over time along with the monoexponential slopes of these curves are shown in 
Figures 3.8A and 3.8B. For comparison, the labeled/unlabeled ratios for the triton-
extracted apoE are also shown in Figure 3.8A. We observed that the peak labeled value is 
of lower intensity and occurs at a later time point for the PBS samples in comparison to 
the Triton samples (Fig. 3.8A). This difference is consistent with the Triton and PBS 
fractions representing a precursor/product relationship. The FCR values for the PBS 
fraction of apoE were slightly faster than for the apoE in the Triton fraction (Table 3.5). 
There was also a similar trend in the FCR values between the apoE isoforms in the PBS 
fraction as for the Triton fraction, with apoE2 having a faster FCR than apoE3 and 
apoE4. However, the differences between the values were not statistically significant. 
Therefore, though the PBS and Triton pools of apoE have different labeling kinetics, 
there does not appear to be a statistically significant difference in the clearance rates 
between the human apoE isoforms in either pool of proteins analyzed. 
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Fig. 3.8. Comparison of pool-dependent 
13
C6-leucine brain apoE labeling 
kinetics. (A) APOE2, APOE3, and APOE4 mice (3.5 months old) were labeled 
with 
13
C6-leucine and the brains isolated after predetermined time points. Human 
apoE was then immunoprecipitated from cortex samples lysed in either a Triton 
lysis buffer or a PBS lysis buffer, and the labeled/unlabeled ratios calculated via 
LC-MS. The labeled/unlabeled ratios were then plotted versus time for each 
genotype. (B) To calculate the FCR for apoE extracted from the PBS lysis buffer, 
the natural log of the labeled/unlabeled ratios were plotted over time and the 
monoexponential slopes were calculated (n=3-5 mice per time point, error bars 
represent SEM, dotted lines represent 95% confidence band). 
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Table 3.5. Human ApoE FCR Values from Triton and PBS Extracts 
Genotype Triton FCR  
(pools/hr) 
PBS FCR  
(pools/hr) 
ApoE2 0.0778±0.00876 0.089±0.0249 
ApoE3 0.0619±0.00482 0.065±0.00161 
ApoE4 0.048±0.0112 0.058±0.047 
P 0.0832 0.7489 
 
Discussion 
Several different approaches have been described to study protein turnover in 
animals using stable isotope labeling. Stable isotope tracers are preferred over the use of 
radioactive tracers because they are safer and can be used to label endogenous proteins. 
Traditionally, stable isotope incorporation was measured by gas chromatography mass 
spectrometry (GC-MS) quantitation of labeled amino acids obtained following protein 
derivatization (Wolfe and Chinkes, 2005). However, this technique is limited to 
measuring large quantities of proteins, and consequently has only been used to analyze 
total tissue protein turnover or the kinetics of highly abundant proteins (Garlick et al., 
1994; Imoberdorf et al., 2001; Zhang et al., 2002). Recently the more sensitive analytical 
technique of LC-MS has been applied to quantify the turnover of specific proteins 
following administration of a stable amino acid in the diet of animals (Doherty et al., 
2005; Price et al., 2010). LC-MS allows for the quantitation of protein-specific peptides, 
and thus does not require breaking proteins down to their amino acid components. 
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Though these techniques have provided useful information on the turnover of abundant 
proteins in various organs, the requirement of labeled amino acid delivery via the diet has 
been a technical issue. Creating a diet enriched with an isotopic label is costly, and 
inability to control feeding patterns in animals such as mice and rats requires long term 
exposure (several hours to days) to the labeled diet to achieve reliable and consistent 
isotope levels in tissues. This is especially problematic in studying proteins with rapid 
turnover rates, as the difficulty in accurately measuring label incorporation over short 
time periods (minutes to hours) limits the sensitivity of kinetic analysis. To create a more 
practical and efficient method of labeling proteins, we have tested whether pulse labeling 
of mice could be used to measure protein turnover rates in the mouse brain. 
Bateman et al. previously described a stable isotope labeling kinetics (SILK) 
technique that can be used to measure the kinetics of proteins in the CSF of humans 
following the infusion of 
13
C6-leucine into the peripheral bloodstream (Bateman et al., 
2007; Bateman et al., 2006). In the method described in this chapter, we adapted this 
technique to an animal model by injecting mice with a bolus of 
13
C6-leucine. The 
incorporation of 
13
C6-leucine is then measured in the brains of several cohorts of mice at 
different time points following injection. Several aspects of the bolus SILK technique 
outlined in this chapter demonstrate its usefulness for studying protein dynamics in the 
mouse brain. First, delivery of the stable isotope through a bolus injection provides 
considerable advantages over administration of the stable isotope label through the diet. 
Unlike feeding, where it is hard to control when and how much food the mice consume, 
bolus injection provides a consistent and easily controllable amount of stable isotope. 
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Since the stable isotope quickly appears in both plasma and brain within minutes of the 
injection, this technique is particularly suitable for measuring the kinetics of proteins that 
turn over rapidly. Second, the use of cell-derived labeled protein standards for the MS 
quantitation insured that our SILK analysis yielded highly reproducible results. The 
labeling of three different cohorts of Wt control mice resulted in very similar FCR values 
for apoE (Table 3.1 and Table 4.1; 0.093, 0.10, and 0.09 pools/hr, mean = 0.094 pools/hr 
± 0.003). Finally, this labeling technique is particularly useful for comparing the kinetics 
of proteins in mice with different genetic manipulations, as we have shown in this chapter 
for mouse and human apoE. 
To demonstrate that the SILK technique could detect differences in the clearance 
rate of a protein, we measured the clearance of apoE from the brains of Wt mice and mice 
that overexpress the LDLR protein. We observed that the FCR of apoE in the LDLR-
overexpressing mice was 2.8-fold faster than in Wt mice. The reason for this effect is 
likely increased LDLR-mediated cellular uptake and catabolism of apoE within the brain. 
We also demonstrated that the SILK technique can measure the clearance rates of 
different pools of a protein by using different tissue lysis conditions. We measured the 
turnover of human apoE extracted from the brains of human apoE targeted-replacement 
mice using either a detergent-based lysis buffer (Triton X-100) or a lysis buffer without 
detergent (PBS). The Triton-containing lysis buffer extracts both intracellular and 
extracellular proteins due to disruption of the cellular membrane, while extraction using 
the PBS buffer yields predominantly extracellular proteins. For the SILK analysis, we 
observed that it took longer for 
13
C6-leucine-labeled apoE to appear in the PBS lysate 
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compared to the Triton lysate. This difference is likely due to the fact that apoE in the 
PBS fraction must be synthesized and secreted into the extracellular environment. While 
labeled apoE will appear in the Triton lysate immediately following synthesis, there will 
be a delay in the appearance of labeled apoE in the PBS fraction that accounts for the 
time it takes for the protein to be secreted. The two different pools therefore exist in a 
precursor/product relationship, as intracellular apoE (Triton lysate) is ultimately secreted 
and detected in the extracellular space (PBS lysate). Because of different pathways of 
protein degradation and removal in the intracellular and extracellular environment, the 
fractional clearance rates of apoE from the Triton and PBS pools may be different. For 
instance, we observed that the FCR of human apoE in the PBS pool was consistently 
faster than the FCR of apoE in the Triton pool, suggesting decreased stability of 
extracellular apoE. Therefore, it is important to take into account the pool from which the 
proteins are obtained when interpreting results from the SILK analysis. 
Studies in mice have shown that both the amount of apoE protein in the brain and 
the isoform of apoE present play an important role in regulating the extent of Aβ 
deposition in the brain (Kim et al., 2009a). Whether more or less apoE is beneficial 
remains unclear. Genetic studies using mice that have one or two copies of either mouse 
or human apoE demonstrate that more apoE promotes amyloid deposition (Bales et al., 
1999; Bales et al., 1997; Kim et al., 2011), while pharmacologic up regulation of apoE in 
the mouse brain decreases Aβ deposition (Cramer et al., 2012). In terms of the apoE 
isoforms, human apoE targeted-replacement mice that express human apoE4 exhibit a 
higher level of Aβ deposition and amyloid plaque load in comparison to mice that express 
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either apoE2 or apoE3 (Bales et al., 2009; Castellano et al., 2011; Fryer et al., 2005b). It 
has been hypothesized that a potential reason for the differential effects of the apoE 
isoforms on Aβ deposition is the total amount of apoE in the brain varies between the 
isoforms. Several studies have detected a difference in total apoE levels between the 
human apoE targeted-replacement mice, with the general trend being 
apoE2>apoE3>apoE4. However, other studies have shown no differences between the 
levels of apoE in the brains of these mice (Korwek et al., 2009; Sullivan et al., 2004). The 
reason for the inconsistent results is unknown, but one possibility may be due to the use 
of multiple antibodies that recognize the isoforms with different affinities. Since these 
mice have become an important tool for the AD research field, it is important to clarify 
this issue. 
Studying the kinetics of apoE in the brains of the human apoE targeted-
replacement mice provides further information on apoE protein stability and a potential 
mechanistic explanation for differences in protein levels. In the experiments described in 
this chapter, we measured apoE protein levels in these mice and observed a significant 
decrease in the amount of apoE4 compared to apoE2 and apoE3. We also applied our 
SILK technique to measure the FCR of apoE in these mice. No significant differences in 
FCR were measured between the isoforms, though there was a trend for apoE4’s FCR to 
being slower than that of apoE2 and apoE3. A decreased clearance does not explain the 
lower total protein levels measured in the brains of the apoE4 mice. However, the apoE4 
mice did have a decreased production rate and lower mRNA levels in comparison to the 
apoE2 and apoE3 mice. Therefore, our results suggest that the differences in apoE levels 
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in the brains of the targeted-replacement mice are likely due to changes in protein 
synthesis rather than clearance. Consequently, further studies are warranted to determine 
the molecular mechanisms dictating different transcription and translation rates between 
the apoE isoforms. 
 
Conclusions 
 In summary, we developed a novel method to measure protein kinetics in the 
mouse brain that uses stable isotope labeling-kinetics (SILK) coupled to multiple reaction 
monitoring mass spectrometry. We validated the technique by demonstrating that the 
clearance rate of apoE is increased in the brain in the setting of elevated LDLR levels. 
We also used this technique to measure the kinetics of human apoE in the brains of the 
human apoE targeted-replacement mice. We propose that our SILK methodology, and its 
applicability to studying the clearance of proteins in genetically modified mouse models, 
will also be useful in studying the kinetics of proteins implicated in other 
neurodegenerative diseases, such as synuclein, tau, and huntingtin. We also hope that this 
technique will aid the development and characterization of therapeutics that target protein 
metabolism in neurodegeneration.
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Chapter 4 
Effect of ABCA1 Levels on ApoE and Aβ Turnover in the Brain 
 
(This work involved the collaboration of several labs and individuals. Hong Jiang aided 
with mouse tissue sample collection. All of the mass spectrometry data collection and 
analysis was done in the lab of Dr. Randall Bateman and performed by Dr. Yuriy 
Pyatkivskyy. Finally, Dr. Bruce Patterson provided expertise and helpful discussion for 
interpreting the data. The work from this chapter was published in the journal Molecular 
Neurodegeneration) 
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Summary 
The lipidation status of apoE has been shown to play an important role in 
regulating both the amount of apoE and the extent of Aβ deposition in the mouse brain. 
One of the main proteins that function in the lipidation of apoE in the brain is the 
cholesterol transporter ATP-binding cassette A1 (ABCA1). Deletion and overexpression 
of ABCA1 in the brains of APP transgenic mice led to an increase and decrease of Aβ 
deposition, respectively. As a result, it has been hypothesized that regulating ABCA1 
levels alters either the clearance of Aβ or its propensity to aggregate into amyloid fibrils. 
In this chapter, we apply the SILK technique described in chapter 3 to determine the 
clearance rates of apoE and Aβ in the brains of APP transgenic mice that either lack or 
overexpress ABCA1. Both overexpression and deletion of ABCA1 increased the 
fractional clearance rate (FCR) of apoE and decreased the total amount of apoE in the 
brain. However, at an age prior to Aβ deposition, the level of ABCA1 had no effect on 
the Aβ FCR or levels of Aβ in the brains of APP transgenic mice. These results therefore 
suggest that ABCA1 does not regulate Aβ metabolism in the brain, but rather exerts its 
effect on Aβ deposition via another mechanism. 
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Introduction 
ABCA1 is a transmembrane protein that plays an important role in the elimination 
of excess cellular cholesterol during the process of reverse cholesterol transport (RCT) 
(Lawn et al., 1999). In the periphery, ABCA1 functions in the rate-limiting step of high-
density lipoprotein (HDL) formation by facilitating the transport of cholesterol and 
phospholipids to lipid-poor apolipoprotein A-I (apoA-1) to form discoidal pre-HDL 
particles (Brewer et al., 2004; Wang et al., 2007). Further lipidation of the pre-HDL 
particles via the ATP-binding cassette transporters G1 and G4 (ABCG1 and ABCG4) and 
esterification of the cholesterol via the enzyme lecithin: cholesterol acyltransferase 
(LCAT) leads to the formation of mature HDL particles, which are ultimately transported 
to the liver (Jonas, 1998; Vaughan and Oram, 2006). Mutations in the ABCA1 gene that 
lead to a deficiency in the ABCA1 protein cause Tangier’s disease in humans, which is 
characterized by a dramatic decrease in plasma HDL and apoA-I, accumulation of tissue 
cholesteryl esters, and increased risk for cardiovascular disease (Bodzioch et al., 1999; 
Brooks-Wilson et al., 1999; Lawn et al., 1999; Rust et al., 1999). The decrease in apoA-I 
in these individuals has been shown to be due to increased metabolism of the lipid-poor 
apoA-I containing lipoprotein particles (Schaefer et al., 1981; Schaefer et al., 1978). 
ApoE appears to be the primary lipoprotein receptor for ABCA1 in the brain, as 
apoA-I is present at levels that are only 0.5% of the amount found in plasma (Demeester 
et al., 2000). The level of ABCA1 in the brain has been shown to modulate the extent of 
apoE lipidation and apoE levels. Surprisingly, both deletion and overexpression of 
ABCA1 in the mouse brain led to a decrease in apoE levels (Hirsch-Reinshagen et al., 
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2004; Wahrle et al., 2008; Wahrle et al., 2004). However, the decrease was greater in 
mice lacking ABCA1. ABCA1 overexpression and deletion had different effects on apoE 
lipidation. The apoE-containing lipoprotein particles isolated from the cerebral spinal 
fluid (CSF) of ABCA1
-/-
 mice were poorly lipidated, while those from the CSF of mice 
overexpressing ABCA1 had higher levels of lipidation compared to wild type animals 
(Wahrle et al., 2008; Wahrle et al., 2004). 
Since lowering apoE levels decreased amyloid deposition in the mouse brain 
(Bales et al., 1999; Bales et al., 1997), it was hypothesized that altering ABCA1 levels 
would also alter amyloid deposition in APP transgenic mice. Despite decreased apoE 
levels with both ABCA1 deletion and overexpression, only ABCA1 overexpression 
caused a significant decrease in amyloid load in the mouse brain of APP transgenic 
animals (Wahrle et al., 2008). The amyloid load in APP transgenic mice deficient in 
ABCA1 did not change, or even increased, when ABCA1
-/-
 mice were crossed to various 
APP transgenic models (Hirsch-Reinshagen et al., 2005; Koldamova et al., 2005a; 
Wahrle et al., 2005). Because of the opposing effects of ABCA1 deletion and 
overexpression on Aβ accumulation, ABCA1 likely alters Aβ levels through a 
mechanism distinct from solely modulating apoE levels. One proposed mechanism is 
ABCA1 levels could alter Aβ clearance from the brain (Hirsch-Reinshagen and 
Wellington, 2007; Wahrle et al., 2008); however this hypothesis has yet to be tested in 
vivo.  
In this chapter, we used stable isotope labeling kinetics (SILK) to study the effect 
of ABCA1 levels on both apoE and Aβ clearance rates in the mouse brain. APP 
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transgenic mice were generated that either overexpressed or lacked ABCA1, and they 
were subsequently injected with a bolus of 
13
C6-leucine. Both overexpression and 
deletion of ABCA1 resulted in an increased fractional clearance rate of apoE. However, 
ABCA1 levels did not alter the clearance rate of Aβ in the mouse brain, suggesting 
ABCA1 acts via another pathway, such as directly influencing Aβ aggregation, to 
regulate amyloid deposition.  
 
Experimental Procedures 
Materials - 
13
C6-leucine was obtained from Cambridge Isotope Laboratories (Andover, 
MA, USA). HJ5.2 (Aβ) and HJ6.3 (ApoE) antibodies were made in-house. Protein G 
Sepharose 4 Fast Flow beads were obtained from GE Healthcare (Piscataway, NJ, USA). 
Formic acid (Optima LC-MS) was obtained from Fisher Scientific and triethylammonium 
bicarbonate was obtained from Sigma-Aldrich (St. Louis, MO, USA). Trypsin Gold 
(mass spec grade) was purchased from Promega (Madison, WI, USA). 
 
Animal labeling and tissue collection - ABCA1
+/-
 mice on a DBA background were 
obtained from the Jackson Laboratory (Bar Harbor, ME, USA). PDAPP mice on a 
C57/BL/6J background were a generous gift from Eli Lilly (Indianapolis, IN, USA). 
ABCA1 Tg mice were backcrossed to C57/BL/6J mice for 8 generations, and then 
crossed to DBA mice. PDAPP mice were also crossed to DBA mice and ABCA1
+/-
 mice 
were crossed to C57/BL/6J mice to create strains that were on a 50% C57/BL/6J 
/50%DBA background. The ABCA1 Tg
+/-
 and PDAPP
+/-
 mice were then bred to each 
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other to generate ABCA1 Tg
+/-
/PDAPP
+/-
 and ABCA1 Tg
-/-
/PDAPP
+/- 
mice that were 
used for the experiments. ABCA1
+/- 
mice were crossed to PDAPP
+/- 
mice to generate 
mice that were PDAPP
+/-
/ABCA1
+/-
. These mice were then bred to ABCA1
+/- 
mice to 
generate mice that were PDAPP
+/-
/ABCA1
+/+
, PDAPP
+/-
/ABCA1
+/-
, and PDAPP
+/-
/ABCA1
-/-
. The PDAPP
+/-
/ABCA1
+/+ 
and PDAPP
+/-
/ABCA1
-/-
 mice were used for all 
experiments. Mice were maintained under constant light/dark conditions and had free 
access to food and water. All experimental protocols were approved by the Animal 
Studies Committee at Washington University in St. Louis.  
 Prior to injection, the 
13
C6-leucine was dissolved in medical-grade normal saline 
to a concentration of 7.5 mg/mL. The mice were weighed and then intraperitoneally 
injected with the 
13
C6-leucine (200 mg/kg of body weight). After predetermined time 
points, the animals were anesthetized and the blood was collected by cardiac puncture. 
The mice were then perfused with PBS-heparin and regional brain dissection was 
performed. All brain samples were subsequently frozen on dry ice. 
 
Primary astrocyte cell culture and in vitro labeling - Primary astrocytes were cultured 
from postnatal day 1 (P1) C57/BL/6J mouse pups as described previously (Kim et al., 
2009b). Cells were cultured in serum-containing growth media (DME/F12, 15% fetal 
bovine serum, 10 ng/mL epidermal growth factor, 100 units/mL penicillin/streptomycin, 
and 1 mM sodium pyruvate) until they reached 70 percent confluency. The cell medium 
was then changed to serum free medium that did not contain any leucine (DME/F12 
without leucine prepared by the Washington University Tissue Culture Support Center, 
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N2 growth supplement, 100 units/mL penicillin/streptomycin, and 1 mM sodium 
pyruvate) and cultured for 12 hr. 
13
C6-leucine was then diluted into unlabeled leucine to 
make labeled/unlabeled percentages that were either 0, 1.25, 2.5, 5, 10, or 20%. These 
different percent-labeled leucine solutions were then added to separate flasks of primary 
astrocytes, and the cells were cultured for an additional 48 hrs. The medium was then 
collected from the cells, spun down at 1500 rpm to clear cellular debris, and stored at -
80°C. 
 
ApoE and Aβ immunoprecipitation - Antibody beads were prepared by covalently 
binding either HJ6.3 (apoE) or HJ5.2 (Aβ) to Protein G Sepharose 4 Fast Flow beads. 
The beads initially were washed 3 times with ice-cold PBS and then resuspended in ice-
cold PBS to make a 50% slurry of beads. 300 µL of the washed 50% beads were then 
mixed with antibody (0.4 µg/µL of 50% bead mixture), 10 µL of 1% Triton X-100 and 
ice-cold PBS to make a final volume of 1000 µL. This mixture was then tumble 
incubated overnight at 4°C. The beads were then washed 3 times with 1% Triton X-100 
lysis buffer (Triton X-100, 150 mM NaCl, 50 mM Tris-HCl) and 2 times with 0.2 M 
triethanolamine (pH = 8.2). Freshly prepared dimethyl pimelimidate in 0.2 M 
triethanolamine (pH = 8.2) was then added to the beads, followed by a 30 min incubation 
with tumbling at room temperature to allow for crosslinking. The beads were then 
washed once with 50 mM Tris (pH = 7.5) to stop the crosslinking reaction, and twice 
with 0.1% Triton X-100 in PBS. The washing solution was removed by vacuum 
aspiration, and the beads were resuspended in PBS to make a 50% bead slurry. 
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 Brain cortex samples were weighed and 1% Triton X-100 lysis buffer (Triton X-
100, 150 mM NaCl, 50 mM Tris-HCl, 1 X Roche Complete Protease Tablet) was added 
at a concentration of 150 mg brain tissue/mL of lysis buffer. The samples were then 
sonicated (2 rounds of 20 1-sec pulses) and centrifuged at 14,000 rpm for 30 min. The 
supernatant was collected and used for subsequent immunoprecipitation steps. Brain 
lysates and cell media were pre-cleared with beads not conjugated to antibody by tumble 
incubating the samples with 50 µL of the 50% bead slurry for 4 hrs at 4°C. The pre-
cleared lysate and media samples were then tumble incubated with antibody-conjugated 
beads overnight at 4°C. The beads were then washed 3 times with PBS and 3 times with 
25 mM triethylammonium bicarbonate (TEABC). Following the last TEABC wash, the 
washing solution was removed via vacuum aspiration with a pipette tip. Formic acid was 
then added to the beads to elute the bound proteins, and the mixture was vortexed for 20 
minutes. The beads were then centrifuged at 14,000 rpm for 5 minutes and the 
supernatant was collected from the beads. The formic acid supernatant was transferred to 
a new microcentrifuge tube and evaporated in a Savant SpeedVac for 60 min (37°C). The 
dried proteins were then resuspended in 20% acetonitrile/80% 25 mM TEABC and 
vortexed for 30 minutes. The samples were then digested with 500 ng of mass 
spectrometry-grade trypsin (Promega) and incubated at 37°C for 16 hrs. The digested 
samples were dried again by vacuum evaporation, resuspended in 10% acetonitrile and 
0.1% formic acid in water, and transferred to mass spec vials.  
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Liquid Chromatography/Mass Spectrometry - LC-MS/MS measurements were 
performed on a Waters Xevo TQ-S triple quadrupole mass spectrometer (Waters Inc., 
Milford, MA) coupled to a Waters nano-ACQUITY ultra performance liquid 
chromatography (UPLC) system, equipped with a Waters nano-ESI ionization source. To 
identify multiple reaction monitoring (MRM) transitions, the synthetic ApoE peptide 
LQAEIFQAR and synthetic Aβ peptide LVFFAEDVGSNK were purchased from 
AnaSpec, Inc. (Fremont, CA), and directly infused into the LC-MS for automatic tuning 
of optimized MRM transitions produced by the peptide. For both the apoE and Aβ 
peptide, optimal conditions were identified as a capillary voltage of 3.3 kV, source 
temperature of 80
°
C, cone voltage of 52 V, purge gas flow rate set at 100 L/hr, and cone 
gas at 50 L/hr. Obtained MRM transitions (Table 4.1) were then validated by the analysis 
of apoE and Aβ cell culture media standards. For the actual experiments, all digested 
peptide samples were kept at 4
°C and 1 μL aliquots were injected onto a Waters BEH130 
nanoAcquity UPLC column (C18 particle, 1.7 μm, 100 μm x 100 mm). The peptide 
mixtures were separated on a reverse-phase nanoUPLC operated at a flow rate of 500 
nL/min with a gradient mixture of solvents A (0.1% formic acid in water) and B (0.1% 
formic acid in acetonitrile). For apoE, the column was initially kept at 99% solvent A for 
1.5 min, followed by a separation gradient of 1% to 97% solvent B from 1.5 to 18 min. 
The column was then kept at 97% solvent B for another 5 min followed by 1% solvent B 
to re-equilibrate for 10 min to prepare for the next injection. For Aβ, the column was 
initially kept at 90% solvent A for 7.0 min, followed by a separation gradient of 10% to 
45% solvent B from 7 to 12 min. The column was then kept at 45% to 95% solvent B 
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from 12 to 14 min, and at 95% solvent B for another 3 min followed by 10% solvent B to 
re-equilibrate for 15 min to prepare for the next injection.  All raw data were acquired 
and quantified using Waters MassLynx 4.1 software suite. The labeled/unlabeled ratio 
was obtained by dividing the area under the curve (AUC) of the MRM total ion for the 
labeled peptide by the AUC for the unlabeled peptide, and converted to tracer-to-tracee 
ratios (TTRs) by reference to the standard curve. 
Table 4.1. MRM Transitions for ApoE and Aβ Analysis 
Protein Peptide sequence Precursor m/z Product m/z Collision 
Energy (V) 
ApoE LQAEIFQAR 538.2852 634.2609 14 
ApoE LQAEIFQAR 538.2852 763.2590 12 
ApoE LQAEIFQAR 538.2852 834.2775 14 
ApoE [
13
C
6
]LQAEIFQAR 541.2852 634.2609 14 
ApoE [
13
C
6
]LQAEIFQAR 541.2852 763.2590 12 
ApoE [
13
C
6
]LQAEIFQAR 541.2852 834.2775 14 
Aβ LVFFAEDVGSNK 663.3405 819.3840 24 
Aβ LVFFAEDVGSNK 663.3405 966.4520 24 
Aβ LVFFAEDVGSNK 663.3405 1113.5210 24 
Aβ [
13
C
6
]LVFFAEDVGSNK 666.3500 819.3840 24 
Aβ [
13
C
6
]LVFFAEDVGSNK 666.3500 966.4520 24 
Aβ [
13
C
6
]LVFFAEDVGSNK 666.3500 1113.5210 24 
 
Kinetic analysis - The mice were in steady-state conditions, since the amount of apoE 
and Aβ did not significantly change over the time period of the kinetic analysis. This was 
determined by measuring the protein level (via ELISA as described below) for the 
cohorts of mice at each time point following the stable isotope injection, and comparing 
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across groups. At metabolic steady state, the fraction of the pool that is synthesized per 
unit time equals the fraction of the pool catabolized per unit time (FCR), which can be 
calculated as the negative of the slope of the natural log of TTR plotted over time 
(Patterson et al., 2002). Production rates (PRs) were determined as: PR (protein 
amount/mg/hr) = [FCR (pools/hr) x protein concentration (protein amount/mL) x lysate 
volume (mL)]/brain weight (mg). The half-lives (t½) were calculated using the equation 
t½ = ln 2/FCR. Protein concentrations of apoE and Aβ in the lysates were determined by 
protein-specific sandwich ELISAs using in-house antibodies. For apoE, HJ6.2 was used 
as the coating antibody and biotinylated HJ6.3 as the detection antibody. Pooled 
C57/BL/6J mouse plasma was used as a standard. For Aβ, HJ2 (anti-Aβ35-40) and 
biotinylated HJ5.1 (anti-Aβ13-28) were used as the coating and detection antibody, 
respectively. 
 
Statistical Analysis - Data were analyzed using GraphPad Prism Software and presented 
as mean ± standard error of the mean (SEM). For analyzing differences in protein levels 
and production rates, a two-tailed student’s t-test was used. Differences in the FCR 
values were compared using analysis of covariance (ANCOVA) of the slope of the 
natural log of TTR plotted over time, which was determined using linear regression 
analysis. 
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Results 
Effect of ABCA1 levels on apoE clearance rate 
 Both the overexpression and deletion of ABCA1 from the mouse brain led to a 
decrease in the amount of apoE in the brain (Hirsch-Reinshagen et al., 2005; Wahrle et 
al., 2005; Wahrle et al., 2008). To determine whether this decrease in apoE is due to 
increased clearance of apoE, we used SILK analysis to measure the fractional clearance 
rate (FCR) of apoE in the brains of APP transgenic mice crossed to ABCA1
-/-
 and 
ABCA1 Tg mice. To generate APP transgenic mice that either overexpressed or were 
deficient in ABCA1 levels, we crossed PDAPP mice with ABCA1 Tg and ABCA1
-/-
 
mice. These animals were then injected with 
13
C6-leucine and the brain tissue was 
collected and lysed. The same tissue lysates were used to immunoprecipitate both apoE 
and Aβ (see following section for discussion on Aβ analysis). Following 
immunoprecipitation of apoE from the lysates, the FCRs of apoE were measured using 
liquid chromatography mass spectrometry (LC-MS). Plots of the labeled/unlabeled apoE 
values over time along with the monoexponential slopes of these curves for the ABCA1 
Tg and ABCA1
-/-
 mice are shown in Figures 4.1A,B and 4.2A,B, respectively. Different 
groups of wildtype (Wt) control mice were used for the ABCA1 Tg and ABCA1
-/-
 mice. 
The PS, FCR, PR, and half-life values are given in Table 4.2. The apoE FCR was 1.5 fold 
faster in ABCA1 Tg mice and 1.9 fold faster in ABCA1
-/-
 mice compared to Wt mice; 
however the difference was only statistically significant for the ABCA1
-/-
 mice. The apoE 
PS decreased by 20% in ABCA1 Tg mice and by 51% in ABCA1
-/-
 mice compared to Wt 
mice. No statistical differences existed between the calculated values for the PR.  
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Fig. 4.1.
 13
C6-leucine brain apoE labeling in the presence of ABCA1 
overexpression. (A) Cohorts of wildtype and ABCA1 transgenic mice were 
labeled with 
13
C6-leucine and the brains isolated after predetermined time points. 
ApoE was then immunoprecipitated from the cortex and the labeled/unlabeled 
ratios calculated via LC-MS. The labeled/unlabeled ratios were then plotted 
versus time for each genotype. (B) For FCR measurements, the monoexponential 
slopes of the ln (labeled/unlabeled apoE) curve were measured for ABCA1 Tg 
and Wt control mice (n=5-6 mice per time point, error bars represent SEM, dotted 
lines represent 95% confidence band). 
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Fig. 4.2. 
13
C6-leucine brain apoE labeling in the setting of ABCA1 deletion. 
(A) Cohorts of wildtype and ABCA1
-/-
 mice were labeled with 
13
C6-leucine and 
the brains isolated after predetermined time points. The apoE labeled/unlabeled 
ratios were then calculated and the data plotted as in Fig. 4.1. (B) For FCR 
measurements, the monoexponential slopes were measured for ABCA1
-/-
 mice 
and Wt control mice as in Fig. 4.1. (n=5-6 mice per time point, error bars 
represent SEM, dotted lines represent 95% confidence band). 
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These results demonstrate that the decrease in apoE levels both with ABCA1 deletion and 
overexpression is due to an increase in the clearance of apoE from the brain. 
 
Table 4.2. Pool Sizes (PS), Fractional Clearance Rates (FCR), Production Rates 
(PR), and Half-lives for ApoE by Mouse Genotype 
 
Genotype PS 
(ng/mg) 
FCR  
(pools/hr) 
PR 
(ng/mg/hr) 
Half-life 
(t
1/2
, hrs) 
Wt (ABCA1 Tg 
control) 
135.5±4.8 0.10±0.019 14.08±1.64 6.9 
ABCA1 Tg 109.2±3.8 0.15±0.022 16.81±0.96 4.6 
P <0.0001 0.106 0.46  
     
Wt (ABCA1-/- 
control) 
230.5±12.1 0.09±0.015 20.76±3.64 7.7 
ABCA1-/- 117.6±8.0 0.17±0.010 20.41±2.13 4.1 
P <0.0001 <0.0001 0.94  
 
Effect of ABCA1 levels on Aβ clearance rate 
To determine whether ABCA1 levels regulate Aβ clearance from the brain, we 
used SILK analysis to measure the FCR of Aβ in the brains of PDAPP crossed to 
ABCA1
-/-
 and ABCA1 Tg mice. To limit complications due to incomplete Aβ extraction 
from tissue with amyloid plaques, all experiments were performed on young animals (3.5 
months old) prior to the onset of detectable plaque deposition. For the 
immunoprecipitation step, we used an antibody to the central domain of Aβ (amino acids 
13-28). As a result, the FCR values we obtained for Aβ represent the kinetic parameters 
for the total amount of Aβ and likely represent the average kinetic rates of all Aβ species 
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in the brain. Plots of the labeled/unlabeled Aβ values over time along with the 
monoexponential slopes of these curves for the ABCA1 Tg and ABCA1
-/-
 mice are 
shown in Figures 4.3A,B and 4.4A,B, respectively. The PS, FCR, and PR and half-life 
values are given in Table 4.3. The FCR and half-life of Aβ were approximately 0.24 
pools/hr and 2.8 to 2.9 hrs, respectively. No statistical differences were observed for 
these values between the Wt, ABCA1 Tg, and ABCA1
-/-
 genotypes. There were also no 
differences in the PS or PR between any of the genotypes. Therefore, the amount of 
ABCA1 in the brain does not appear to regulate Aβ turnover in the mouse brain at an age 
prior to plaque deposition. 
 
Table 4.3. PS, FCR, PR, and Half-life Values for Aβ by Mouse Genotype 
 
Genotype PS 
(pg/mg) 
FCR  
(pools/hr) 
PR 
(pg/mg/hr) 
Half-life 
(t
1/2
, hrs) 
Wt (ABCA1 
Tg control) 
11.23±0.56 0.238±0.016 2.65±0.21 2.91 
ABCA1 Tg 11.14±0.46 0.247±0.016 2.77±0.23 2.81 
P 0.90 0.69 0.68  
     
Wt (ABCA1-/- 
control) 
7.67±0.26 0.247±0.023 1.91±0.15 2.81 
ABCA1-/- 7.87±0.33 0.243±0.016 1.89±0.19 2.85 
P 0.64 0.88 0.94  
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Fig. 4.3. 
13
C6-leucine brain Aβ labeling in the presence of ABCA1 
overexpression. (A) Cohorts of wildtype and ABCA1 transgenic mice were 
labeled with 
13
C6-leucine and the brains isolated after predetermined time points. 
Total Aβ was immunoprecipitated from the cortex and the labeled/unlabeled 
ratios were then plotted versus time for each genotype. (B) For FCR 
measurements, the data was plotted as in Figure 4.1B and the monoexponential 
slopes were calculated for ABCA1 Tg mice and their respective Wt controls (n=5-
6 mice per time point, error bars represent SEM, dotted lines represent 95% 
confidence band). 
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Fig. 4.4. 
13
C6-leucine brain Aβ labeling in the setting of ABCA1 deletion. (A) 
Cohorts of wildtype and ABCA1
-/-
 mice were labeled with 
13
C6-leucine and the 
brains isolated after predetermined time points. The Aβ labeled/unlabeled ratios 
were then calculated and the data plotted as in Fig. 4.3A. (B) For FCR 
measurements, the monoexponential slopes were measured for ABCA1
-/-
 mice 
and Wt control mice as in Fig. 4.3B. (n=5-6 mice per time point, error bars 
represent SEM, dotted lines represent 95% confidence band). 
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Discussion 
Previous studies in mice have demonstrated that altering ABCA1 levels in the 
brain affects both the amount of apoE and the extent of Aβ deposition in the brain. ApoE 
levels were significantly decreased in the brains of both ABCA1
-/-
 and ABCA1 Tg mice, 
though to a greater extent in ABCA1
-/- 
mice (Hirsch-Reinshagen et al., 2004; Wahrle et 
al., 2008; Wahrle et al., 2004). The reason for the decreased apoE levels was 
hypothesized to be due to the increased catabolism of apoE in both cases. When bred 
with APP transgenic mice, ABCA1 deficient mice had either similar amounts or 
increased Aβ accumulation in the brain (Hirsch-Reinshagen et al., 2005; Koldamova et 
al., 2005a; Wahrle et al., 2005). Conversely, increasing brain ABCA1 levels in APP 
transgenic mice led to a significant decrease in the extent of Aβ and amyloid deposition 
in the brain (Wahrle et al., 2008). Because ABCA1 deletion and overexpression both 
decreased apoE levels but exerted opposing effects on Aβ deposition, it was hypothesized 
that ABCA1 functions in regulating Aβ deposition via a process other than solely 
regulating apoE levels. One possibility is that the effect of ABCA1 on the extent of apoE 
lipidation regulates the ability of apoE to alter either Aβ clearance or fibrillization. In this 
chapter, we used stable isotope labeling kinetics (SILK) to analyze how deleting or 
overexpressing ABCA1 alters the kinetic properties of apoE and Aβ in the mouse brain. 
Both ABCA1 overexpression and deletion increased the fractional clearance rate of apoE 
from the brain and decreased the total amount of apoE. However, altering ABCA1 levels 
had no effect on the Aβ fractional clearance rate or Aβ levels in the brain.  
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The increased FCR of apoE in the ABCA1
-/-
 mice parallels nicely with plasma 
kinetic studies performed in humans with loss-of-function mutations in ABCA1 
(Schaefer et al., 1981; Schaefer et al., 2001). These studies infused radioiodinated apoA-I 
or apolipoprotein B-100 (apoB-100) into individuals with Tangier’s disease and control 
individuals and measured the disappearance of the labeled apoA-I and apoB-100 over 
time. The catabolism of apoA-I high density lipoprotein (HDL) and low density 
lipoprotein apolipoprotein B-100 (LDL B-100) were increased in the plasma of Tangier’s 
disease patients, suggesting decreased stability of poorly-lipidated lipoprotein particles. 
The mechanism underlying the rapid catabolism of apoA-I in these individuals and the 
apoE in our mouse studies is unclear, but could be due to abnormalities in either receptor 
function or degradative enzyme activity caused by changes in the structural 
characteristics of the lipoprotein particles. It is also possible that the mechanisms 
underlying the increased apoE catabolism in mice with ABCA1 overexpression and 
deletion are not the same. The lipidation of apoE significantly alters its propensity to bind 
to LDLR, with increased lipid levels leading to enhanced binding (Innerarity and Mahley, 
1978). As a result, the faster apoE clearance rate in the ABCA1 Tg mice may be due to 
increased LDLR-mediated clearance of the more highly lipidated apoE-containing 
lipoprotein particles. 
In the experiments described in this chapter, we first used SILK to measure the 
kinetics of Aβ in the mouse brain. Previous studies have measured Aβ clearance from the 
brain either using [
35
S]methionine labeling (Savage et al., 1998), or by measuring the 
disappearance of Aβ following the pharmacological inhibition of Aβ production 
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(Abramowski et al., 2008; Barten et al., 2005; Cirrito et al., 2003). The half-life of Aβ 
clearance in these studies ranged from 30 min to 2 hr. Consistent with these studies, we 
observed a half-life for Aβ of approximately 2.8-2.9 hrs (Table 4.3). In comparison to 
other studies, our technique has unique advantages in that it does not require a radioactive 
tracer and kinetics are determined in the steady-state, which is not possible with the 
inhibition of Aβ production. Future SILK studies in mice could compare the kinetics of 
specific species of Aβ (such as Aβ38, Aβ40, and Aβ42) and analyze how Aβ metabolism 
changes as mice age. 
Several studies in cell culture have shown that ABCA1 regulates both the 
production and clearance of Aβ. Overexpression of ABCA1 decreased the production and 
secretion of Aβ in both neuronal and non-neuronal cell lines (Kim et al., 2007; Sun et al., 
2003). In primary microglia, ABCA1 deletion decreased the intracellular degradation of 
Aβ (Jiang et al., 2008). Less evidence exists in vivo that ABCA1 levels alter the 
production or clearance of Aβ. No changes in the proteolytic processing of APP were 
observed in APP transgenic mice crossed to ABCA1
-/-
 or ABCA1 Tg mice (Koldamova 
et al., 2005a; Wahrle et al., 2008). A study measuring the disappearance of radiolabeled 
Aβ injected into the brains of ABCA1-/- mice also found no effect on Aβ clearance across 
the blood-brain barrier (Akanuma et al., 2008). In this chapter, we used SILK analysis to 
determine the effect of ABCA1 overexpression and deletion on the clearance and 
production rates of endogenously-produced Aβ. Our results suggest that at a young age 
prior to the onset of plaque deposition, ABCA1 levels do not alter Aβ clearance or 
production in the mouse brain. Though we cannot rule out the possibility that changes in 
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Aβ clearance develop as the mice age, our current data suggests that the effect of ABCA1 
on Aβ deposition in the brain may not occur due to altered metabolism of Aβ.  
Future studies should analyze other possible mechanisms for how ABCA1 could 
regulate Aβ levels and deposition in the brain. It is possible that the effect of ABCA1 is 
caused by altered modulation of differentially lipidated forms of apoE on Aβ aggregation 
or fibrillogenesis. A previous study has shown that increasing the lipidation of apoE 
enhances the ability of apoE to bind to Aβ in vitro (Tokuda et al., 2000). However, 
whether or not increased apoE-Aβ binding leads to more or less Aβ deposition in vivo is 
currently unknown. The possibility also exists that ABCA1 modulates Aβ deposition in a 
manner that is independent of apoE. ABCA1 levels may regulate the extent of 
intracellular cholesterol levels, which in turn could alter Aβ secretion (Di Paolo and Kim, 
2011). ABCA1 could also modulate the function of other proteins involved in brain 
lipoprotein metabolism, such as apoA-I or apolipoprotein J (apoJ). Therefore, further 
work is needed to determine the molecular mechanism responsible for the role ABCA1 
plays in regulating Aβ amyloidogenesis 
 
Conclusions 
 In this chapter, we have used stable isotope labeling kinetics (SILK) coupled with 
mass spectrometry to analyze the effect of ABCA1 levels on the metabolism of apoE and 
Aβ in the mouse brain. ABCA1 had previously been shown to regulate both the amount 
of apoE in the brain, along with the extent of Aβ deposition, and represents a potential 
molecular target for lowering brain amyloid levels in AD patients. The FCR of apoE was 
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increased 1.9- and 1.5-fold in mice that either lacked or overexpressed ABCA1, 
respectively. ABCA1 deletion and overexpression also decreased the total amount of 
apoE protein in the brain. However, ABCA1 had no effect on the FCR or production rate 
of Aβ, suggesting that ABCA1 does not regulate Aβ metabolism in the brain. 
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Chapter 5 
Preliminary Studies: 
Effect of the LDLR-regulatory Protein PCSK9 on Aβ Levels and Deposition 
 
(This work was completed with the assistance of several individuals. Dr. Jungsu Kim, 
Devika Bagchi, and Floy Stewart performed the staining experiments and plaque 
analysis. Hong Jiang helped with the brain tissue collection and ELISA experiments.) 
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Summary 
 Previously we have shown that increasing LDLR levels in the brains of APP 
transgenic mice decreases the extent of Aβ deposition and enhances the clearance of Aβ. 
In chapter 2 of this thesis, we have also demonstrated that increasing LDLR levels 
enhances the uptake and degradation of Aβ by astrocytes. Therefore, these results suggest 
that finding pathways that regulate brain LDLR levels will identify potential therapeutic 
targets for the treatment of Alzheimer’s disease. The protein proprotein convertase 
subtilisin/kexin type 9 (PCSK9) has been shown to play an important role in the 
degradation of LDLR in cell lines and peripheral tissues. However, the ability of PCSK9 
to regulate LDLR levels in the brain has not been studied. In this chapter, we describe 
preliminary studies that analyzed the effect of PCSK9 on LDLR protein levels in the 
mouse brain. We also analyzed the effect of PCSK9 deletion on Aβ deposition in the 
brains of APP transgenic mice. Our preliminary results suggest that PCSK9 does not 
regulate LDLR levels in the brain, but the level of PCSK9 does alter the extent of Aβ 
deposition through an unknown mechanism. 
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Introduction 
 Increasing the amount of LDLR in the brain decreases the extent of Aβ deposition 
and enhances Aβ clearance from the brains of APP transgenic mice (Kim et al., 2009b). 
Based on the experiments in chapter 1 of this thesis, LDLR also promotes the cellular 
uptake and degradation of soluble Aβ by glial cells. These results suggest that increasing 
brain LDLR levels represents a potential therapeutic avenue for lowering amyloid load in 
the Alzheimer’s disease (AD) brain. One method to increase LDLR levels would be to 
inhibit LDLR degradation in the brain. However, the molecular pathways mediating 
LDLR degradation in the brain are not well-characterized. 
 PCSK9 is an important regulator of peripheral LDL catabolism via its ability to 
facilitate LDLR degradation (Horton et al., 2009). In humans, gain-of-function and loss-
of-function mutations in PCSK9 have been identified that cause hyper- and 
hypocholesterolemia, respectively (Abifadel et al., 2003; Cohen et al., 2005). Studies in 
mice demonstrated that the cause of the cholesterol metabolism abnormalities with 
altered PCSK9 levels was the ability of PCSK9 to alter LDLR levels. Hepatic 
overexpression of PCSK9 resulted in hypercholesterolemia and a significant decrease in 
the amount of LDLR protein (Maxwell and Breslow, 2004; Park et al., 2004), while 
PCSK9 deletion caused a decrease in plasma cholesterol and increased LDLR protein 
levels (Rashid et al., 2005). In these experiments, altering PCSK9 levels had no effect on 
the amount of LDLR mRNA, suggesting that PCSK9 regulates LDLR post-
transcriptionally. Subsequent studies in both cell culture and mouse models have 
demonstrated that PCSK9 is a secreted protein that circulates in the blood, and secreted 
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PCSK9 is capable of decreasing liver LDLR levels (Benjannet et al., 2004; Lagace et al., 
2006; Seidah et al., 2003). At a molecular level, PCSK9 appears to exert its effect on 
LDLR by directly binding to LDLR on the cell surface and facilitating its trafficking to 
the lysosomal pathway following endocytosis (Fisher et al., 2007; Lagace et al., 2006; 
Yamamoto et al., 2011; Zhang et al., 2007). Because of its effects on peripheral 
cholesterol levels, PCSK9 has gained significant attention as a potential therapeutic target 
to treat cardiovascular disease (Horton et al., 2009). 
The role of PCSK9 in the brain and its effect on brain LDLR levels has not been 
extensively studied. In the developing mouse brain, PCSK9 deletion has been shown to 
increase LDLR levels and decrease apoE levels (Rousselet et al., 2011). However, two 
studies have shown that adult PCSK9
-/-
 mice do not have changes in brain LDLR levels 
(Liu et al., 2010; Rousselet et al., 2011). Interestingly, PCSK9
-/-
 mice have been shown to 
have increased levels of mouse Aβ in the brain due to increased levels of the enzyme 
beta-site APP cleaving enzyme 1 (BACE1) that cleaves the amyloid precursor protein 
(APP) to produce Aβ (Jonas et al., 2008). In the preliminary data described in this 
chapter, we have evaluated in our hands the levels of LDLR and apoE in the brains of 
PCSK9
-/-
 mice. We also crossed the PCSK9
-/-
 mice to an APP transgenic mouse model to 
evaluate the effect of PCSK9 deletion on Aβ deposition in the brain. 
 
Experimental Procedures 
Mouse breeding - APPswe/PSEN1ΔE9 (APP/PS1) transgenic mice were bred with 
PCSK9
-/-
 mice (purchased from Jackson Labs, Bar Harbor, ME) (Rashid et al., 2005) to 
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generate mice that were APP/PS1
+/-
PCSK9
+/-
. The APP/PS1
+/-
 PCSK9
+/-
 mice were then 
bred to PCSK9
+/-
 mice to produce mice of the following genotypes used in the 
experiments: APP/PS1/PCSK9
+/+
, APP/PS1/PCSK9
+/-
, and APP/PS1/PCSK9
-/-
. All 
experiments were approved by the animal studies committee of Washington University 
School of Medicine. 
 
Quantitative analyses of amyloid deposition - Brain hemispheres from 7-month-old 
mice were placed in 30% sucrose prior to freezing and cutting on a freezing sliding 
microtome. Serial coronal sections of the brain at 50 μm intervals were collected using 
the rostral (anterior commissure) to the caudal edge of the hippocampus as landmarks. 
Sections were stained with biotinylated Aβ (HJ3.4) antibody to detect Aβ in the brain, or 
X-34 dye to detect fibrillar amyloid. All stained brain sections were scanned using a 
NanoZoomer slide scanner. The scanned images of sections stained with Aβ antibody 
were then converted to grayscale and exported using NDP viewer software. These 
exported images were set at a threshold to highlight plaques and then the cortex and 
hippocampus were analyzed by the “Analyze Particles” function in the Image J software. 
The particles identified as plaques by the program were individually inspected to verify 
whether the particle was a plaque or not. The X-34 stained sections were converted to 
grayscale and exported using ACDSee Pro 2 software. These exported images were also 
set at a threshold to highlight fibrillar plaques and quantified in a similar manner to the 
Aβ antibody stained sections.  Three brain sections per mouse, each separated by 300 
microns, were used for quantification. The average of the results from three sections was 
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used to represent plaque load for each mouse. For analysis of Aβ plaque in the cortex, the 
cortex immediately dorsal to the hippocampus was assessed. All analyses were performed 
in a blinded manner. Our sample size for the Aβ (HJ3.4) and X-34 staining were as 
follows: n=7 APP/PS1/PCSK9
+/+
 males, n=8 APP/PS1/PCSK9
-/-
 males, n=6 
APP/PS1/PCSK9
+/+
 females, and n=11 APP/PS1/PCSK9
-/-
 females. 
 
ELISA to measure brain apoE and Aβ levels - A sequential tissue extraction was 
performed on cortical brain hemispheres from 7-month-old mice. The brains were 
sequentially homogenized with PBS, modified RIPA buffer (Millipore, USA), and 5M 
Guanidine HCl in the presence of a protease inhibitor mixture (Roche, USA). The levels 
of Aβ and apoE were measured using sandwich enzyme-linked immunosorbent assays 
(ELISA). For the Aβ ELISA, HJ2 (Aβ35-40) and HJ7.4 (Aβ37-42) were used as the 
capture antibodies and HJ5.1-biotin (Aβ13-28) was used as the detection antibody. HJ6.2 
and HJ6.3-biotin were used as the capture and detection antibodies, respectively, for the 
apoE ELISA. Sample sizes for the ELISAs were as follows: 4 APP/PS1/PCSK9
+/+
 males, 
2 APP/PS1/PCSK9
-/-
 males, 5 APP/PS1/PCSK9
+/+
 females, and 8 APP/PS1/PCSK9
-/- 
females.  
 
Immunoblot detection of PCSK9 and LDLR levels – Brain tissue was lysed by the 
addition of RIPA buffer (1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 25 mM Tris-
HCl, 150 mM NaCl) followed by sonication (2 rounds of 20-1 sec pulses). The lysates 
were then spun down at 14,000 rpm for 20 minutes and the supernatant was collected. 
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Protein concentration was determined by bicinchoninic acid (BCA) protein assay. Equal 
amounts of protein for each sample were run on 4-12% Bis-Tris XT gels and transferred 
to polyvinylidene fluoride (PVDF) membranes (0.45 µm pore size). All membranes were 
then blocked in 5% milk in TBS-T (tris-buffered saline with 0.125% Tween-20). Blots 
were probed for LDLR (Novus Cat#NB110-57162 and MBL Cat#JM3839-100) and 
PCSK9 (R&D Systems). Protein signal from the membranes was measured using the 
Lumigen TMA-6 ECL detection kit (Lumigen, USA). 
 
Statistics - All data are presented as mean ±standard error of the mean (SEM) unless 
otherwise noted. Statistical significance (*p<0.05, **p<0.01, ***p<0.001) was 
determined using GraphPad Prism Software using a two-tailed student’s t-test.  
 
Results 
PCSK9 deletion does not affect LDLR and apoE levels in the brain. In the mouse 
liver, PCSK9 deletion has previously been shown to cause a significant increase in the 
level of LDLR (Rashid et al., 2005). To determine whether PCSK9 deletion exerts a 
similar effect in the brain, we measured LDLR levels by immunoblot in the brains of both 
PCSK9
+/+ 
and PCSK9
-/-
 mice (Fig. 5.1A). In the brain cortex, we observed no differences 
in the LDLR levels between PCSK9
+/+ 
and PCSK9
-/-
 mice. Similar to previous studies, 
LDLR levels were increased in the livers of PCSK9
-/-
 mice. Somewhat surprisingly, we 
could not detect any PCSK9 protein in the brain via immunoblot analysis (Fig. 5.1A). 
Whether PCSK9 protein is present at a level below the sensitivity of this assay or PCSK9 
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protein is not expressed in the brain cortex is currently unknown. We also measured apoE 
levels in both the plasma (Fig. 5.1B) and brain cortex (Fig. 5.1C) of the PCSK9
+/+ 
and 
PCSK9
-/-
 mice. In the plasma, apoE levels were significantly decreased in the PCSK9
-/- 
mice, likely due to the increased amount of LDLR. However, PCSK9 deletion had no 
effect on the amount of apoE present in the brain. Therefore, these results confirm that 
PCSK9 deletion does not alter LDLR levels in the mouse brain. 
 
PCSK9 deletion decreases Aβ and amyloid deposition in the mouse brain. Despite 
the fact that the amount of PCSK9 had no effect on LDLR levels in the brain, we decided 
to analyze the effect of PCSK9 deletion on Aβ deposition in the brain. The possibility 
still remained that PCSK9 could affect Aβ through an LDLR-independent mechanism, 
such as through modulation of BACE1 levels has had previously been shown (Jonas et 
al., 2008). We bred APP/PS1 mice with PCSK9
-/-
 mice to generate APP/PS1/PCSK9
+/+
 
and APP/PS1/PCSK9
-/-
 mice. The extent of Aβ deposition was analyzed by both 
histochemical and biochemical methods. We analyzed male and female mice as separate 
groups because of previously noted differences between sex in the amount of Aβ 
deposition (Kim et al., 2009b). Brain sections from 7-month old APP/PS1/PCSK9
+/+ 
and 
APP/PS1/PCSK9
-/-
 mice were immunostained with biotinylated-HJ3.4 antibody (anti-Aβ 
1-16) (Fig. 5.2A). Quantitative analyses of anti-Aβ immunostaining demonstrated that the 
amount of Aβ deposition was significantly decreased in both the cortex (Fig. 5.2B) and 
hippocampus (Fig. 5.2C) of female mice. The inhibitory effect of PCSK9 deletion on Aβ 
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deposition was not statistically significant in male mice, though a trend toward decreased 
Aβ accumulation was observed. 
 To determine the effect of PCSK9 deletion on fibrillar amyloid deposition, brain 
sections were stained with X-34 dye (Fig. 5.3A). Similar to the Aβ immunostaining 
results, female APP/PS1/PCSK9
-/-
 mice had significantly decreased levels of X-34-
positive fibrillar plaque load in both the cortex (Fig. 5.3B) and hippocampus (Fig. 5.3C). 
Male APP/PS1/PCSK9
-/-
 mice had statistically significant decreased levels of X-34-
positive fibrillar plaque load in the cortex (Fig. 5.3B), but not the hippocampus (Fig. 
5.3C). Biochemical analyses of cortical Aβ levels demonstrated a trend toward a 
reduction in insoluble Aβ40 levels (Fig. 5.4A) and insoluble Aβ42 levels (Fig. 5.4B) with 
PCSK9 deletion. However, the decrease was only significant for insoluble Aβ40 levels in 
male mice. The reason for the discrepancy in the differences between Aβ deposition 
between genotypes and the lack of a strong difference in the biochemical analysis is 
unknown. In summary, PCSK9 deletion causes a significant reduction in the extent of Aβ 
deposition and amyloid load in female APP/PS1/PCSK9
-/-
 mice, and a trend toward a 
reduction in male APP/PS1/PCSK9
-/-
 mice. 
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Fig. 5.1. LDLR and apoE levels in the brain and periphery of PCSK9
-/-
 mice. 
(A) PCSK9 and LDLR levels were measured in the liver and brain cortex by 
immunoblot. The levels of apoE were measured in the (B) plasma and (C) cortex 
via ELISA. Mean ± SEM * denotes p<0.05, ** denotes p<0.01, n.s. not 
significant 
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Fig. 5.2. Effect of PCSK9 deletion on Aβ deposition. (A) PCSK9+/+ and  
PCSK9
+/-
 brain sections were stained with an anti-Aβ antibody. The % area 
covered by Aβ staining was quantified for both the (B) cortex and (C) 
hippocampus of male and female mice. The representative images shown are from 
female mice. Mean ± SEM * denotes p<0.05, *** denotes p<0.001, n.s. not 
significant 
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Fig. 5.3. Effect of PCSK9 deletion on amyloid deposition. (A) PCSK9
+/+ 
and 
PCSK9
+/-
 brain sections were stained with X-34 to detect amyloid plaques. The % 
area covered by X-34 staining was quantified for both the (B) cortex and (C) 
hippocampus of male and female mice. The representative images shown are from 
female mice. Mean ± SEM * denotes p<0.05, *** denotes p<0.001, n.s. not 
significant 
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Fig. 5.4. Effect of PCSK9 deletion on Aβ levels in the brain. Insoluble cortex 
Aβ levels were measured in the guanidine tissue lysate using (A) Aβ40 and (B) 
Aβ42 ELISA’s. Mean ± SEM  * denotes p<0.05, n.s. not significant 
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Discussion and Future Directions 
 Since the accumulation of Aβ in the brain has been hypothesized to be one of the 
primary pathogenic events in AD (Hardy and Selkoe, 2002), significant effort has been 
devoted to understanding the molecular pathways that modulate Aβ clearance from the 
brain. We have previously demonstrated that increasing the expression of LDLR in the 
mouse brain significantly decreased the amount of Aβ deposition and amyloid load (Kim 
et al., 2009b). Therefore, identifying methods of promoting the expression of LDLR or 
inhibiting the degradation of LDLR in the brain represents a potential means of lowering 
Aβ levels. PCSK9 is a protein that has been shown to directly promote LDLR 
degradation, and for this reason has been the focus of attention for developing 
therapeutics to lower peripheral cholesterol levels (Horton et al., 2009). However, the 
effect of PCSK9 on LDLR in the brain has not been extensively studied. In this chapter, 
we analyzed the effect of PCSK9 deletion on brain LDLR and apoE levels. We also 
crossed PCSK9
-/-
 mice with an APP transgenic mouse model to analyze the effect of 
PCSK9 levels on Aβ deposition in the brain. We hypothesized that PCSK9-/- mice would 
have increased LDLR levels, and as a result the amount of Aβ deposition would decrease. 
 Our preliminary studies suggest that PCSK9 does not regulate LDLR or apoE 
levels in the mouse brain. While we observed an increase in liver LDLR levels and 
decrease in plasma apoE levels in PCSK9
-/-
 mice, brain LDLR and apoE levels did not 
change. These results are similar to the findings published previously by two other groups 
(Liu et al., 2010; Rousselet et al., 2011). Despite no observed effect on brain LDLR 
levels, PCSK9 deletion decreased both Aβ deposition and amyloid plaque load in female 
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mice. The mechanism underlying this observation is currently unclear, but it still may 
occur through the effect of PCSK9 on LDLR. A previous study has shown that in the 
ischemic stroke mouse model, PCSK9 levels are upregulated in the dentate gyrus while 
hippocampal LDLR levels decrease (Rousselet et al., 2011). The decrease in LDLR 
levels is attenuated in mice that lack PCSK9. A similar effect could be occurring in mice 
with Aβ deposition, leading to a local increase in PCSK9 and decrease in LDLR levels in 
the vicinity of Aβ plaques and ultimately resulting in impaired clearance of Aβ. With 
PCSK9 deletion, the effect of Aβ deposition on LDLR levels may be attenuated. Further 
experiments could look at the levels of PCSK9 and LDLR in regions surrounding plaque 
deposition. It is also possible that PCSK9 may effect Aβ deposition in the brain through 
its effect on peripheral apoE levels. The role of peripheral apoE in central nervous system 
Aβ clearance has not been thoroughly evaluated. The possibility exists that peripheral 
apoE can regulate brain Aβ levels and amyloidosis by influencing plasma Aβ clearance. 
However, this has yet to be tested experimentally. Therefore, further work is needed to 
determine what role peripheral apoE levels have on CNS Aβ levels and pathology. 
 PCSK9 could also regulate Aβ deposition through an LDLR-independent 
mechanism. PCSK9 has been shown to facilitate the degradation of BACE1 in both cell 
culture and the mouse brain (Jonas et al., 2008). Though we have yet to measure BACE1 
levels in the APP/PS1/PCSK9
-/-
 mice, the effect of PCSK9 on decreasing BACE1 levels 
would predict higher Aβ levels in the PCSK9-/- mouse brain. Since we observed lower 
levels of Aβ deposition, the BACE1 mechanism likely is not responsible for our results. 
Another possibility is that PCSK9 regulates the levels of other LDLR family members in 
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the brain. A previous study has shown that PCSK9 also facilitates the degradation of 
VLDLR and ApoER2 (Poirier et al., 2008). However, it is not yet known whether either 
of these receptors modulates Aβ levels in the mouse brain. Finally, it is possible that the 
effect of PCSK9 on Aβ deposition is due to an effect on an unidentified target of PCSK9. 
For instance, several recent studies have shown via microarray technology that PCSK9 
affects the expression of genes in multiple cellular pathways, including the unfolded 
protein response, inflammation and stress response, and protein ubiquitination (Lan et al., 
2010; Ranheim et al., 2008). Therefore, further studies are necessary in the mouse brain 
to identify novel targets of PCSK9 that may influence the extent of Aβ degradation in the 
brain. 
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Chapter 6 
Conclusions and Future Directions
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Summary 
 The initial description and evolution of the amyloid cascade hypothesis as an 
underlying factor in AD pathogenesis has spurred extensive research to characterize the 
factors involved in Aβ homeostasis in the brain. In particular, significant effort has been 
devoted to defining the molecular and systemic pathways that modulate Aβ clearance 
from the brain. Significant evidence exists from both cellular and animal models that the 
isoform of apoE and the amount of apoE in the brain influence both the extent of Aβ 
aggregation and its metabolism (Kim et al., 2009a). Therefore, understanding how apoE 
levels are modulated in the brain will further elucidate the mechanisms underlying Aβ 
clearance and identify novel therapeutic targets. Receptors for apoE (such as LDLR) and 
proteins that influence apoE lipidation status (such as ABCA1) both have been shown to 
affect Aβ levels and deposition in the brain. In this thesis work, we have analyzed how 
the modulation of LDLR and ABCA1 levels alters the clearance of apoE and Aβ at a 
cellular and systemic level. 
 In chapter two, we demonstrated that the amount of LDLR in astrocytes regulates 
the extent of Aβ uptake and degradation. We showed that increasing LDLR levels in 
primary astrocytes increased both the uptake and clearance of Aβ, while deletion of 
LDLR impaired the uptake of Aβ. Overexpression of LDLR also enhanced the cellular 
degradation of Aβ and facilitated the vesicular transport of Aβ to lysosomes. The 
increased Aβ uptake and clearance in the setting of LDLR overexpression occurred even 
in the absence of apoE, suggesting an apoE-independent effect of LDLR on Aβ. Finally, 
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we provided evidence that Aβ can directly bind to LDLR, suggesting LDLR-mediated Aβ 
uptake could occur through an interaction between LDLR and Aβ. 
 In the third chapter, we described a novel method to measure the kinetics of 
proteins in the brain using stable isotope labeling coupled with mass spectrometry. In this 
technique, we pulse labeled various cohorts of mice with 
13
C6-leucine and isolated the 
brains after pre-determined time points. We then measured the extent of 
13
C6-leucine 
incorporation in the brain tissue lysate over time using mass spectrometry to measure the 
ratio of labeled to unlabeled protein. The fractional clearance rate was then calculated by 
analyzing the time course of disappearance for the labeled protein. We validated this 
technique by demonstrating that the clearance of apoE is enhanced in the brains of mice 
overexpressing LDLR. We also applied this technique to measure the clearance of the 
apoE isoforms from the brains of the human apoE targeted-replacement mice. No 
significant differences in the fractional clearance rate were measured between the 
isoforms, though there was a trend for apoE4 being cleared more slowly than apoE2 and 
apoE3. 
 In the experiments in chapter 4, we used our stable isotope labeling kinetics 
technique to analyze the effect of ABCA1 levels on the clearance of apoE and Aβ from 
the mouse brain. We observed that the fractional clearance rate of apoE was increased 
1.9- and 1.5- fold in mice that either lacked or overexpressed ABCA1, respectively. Both 
ABCA1 deletion and overexpression also decreased the total amount of apoE protein in 
the brain. To measure the effect of ABCA1 levels on Aβ clearance, we crossed PDAPP 
transgenic mice with either ABCA1
-/-
 mice or ABCA1 transgenic mice. After labeling the 
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mice with 
13
C6-leucine, we observed that ABCA1 levels had no effect on the FCR or 
production rate of Aβ, suggesting that ABCA1 does not regulate Aβ metabolism in the 
brain. 
 Finally, in the fifth chapter we describe preliminary studies analyzing the effect of 
PCSK9 levels on the amount of LDLR and Aβ deposition in the brain. We found that 
deletion of PCSK9 increased LDLR levels and decreased apoE levels in the periphery, 
but had no effect on LDLR and apoE levels in the brain. However, we did observe that 
PCSK9 deletion decreased the amount of Aβ deposition and amyloid load in the mouse 
brain through a mechanism that has yet to be defined. 
 
Cellular degradation of Aβ in vivo and the role of LDLR 
 Though cells in culture have been shown to endocytose and degrade Aβ, the role 
of cellular degradation in the clearance of Aβ in the brain remains unclear. Two 
approaches have been taken to study the potential ability of cells to degrade Aβ in vivo. 
One approach has been to ablate a whole population of cells and analyze the effect on Aβ 
levels and deposition in the brain. This approach has primarily been used to study the 
ability of microglia to degrade soluble and fibrillar Aβ. By treating mice that express the 
thymidine kinase (TK) of herpes simplex virus under the CD11b promoter with 
ganciclovir, it is possible to selectively ablate all microglial cells in the brain. The 
CD11b-TK mice have been crossed with APP transgenic mouse models to analyze the 
effect of microglia on Aβ deposition (Grathwohl et al., 2009; Simard et al., 2006). 
Somewhat surprisingly, the results from these studies have suggested that resident 
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microglia in the brain play little to no role in modulating brain Aβ deposition, as Aβ 
levels do not change when microglia are absent. Another approach has been to 
manipulate specific enzymes that function in cellular degradation, such as those in the 
endolysosomal pathway. For instance, genetic deletion of the lysosomal protein cathepsin 
B has been shown to increase Aβ levels and worsen plaque pathology while 
overexpression of cathepsin B reduced plaques (Mueller-Steiner et al., 2006; Sun et al., 
2008). However, in these studies it is difficult to attribute the effect of cathepsin B solely 
to intracellular Aβ degradation because cathepsin B is also secreted into the extracellular 
environment and is present within amyloid plaques. Therefore, new approaches are 
needed that solely alter cellular degradation pathways in order to definitively determine 
whether cellular clearance pathways alter Aβ pathology in vivo. 
 Despite evidence of extensive astrogliosis in the AD brain, the role of astrocytes 
in the cellular degradation of Aβ and clearance of Aβ deposits in vivo is unknown. The 
likely reason for this is the lack of animal models that have increased or decreased 
astrocytic function. Similar to microglia, attempts have been made to ablate the astrocyte 
population in vivo using ganciclovir treatment of mice expressing TK under the astrocyte-
specific GFAP promoter (Bush et al., 1999; Bush et al., 1998). However, since the effect 
of ganciclovir treatment requires cell division, the loss of astrocytes in this model was 
minimal and only occurred following tissue injury. Another approach has been to target 
specific proteins that are upregulated in astrocytes following injury, such as vimentin, 
glial fibrillary acidic protein (GFAP), and signal transducer and activator of transcription 
3 (STAT3). In both a vimentin/GFAP double knockout mouse and a STAT3 astrocyte-
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specific knockout mouse (Herrmann et al., 2008; Okada et al., 2006; Pekny et al., 1999), 
the ability of astrocytes to respond to injury was impaired. However, the effect on brain 
Aβ levels and deposition when these proteins are deleted in the astrocytes of APP-
transgenic mice has yet to be described. 
 Rather than targeting cellular function as a whole, a more feasible method of 
analyzing the ability of cells to degrade Aβ in vivo would be to target pathways that 
specifically play a role in Aβ uptake and degradation. Since we have shown in chapter 2 
that LDLR functions in the uptake of Aβ by astrocytes in culture, it would be interesting 
to determine if selectively overexpressing or deleting LDLR in astrocytes plays a role in 
regulating Aβ levels and deposition in the brain. LDLR could be selectively 
overexpressed in astrocytes in the mouse brain using either a transgene or virus with a 
GFAP promoter. Selective deletion of LDLR could be achieved in mice by crossing mice 
expressing the Cre recombinase under a GFAP promoter to mice expressing a floxed 
construct of LDLR. In both cases, it would be ideal to manipulate LDLR levels in apoE
-/-
 
mice to avoid the confounding effect of changes in apoE levels. If astrocyte-specific 
alteration of LDLR levels in the setting of apoE deletion alters Aβ deposition or 
clearance, it would strongly suggest that LDLR facilitates the cellular degradation of Aβ 
in vivo. 
 
Role of LDLR in other modes of Aβ clearance 
 Though we have hypothesized that LDLR affects Aβ levels in the brain by 
facilitating its cellular degradation, LDLR may also function in other pathways of Aβ 
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clearance. LDLR may facilitate the transport of Aβ across the blood-brain-barrier (BBB), 
as has been shown for LRP1 (Deane et al., 2004; Shibata et al., 2000). This could be 
assessed both in vitro and in the mouse brain. The ability of LDLR to facilitate Aβ 
endocytosis and clearance by brain endothelial cells could be assessed by measuring the 
uptake and degradation of Aβ by mouse brain capillary preparations isolated from LDLR 
transgenic and knock-out brains. LDLR-mediated clearance across the BBB could also be 
assessed in LDLR transgenic and knockout mice brains by measuring the transcytosis of 
a labeled form of Aβ from the brain to the blood, as has been done before for I125-labeled 
Aβ (Shibata et al., 2000). It is important to emphasize that astrocytes are one of the main 
cell types that make up the BBB, and as such, they could play a role in both the cellular 
degradation of Aβ and its clearance across the BBB. 
 It is also possible that LDLR regulates Aβ deposition in the brain by facilitating 
Aβ clearance in the periphery. Several studies have suggested that brain Aβ levels are 
altered by regulating the amount of Aβ-binding proteins in the plasma, which act as an 
Aβ sink (DeMattos et al., 2001a; Matsuoka et al., 2003; Sagare et al., 2007). However, 
the ability of peripheral proteins to function as Aβ sinks remains controversial. 
Peripherally injected Aβ-binding proteins may enter the brain (Yamada et al., 2009), and 
as such it is not easy to determine whether differences in brain Aβ levels are due to 
altered stability of Aβ due to binding to the injected protein, or actual differences in Aβ 
clearance.  Despite these issues, the possibility remains that a dynamic equilibrium exists 
between plasma and brain Aβ levels, and through regulating peripheral Aβ levels the 
amount of Aβ clearance in the brain may be altered. In terms of LDLR, this hypothesis 
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could be tested by crossing mice that overexpress LDLR selectively in the liver (Pathak 
et al., 1990) with APP transgenic mice. In these mice, LDLR should only regulate Aβ 
clearance from the plasma. If brain Aβ levels and plaque loads are decreased with liver-
specific LDLR overexpression, it would suggest that peripheral LDLR or its effect on 
plasma apoE levels could regulate brain Aβ deposition. 
 
Effect of apoE on LDLR:Aβ interaction 
 Another major question that remains to be addressed is to what extent apoE 
modulates Aβ binding to apoE receptors, and how this modulation affects Aβ uptake into 
cells. Though our experiments in chapter 2 demonstrate that LDLR regulates soluble Aβ 
uptake and clearance in an apoE-independent manner, apoE may still have a role in the 
receptor-mediated uptake of Aβ. For instance, apoE has been shown to directly interact 
with the Aβ peptide in culture and in the brain (LaDu et al., 1994; Namba et al., 1991; 
Strittmatter et al., 1993b; Tokuda et al., 2000; Wisniewski et al., 1993). Whether soluble 
Aβ bound to apoE is endocytosed to a greater or lesser extent than free Aβ by apoE 
receptors remains unknown. For instance, if the clearance of Aβ through an apoE/Aβ 
complex is more efficient than the pathways involved in the clearance of unbound Aβ, 
apoE will promote Aβ clearance. Further studies are needed in culture to determine the 
rates of Aβ clearance when it is unbound and bound to apoE, and how each of the apoE 
receptors influences Aβ clearance in these different states. 
 Since Aβ has been shown to bind to both LDLR and LRP1, it is also possible that 
apoE could compete with free Aβ for binding to these receptors. A previous study has 
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shown that Aβ competes with apoE-containing VLDL particles for receptor-mediated 
endocytosis in human skin fibroblasts (Winkler et al., 1999). However, the specific 
receptors involved in this competition were not defined. If this competition occurred in 
vivo, more apoE in the brain would likely impair the clearance of Aβ via LDLR and 
LRP1 and lead to accumulation of Aβ in the brain. Results from the genetic manipulation 
of apoE in mice support this possibility, as increased amounts of apoE led to increased 
levels of Aβ deposition in the brain (Bales et al., 1999; Bales et al., 1997; Kim et al., 
2011). In the future, competition experiments between apoE and Aβ for binding to both 
LDLR and LRP1 could be performed in both cell-free conditions and in the setting of a 
cellular membrane. By demonstrating that apoE impairs the ability of Aβ to co-
immunoprecipitate with LDLR or LRP1, this would suggest that apoE impairs the ability 
of Aβ to bind to these receptors. It would also be interesting to determine whether 
increasing levels of apoE abrogates the effect of LDLR overexpression on Aβ uptake and 
clearance by primary astrocytes. 
 If apoE does compete with Aβ for binding to LDLR or LRP1, it would be 
illuminating to determine if there is an isoform-dependent difference in the ability of 
apoE to compete with Aβ. ApoE has been shown to bind to LDLR in an isoform-specific 
manner, with apoE2 having a much weaker binding than apoE3 and apoE4 (Weisgraber 
et al., 1982). As a result, apoE2 would theoretically be a much weaker competitor for Aβ 
binding to LDLR than apoE3 and apoE4, and consequently impair LDLR-mediated Aβ 
uptake to a much lesser extent than apoE3 and apoE4. This could in part explain the 
lower Aβ deposition in the brains of APP-transgenic mice that express human apoE2 
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versus apoE3 and apoE4 (Bales et al., 2009; Fagan et al., 2002), and in humans with the 
apoE2 allele (Morris et al., 2010). The amount of LDLR could also be important in 
determining whether apoE and Aβ compete for binding. For instance, when LDLR is 
sufficiently expressed there may be little competition of apoE and Aβ for binding to 
LDLR. However, when LDLR levels decrease the level of competition may increase and 
apoE may impair Aβ uptake. Interestingly, a recent study has shown that the amount of 
LDLR in the brain decreases with age in rats (Segatto et al., 2011). Therefore, if a similar 
phenomenon occurs in mice or humans, one hypothesis may be that the decrease in 
LDLR levels with age leads to greater competition between apoE and Aβ for binding to 
LDLR and impaired clearance of Aβ. Future studies should look at the levels of LDLR in 
the mouse and human brain at different ages. 
 
LDLR, Idol, and LXR treatment 
 Two proteins that have been shown to play an important role in regulating the 
degradation of LDLR are PCSK9 and the inducible degrader of LDLR (Idol). Our 
preliminary data presented in chapter 5 suggest that PCSK9 does not regulate LDLR 
levels in the brain. The function of Idol in the brain has yet to be defined. Idol is an E3 
ubiquitin ligase that is activated by the sterol-sensitive liver X receptors (LXRs) and  
ubiquitinates LDLR in order to target it for degradation (Scotti et al., 2011; Zelcer et al., 
2009). Idol levels are upregulated following LXR activation, which leads to a decrease in 
LDLR levels (Zelcer et al., 2009). In cells that lack Idol, LDLR levels are significantly 
increased and the ability of LXR ligands to decrease LDLR levels is diminished (Scotti et 
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al., 2011). Inhibition of the Idol pathway therefore represents an attractive therapeutic 
target for increasing LDLR levels. 
 Future experiments should address whether Idol can regulate LDLR levels in the 
brain. Mice could first be treated with LXR agonists to determine if LDLR is down 
regulated, and Idol levels in the brain could be assessed. Viral-mediated expression of 
Idol in the brain could then be used to determine if increasing Idol levels in the brain 
decreases LDLR. If Idol does regulate brain LDLR levels, its function in the mouse brain 
could be deleted by making a knock-out mouse or decreased by knocking-down the 
IDOL gene via viral-delivered shRNA. Assuming LDLR levels increase with Idol 
deletion, the Idol
-/-
 mice could be crossed with APP transgenic mice to analyze the effect 
of Idol deletion on Aβ levels and deposition in the mouse brain. One would hypothesize 
that Idol deletion would decrease Aβ plaque load due to the LDLR upregulation. 
 Since ABCA1 and apoE are transcriptionally upregulated by LXR (Beaven and 
Tontonoz, 2006), synthetic LXR ligands have attracted attention for their potential use as 
AD therapeutics. Animal studies have shown that treatment with various synthetic LXR 
agonists decreases Aβ and plaque levels. In young APP transgenic mice that do not yet 
exhibit Aβ deposition, treatment with the LXR agonist TO901317 led to a decrease in the 
levels of Aβ40 (Koldamova et al., 2005b) and Aβ42 (Koldamova et al., 2005b; Riddell et 
al., 2007). Treatment of APP transgenic mice with the LXR agonist GW3965 for 4 
months at an age in which plaque deposition has occurred led to a significant decrease in 
plaque numbers along with Aβ40 and Aβ42 levels (Jiang et al., 2008). Since LXR 
upregulation also decreases LDLR levels via the Idol pathway, this effect may lessen the 
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ability of LXR agonists to decrease Aβ levels. Therefore, a valuable follow-up to these 
studies would be to treat APP mice that lack Idol and see if the effects of LXR agonists 
on Aβ pathology are enhanced. 
 
ApoE levels and the effect on Aβ pathology 
 The issue of whether more or less apoE is beneficial in decreasing brain Aβ levels 
remains an important issue, since targeting apoE levels is an attractive therapeutic 
approach for treating AD. Results from the genetic manipulation of apoE levels in mice 
suggested that increasing apoE levels leads to more Aβ deposition in the brain (Bales et 
al., 1999; Bales et al., 1997; Holtzman et al., 2000b; Kim et al., 2011). However, 
treatment of mice with drugs that increase apoE levels, such as LXR agonists and the 
retinoid X receptor (RXR) agonist bexarotene, decreased Aβ levels and amyloid 
deposition in the brain (Cramer et al., 2012; Jiang et al., 2008). The reason for this 
discrepancy is unclear. The genetic studies have the caveat that apoE levels are different 
from birth, which could have other effects that modulate brain Aβ levels (such as altered 
membrane cholesterol content). In the pharmacologic upregulation of apoE, it is difficult 
to solely attribute the effect of the drugs to their effect of apoE levels due to multiple 
targets. Future experiments could more definitively demonstrate whether apoE levels are 
beneficial for decreasing Aβ levels by decreasing apoE levels in adult mice. ApoE2, 
apoE3, or apoE4 targeted-replacement mice could be altered such that the apoE locus is 
flanked by lox sites. These mice could then be crossed to inducible Cre mice and APP 
transgenic mice, and the levels of apoE could be decreased in adult mice both prior to and 
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after the onset of plaque deposition. ApoE levels in APP transgenic mice could also be 
decreased using RNA interference or increased via viral transduction. In either case, the 
changes in Aβ levels and deposition after decreasing apoE levels in these models would 
definitively demonstrate whether less apoE is beneficial for Aβ pathology and a target for 
future therapies. 
 Finally, the mechanism by which the amount of human apoE affects Aβ 
deposition remains to be determined. Solid evidence exists that the human apoE isoforms 
differentially modulate Aβ clearance from the brain (Castellano et al., 2011; Deane et al., 
2008). However, whether altering human apoE levels in the brain affects Aβ clearance 
has not directly been tested. Our SILK technique could be applied to address this issue in 
the mouse brain. Aβ clearance rates could be measured in both homozygous and 
hemizygous human apoE targeted-replacement mice crossed to an APP transgenic mouse 
line. Regardless of the results from this experiment, it is important to emphasize that 
apoE levels may also affect Aβ deposition by directly altering the propensity for Aβ to 
aggregate and form fibrillar structures. 
 
Concluding Remarks 
 The work presented in this thesis adds to the growing body of knowledge 
demonstrating that proteins that influence apoE levels and function in the brain play an 
important role in the pathogenesis of AD. We show for the first time that LDLR 
modulates the cellular metabolism of Aβ by glial cells. We also provided evidence that 
LDLR can directly interact with Aβ, a finding that could potentially be exploited for the 
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design of therapeutics that target Aβ clearance in the brain. We have also described a 
stable isotope labeling method that can be used to measure the turnover of proteins in the 
mouse brain. We used this technique to analyze the kinetics of both mouse and human 
apoE in the mouse brain for the first time, and demonstrated that both LDLR and ABCA1 
levels alter apoE clearance. We also demonstrated that the levels of the protein ABCA1 
do not regulate the clearance of Aβ from the mouse brain. This technique will be of value 
for future studies attempting to elucidate the mechanisms underlying the pathogenesis of 
both AD and other neurodegenerative disease, and also for characterizing the efficiency 
of therapeutics that target protein turnover in the brain. 
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